#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Differential neural reward mechanisms in treatment responsive and treatment resistant schizophrenia
#Text=Background:
#Text=The significant proportion of schizophrenia patients refractory to treatment, primarily directed at the dopamine system, suggests that multiple mechanisms may underlie psychotic symptoms.
1-1	0-12	Differential	_	
1-2	13-19	neural	_	
1-3	20-26	reward	_	
1-4	27-37	mechanisms	_	
1-5	38-40	in	_	
1-6	41-50	treatment	_	
1-7	51-61	responsive	_	
1-8	62-65	and	_	
1-9	66-75	treatment	_	
1-10	76-85	resistant	_	
1-11	86-99	schizophrenia	_	
1-12	100-110	Background	_	
1-13	110-111	:	_	
1-14	112-115	The	_	
1-15	116-127	significant	_	
1-16	128-138	proportion	_	
1-17	139-141	of	_	
1-18	142-155	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-19	156-164	patients	_	
1-20	165-175	refractory	_	
1-21	176-178	to	_	
1-22	179-188	treatment	_	
1-23	188-189	,	_	
1-24	190-199	primarily	_	
1-25	200-208	directed	_	
1-26	209-211	at	_	
1-27	212-215	the	_	
1-28	216-224	dopamine	_	
1-29	225-231	system	_	
1-30	231-232	,	_	
1-31	233-241	suggests	_	
1-32	242-246	that	_	
1-33	247-255	multiple	_	
1-34	256-266	mechanisms	_	
1-35	267-270	may	_	
1-36	271-279	underlie	_	
1-37	280-289	psychotic	_	
1-38	290-298	symptoms	_	
1-39	298-299	.	_	

#Text=Reinforcement learning tasks have been employed in schizophrenia to assess dopaminergic functioning and reward processing, but these have not directly compared groups of treatment-refractory and non-refractory patients.
2-1	300-313	Reinforcement	_	
2-2	314-322	learning	_	
2-3	323-328	tasks	_	
2-4	329-333	have	_	
2-5	334-338	been	_	
2-6	339-347	employed	_	
2-7	348-350	in	_	
2-8	351-364	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-9	365-367	to	_	
2-10	368-374	assess	_	
2-11	375-387	dopaminergic	_	
2-12	388-399	functioning	_	
2-13	400-403	and	_	
2-14	404-410	reward	_	
2-15	411-421	processing	_	
2-16	421-422	,	_	
2-17	423-426	but	_	
2-18	427-432	these	_	
2-19	433-437	have	_	
2-20	438-441	not	_	
2-21	442-450	directly	_	
2-22	451-459	compared	_	
2-23	460-466	groups	_	
2-24	467-469	of	_	
2-25	470-490	treatment-refractory	_	
2-26	491-494	and	_	
2-27	495-509	non-refractory	_	
2-28	510-518	patients	_	
2-29	518-519	.	_	

#Text=Methods:
#Text=In the current fMRI study 21 patients with treatment resistant schizophrenia (TRS), 21 patients with non-treatment resistant schizophrenia (NTR), and 24 healthy controls (HC) performed a probabilistic reinforcement learning task, utilising emotionally valenced face stimuli which elicit a social bias toward happy faces.
3-1	520-527	Methods	_	
3-2	527-528	:	_	
3-3	529-531	In	_	
3-4	532-535	the	_	
3-5	536-543	current	_	
3-6	544-548	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
3-7	549-554	study	_	
3-8	555-557	21	_	
3-9	558-566	patients	_	
3-10	567-571	with	_	
3-11	572-581	treatment	_	
3-12	582-591	resistant	_	
3-13	592-605	schizophrenia	_	
3-14	606-607	(	_	
3-15	607-610	TRS	_	
3-16	610-611	)	_	
3-17	611-612	,	_	
3-18	613-615	21	_	
3-19	616-624	patients	_	
3-20	625-629	with	_	
3-21	630-643	non-treatment	_	
3-22	644-653	resistant	_	
3-23	654-667	schizophrenia	_	
3-24	668-669	(	_	
3-25	669-672	NTR	_	
3-26	672-673	)	_	
3-27	673-674	,	_	
3-28	675-678	and	_	
3-29	679-681	24	_	
3-30	682-689	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-31	690-698	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-32	699-700	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-33	700-702	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-34	702-703	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-35	704-713	performed	_	
3-36	714-715	a	_	
3-37	716-729	probabilistic	_	
3-38	730-743	reinforcement	_	
3-39	744-752	learning	_	
3-40	753-757	task	_	
3-41	757-758	,	_	
3-42	759-768	utilising	_	
3-43	769-780	emotionally	_	
3-44	781-789	valenced	_	
3-45	790-794	face	_	
3-46	795-802	stimuli	_	
3-47	803-808	which	_	
3-48	809-815	elicit	_	
3-49	816-817	a	_	
3-50	818-824	social	_	
3-51	825-829	bias	_	
3-52	830-836	toward	_	
3-53	837-842	happy	_	
3-54	843-848	faces	_	
3-55	848-849	.	_	

#Text=Behavior was characterized with a reinforcement learning model.
4-1	850-858	Behavior	_	
4-2	859-862	was	_	
4-3	863-876	characterized	_	
4-4	877-881	with	_	
4-5	882-883	a	_	
4-6	884-897	reinforcement	_	
4-7	898-906	learning	_	
4-8	907-912	model	_	
4-9	912-913	.	_	

#Text=Trial-wise reward prediction error (RPE)-related neural activation and the differential impact of emotional bias on these reward signals were compared between groups.
5-1	914-924	Trial-wise	_	
5-2	925-931	reward	_	
5-3	932-942	prediction	_	
5-4	943-948	error	_	
5-5	949-950	(	_	
5-6	950-953	RPE	_	
5-7	953-954	)	_	
5-8	954-955	-	_	
5-9	955-962	related	_	
5-10	963-969	neural	_	
5-11	970-980	activation	_	
5-12	981-984	and	_	
5-13	985-988	the	_	
5-14	989-1001	differential	_	
5-15	1002-1008	impact	_	
5-16	1009-1011	of	_	
5-17	1012-1021	emotional	_	
5-18	1022-1026	bias	_	
5-19	1027-1029	on	_	
5-20	1030-1035	these	_	
5-21	1036-1042	reward	_	
5-22	1043-1050	signals	_	
5-23	1051-1055	were	_	
5-24	1056-1064	compared	_	
5-25	1065-1072	between	_	
5-26	1073-1079	groups	_	
5-27	1079-1080	.	_	

#Text=Results:
#Text=Patients showed impaired reinforcement learning relative to controls, while all groups demonstrated an emotional bias favouring happy faces.
6-1	1081-1088	Results	_	
6-2	1088-1089	:	_	
6-3	1090-1098	Patients	_	
6-4	1099-1105	showed	_	
6-5	1106-1114	impaired	_	
6-6	1115-1128	reinforcement	_	
6-7	1129-1137	learning	_	
6-8	1138-1146	relative	_	
6-9	1147-1149	to	_	
6-10	1150-1158	controls	_	
6-11	1158-1159	,	_	
6-12	1160-1165	while	_	
6-13	1166-1169	all	_	
6-14	1170-1176	groups	_	
6-15	1177-1189	demonstrated	_	
6-16	1190-1192	an	_	
6-17	1193-1202	emotional	_	
6-18	1203-1207	bias	_	
6-19	1208-1217	favouring	_	
6-20	1218-1223	happy	_	
6-21	1224-1229	faces	_	
6-22	1229-1230	.	_	

#Text=The pattern of RPE signaling was similar in the HC and TRS groups, whereas NTR patients showed significant attenuation of RPE-related activation in striatal, thalamic, precentral, parietal, and cerebellar regions.
7-1	1231-1234	The	_	
7-2	1235-1242	pattern	_	
7-3	1243-1245	of	_	
7-4	1246-1249	RPE	_	
7-5	1250-1259	signaling	_	
7-6	1260-1263	was	_	
7-7	1264-1271	similar	_	
7-8	1272-1274	in	_	
7-9	1275-1278	the	_	
7-10	1279-1281	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
7-11	1282-1285	and	_	
7-12	1286-1289	TRS	_	
7-13	1290-1296	groups	_	
7-14	1296-1297	,	_	
7-15	1298-1305	whereas	_	
7-16	1306-1309	NTR	_	
7-17	1310-1318	patients	_	
7-18	1319-1325	showed	_	
7-19	1326-1337	significant	_	
7-20	1338-1349	attenuation	_	
7-21	1350-1352	of	_	
7-22	1353-1364	RPE-related	_	
7-23	1365-1375	activation	_	
7-24	1376-1378	in	_	
7-25	1379-1387	striatal	_	
7-26	1387-1388	,	_	
7-27	1389-1397	thalamic	_	
7-28	1397-1398	,	_	
7-29	1399-1409	precentral	_	
7-30	1409-1410	,	_	
7-31	1411-1419	parietal	_	
7-32	1419-1420	,	_	
7-33	1421-1424	and	_	
7-34	1425-1435	cerebellar	_	
7-35	1436-1443	regions	_	
7-36	1443-1444	.	_	

#Text=TRS patients, but not NTR patients, showed a positive relationship between emotional bias and RPE signal during negative feedback in bilateral thalamus and caudate.
8-1	1445-1448	TRS	_	
8-2	1449-1457	patients	_	
8-3	1457-1458	,	_	
8-4	1459-1462	but	_	
8-5	1463-1466	not	_	
8-6	1467-1470	NTR	_	
8-7	1471-1479	patients	_	
8-8	1479-1480	,	_	
8-9	1481-1487	showed	_	
8-10	1488-1489	a	_	
8-11	1490-1498	positive	_	
8-12	1499-1511	relationship	_	
8-13	1512-1519	between	_	
8-14	1520-1529	emotional	_	
8-15	1530-1534	bias	_	
8-16	1535-1538	and	_	
8-17	1539-1542	RPE	_	
8-18	1543-1549	signal	_	
8-19	1550-1556	during	_	
8-20	1557-1565	negative	_	
8-21	1566-1574	feedback	_	
8-22	1575-1577	in	_	
8-23	1578-1587	bilateral	_	
8-24	1588-1596	thalamus	_	
8-25	1597-1600	and	_	
8-26	1601-1608	caudate	_	
8-27	1608-1609	.	_	

#Text=Conclusion:
#Text=TRS can be dissociated from NTR on the basis of a different neural mechanism underlying reinforcement learning.
9-1	1610-1620	Conclusion	_	
9-2	1620-1621	:	_	
9-3	1622-1625	TRS	_	
9-4	1626-1629	can	_	
9-5	1630-1632	be	_	
9-6	1633-1644	dissociated	_	
9-7	1645-1649	from	_	
9-8	1650-1653	NTR	_	
9-9	1654-1656	on	_	
9-10	1657-1660	the	_	
9-11	1661-1666	basis	_	
9-12	1667-1669	of	_	
9-13	1670-1671	a	_	
9-14	1672-1681	different	_	
9-15	1682-1688	neural	_	
9-16	1689-1698	mechanism	_	
9-17	1699-1709	underlying	_	
9-18	1710-1723	reinforcement	_	
9-19	1724-1732	learning	_	
9-20	1732-1733	.	_	

#Text=The data support the hypothesis that a favourable response to antipsychotic treatment is contingent on dopaminergic dysfunction, characterized by aberrant RPE signaling, whereas treatment resistance may be characterized by an abnormality of a non-dopaminergic mechanism-a glutamatergic mechansim would be a possible candidate.
10-1	1734-1737	The	_	
10-2	1738-1742	data	_	
10-3	1743-1750	support	_	
10-4	1751-1754	the	_	
10-5	1755-1765	hypothesis	_	
10-6	1766-1770	that	_	
10-7	1771-1772	a	_	
10-8	1773-1783	favourable	_	
10-9	1784-1792	response	_	
10-10	1793-1795	to	_	
10-11	1796-1809	antipsychotic	_	
10-12	1810-1819	treatment	_	
10-13	1820-1822	is	_	
10-14	1823-1833	contingent	_	
10-15	1834-1836	on	_	
10-16	1837-1849	dopaminergic	_	
10-17	1850-1861	dysfunction	_	
10-18	1861-1862	,	_	
10-19	1863-1876	characterized	_	
10-20	1877-1879	by	_	
10-21	1880-1888	aberrant	_	
10-22	1889-1892	RPE	_	
10-23	1893-1902	signaling	_	
10-24	1902-1903	,	_	
10-25	1904-1911	whereas	_	
10-26	1912-1921	treatment	_	
10-27	1922-1932	resistance	_	
10-28	1933-1936	may	_	
10-29	1937-1939	be	_	
10-30	1940-1953	characterized	_	
10-31	1954-1956	by	_	
10-32	1957-1959	an	_	
10-33	1960-1971	abnormality	_	
10-34	1972-1974	of	_	
10-35	1975-1976	a	_	
10-36	1977-1993	non-dopaminergic	_	
10-37	1994-2005	mechanism-a	_	
10-38	2006-2019	glutamatergic	_	
10-39	2020-2029	mechansim	_	
10-40	2030-2035	would	_	
10-41	2036-2038	be	_	
10-42	2039-2040	a	_	
10-43	2041-2049	possible	_	
10-44	2050-2059	candidate	_	
10-45	2059-2060	.	_	

#Text=Introduction
#Text=Antipsychotic medication has been used to treat the symptoms of schizophrenia since the early 1950s.
11-1	2061-2073	Introduction	_	
11-2	2074-2087	Antipsychotic	_	
11-3	2088-2098	medication	_	
11-4	2099-2102	has	_	
11-5	2103-2107	been	_	
11-6	2108-2112	used	_	
11-7	2113-2115	to	_	
11-8	2116-2121	treat	_	
11-9	2122-2125	the	_	
11-10	2126-2134	symptoms	_	
11-11	2135-2137	of	_	
11-12	2138-2151	schizophrenia	_	
11-13	2152-2157	since	_	
11-14	2158-2161	the	_	
11-15	2162-2167	early	_	
11-16	2168-2173	1950s	_	
11-17	2173-2174	.	_	

#Text=The mode of action for all currently licensed antipsychotics is via their action on dopamine D2 receptors.
12-1	2175-2178	The	_	
12-2	2179-2183	mode	_	
12-3	2184-2186	of	_	
12-4	2187-2193	action	_	
12-5	2194-2197	for	_	
12-6	2198-2201	all	_	
12-7	2202-2211	currently	_	
12-8	2212-2220	licensed	_	
12-9	2221-2235	antipsychotics	_	
12-10	2236-2238	is	_	
12-11	2239-2242	via	_	
12-12	2243-2248	their	_	
12-13	2249-2255	action	_	
12-14	2256-2258	on	_	
12-15	2259-2267	dopamine	_	
12-16	2268-2270	D2	_	
12-17	2271-2280	receptors	_	
12-18	2280-2281	.	_	

#Text=However, approximately one third of patients with a diagnosis of schizophrenia - – fail to respond adequately to a trial of antipsychotic medication at recommended doses and duration; surprisingly, this occurs despite adequate D2 receptor occupancy.
13-1	2282-2289	However	_	
13-2	2289-2290	,	_	
13-3	2291-2304	approximately	_	
13-4	2305-2308	one	_	
13-5	2309-2314	third	_	
13-6	2315-2317	of	_	
13-7	2318-2326	patients	_	
13-8	2327-2331	with	_	
13-9	2332-2333	a	_	
13-10	2334-2343	diagnosis	_	
13-11	2344-2346	of	_	
13-12	2347-2360	schizophrenia	_	
13-13	2361-2362	-	_	
13-14	2363-2364	–	_	
13-15	2365-2369	fail	_	
13-16	2370-2372	to	_	
13-17	2373-2380	respond	_	
13-18	2381-2391	adequately	_	
13-19	2392-2394	to	_	
13-20	2395-2396	a	_	
13-21	2397-2402	trial	_	
13-22	2403-2405	of	_	
13-23	2406-2419	antipsychotic	_	
13-24	2420-2430	medication	_	
13-25	2431-2433	at	_	
13-26	2434-2445	recommended	_	
13-27	2446-2451	doses	_	
13-28	2452-2455	and	_	
13-29	2456-2464	duration	_	
13-30	2464-2465	;	_	
13-31	2466-2478	surprisingly	_	
13-32	2478-2479	,	_	
13-33	2480-2484	this	_	
13-34	2485-2491	occurs	_	
13-35	2492-2499	despite	_	
13-36	2500-2508	adequate	_	
13-37	2509-2511	D2	_	
13-38	2512-2520	receptor	_	
13-39	2521-2530	occupancy	_	
13-40	2530-2531	.	_	

#Text=The implication is that these occurrences of “treatment resistant” schizophrenia (TRS) are either characterized by a distinct neurochemical deficit, reflecting the heterogeneous nature of schizophrenia, or that the dopaminergic dysfunction is markedly more severe in TRS, sufficient that modulating the dopaminergic system with standard dopamine blocking antipsychotics is not enough to alleviate symptoms in these complex cases.
14-1	2532-2535	The	_	
14-2	2536-2547	implication	_	
14-3	2548-2550	is	_	
14-4	2551-2555	that	_	
14-5	2556-2561	these	_	
14-6	2562-2573	occurrences	_	
14-7	2574-2576	of	_	
14-8	2577-2578	“	_	
14-9	2578-2587	treatment	_	
14-10	2588-2597	resistant	_	
14-11	2597-2598	”	_	
14-12	2599-2612	schizophrenia	_	
14-13	2613-2614	(	_	
14-14	2614-2617	TRS	_	
14-15	2617-2618	)	_	
14-16	2619-2622	are	_	
14-17	2623-2629	either	_	
14-18	2630-2643	characterized	_	
14-19	2644-2646	by	_	
14-20	2647-2648	a	_	
14-21	2649-2657	distinct	_	
14-22	2658-2671	neurochemical	_	
14-23	2672-2679	deficit	_	
14-24	2679-2680	,	_	
14-25	2681-2691	reflecting	_	
14-26	2692-2695	the	_	
14-27	2696-2709	heterogeneous	_	
14-28	2710-2716	nature	_	
14-29	2717-2719	of	_	
14-30	2720-2733	schizophrenia	_	
14-31	2733-2734	,	_	
14-32	2735-2737	or	_	
14-33	2738-2742	that	_	
14-34	2743-2746	the	_	
14-35	2747-2759	dopaminergic	_	
14-36	2760-2771	dysfunction	_	
14-37	2772-2774	is	_	
14-38	2775-2783	markedly	_	
14-39	2784-2788	more	_	
14-40	2789-2795	severe	_	
14-41	2796-2798	in	_	
14-42	2799-2802	TRS	_	
14-43	2802-2803	,	_	
14-44	2804-2814	sufficient	_	
14-45	2815-2819	that	_	
14-46	2820-2830	modulating	_	
14-47	2831-2834	the	_	
14-48	2835-2847	dopaminergic	_	
14-49	2848-2854	system	_	
14-50	2855-2859	with	_	
14-51	2860-2868	standard	_	
14-52	2869-2877	dopamine	_	
14-53	2878-2886	blocking	_	
14-54	2887-2901	antipsychotics	_	
14-55	2902-2904	is	_	
14-56	2905-2908	not	_	
14-57	2909-2915	enough	_	
14-58	2916-2918	to	_	
14-59	2919-2928	alleviate	_	
14-60	2929-2937	symptoms	_	
14-61	2938-2940	in	_	
14-62	2941-2946	these	_	
14-63	2947-2954	complex	_	
14-64	2955-2960	cases	_	
14-65	2960-2961	.	_	

#Text=Schizophrenia has frequently been studied within a framework of reinforcement learning given the involvement of dopamine function in reward prediction.
15-1	2962-2975	Schizophrenia	_	
15-2	2976-2979	has	_	
15-3	2980-2990	frequently	_	
15-4	2991-2995	been	_	
15-5	2996-3003	studied	_	
15-6	3004-3010	within	_	
15-7	3011-3012	a	_	
15-8	3013-3022	framework	_	
15-9	3023-3025	of	_	
15-10	3026-3039	reinforcement	_	
15-11	3040-3048	learning	_	
15-12	3049-3054	given	_	
15-13	3055-3058	the	_	
15-14	3059-3070	involvement	_	
15-15	3071-3073	of	_	
15-16	3074-3082	dopamine	_	
15-17	3083-3091	function	_	
15-18	3092-3094	in	_	
15-19	3095-3101	reward	_	
15-20	3102-3112	prediction	_	
15-21	3112-3113	.	_	

#Text=Reinforcement learning is driven by midbrain dopamine neurons encoding violations of expected reward outcomes, known as reward prediction error (RPE) signals.
16-1	3114-3127	Reinforcement	_	
16-2	3128-3136	learning	_	
16-3	3137-3139	is	_	
16-4	3140-3146	driven	_	
16-5	3147-3149	by	_	
16-6	3150-3158	midbrain	_	
16-7	3159-3167	dopamine	_	
16-8	3168-3175	neurons	_	
16-9	3176-3184	encoding	_	
16-10	3185-3195	violations	_	
16-11	3196-3198	of	_	
16-12	3199-3207	expected	_	
16-13	3208-3214	reward	_	
16-14	3215-3223	outcomes	_	
16-15	3223-3224	,	_	
16-16	3225-3230	known	_	
16-17	3231-3233	as	_	
16-18	3234-3240	reward	_	
16-19	3241-3251	prediction	_	
16-20	3252-3257	error	_	
16-21	3258-3259	(	_	
16-22	3259-3262	RPE	_	
16-23	3262-3263	)	_	
16-24	3264-3271	signals	_	
16-25	3271-3272	.	_	

#Text=Specifically, unexpected reward elicits a phasic increase in firing of dopamine neurons, whereas omission of an expected reward results in a phasic decrease in firing.
17-1	3273-3285	Specifically	_	
17-2	3285-3286	,	_	
17-3	3287-3297	unexpected	_	
17-4	3298-3304	reward	_	
17-5	3305-3312	elicits	_	
17-6	3313-3314	a	_	
17-7	3315-3321	phasic	_	
17-8	3322-3330	increase	_	
17-9	3331-3333	in	_	
17-10	3334-3340	firing	_	
17-11	3341-3343	of	_	
17-12	3344-3352	dopamine	_	
17-13	3353-3360	neurons	_	
17-14	3360-3361	,	_	
17-15	3362-3369	whereas	_	
17-16	3370-3378	omission	_	
17-17	3379-3381	of	_	
17-18	3382-3384	an	_	
17-19	3385-3393	expected	_	
17-20	3394-3400	reward	_	
17-21	3401-3408	results	_	
17-22	3409-3411	in	_	
17-23	3412-3413	a	_	
17-24	3414-3420	phasic	_	
17-25	3421-3429	decrease	_	
17-26	3430-3432	in	_	
17-27	3433-3439	firing	_	
17-28	3439-3440	.	_	

#Text=Midbrain RPE signals are thought to act as a learning signal which is fed through fronto-cortical basal ganglia loops in order to adjust behaviour accordingly.
18-1	3441-3449	Midbrain	_	
18-2	3450-3453	RPE	_	
18-3	3454-3461	signals	_	
18-4	3462-3465	are	_	
18-5	3466-3473	thought	_	
18-6	3474-3476	to	_	
18-7	3477-3480	act	_	
18-8	3481-3483	as	_	
18-9	3484-3485	a	_	
18-10	3486-3494	learning	_	
18-11	3495-3501	signal	_	
18-12	3502-3507	which	_	
18-13	3508-3510	is	_	
18-14	3511-3514	fed	_	
18-15	3515-3522	through	_	
18-16	3523-3538	fronto-cortical	_	
18-17	3539-3544	basal	_	
18-18	3545-3552	ganglia	_	
18-19	3553-3558	loops	_	
18-20	3559-3561	in	_	
18-21	3562-3567	order	_	
18-22	3568-3570	to	_	
18-23	3571-3577	adjust	_	
18-24	3578-3587	behaviour	_	
18-25	3588-3599	accordingly	_	
18-26	3599-3600	.	_	

#Text=Functional magnetic resonance imaging (fMRI) of brain regions which are densely innervated by dopamine neurons, particularly the striatum and aspects of the prefrontal cortex, typically show activation reflective of an RPE response, in line with the notion that the blood oxygen level dependent (BOLD) signal likely reflects the information an area is receiving and processing.
19-1	3601-3611	Functional	_	
19-2	3612-3620	magnetic	_	
19-3	3621-3630	resonance	_	
19-4	3631-3638	imaging	_	
19-5	3639-3640	(	_	
19-6	3640-3644	fMRI	_	
19-7	3644-3645	)	_	
19-8	3646-3648	of	_	
19-9	3649-3654	brain	_	
19-10	3655-3662	regions	_	
19-11	3663-3668	which	_	
19-12	3669-3672	are	_	
19-13	3673-3680	densely	_	
19-14	3681-3691	innervated	_	
19-15	3692-3694	by	_	
19-16	3695-3703	dopamine	_	
19-17	3704-3711	neurons	_	
19-18	3711-3712	,	_	
19-19	3713-3725	particularly	_	
19-20	3726-3729	the	_	
19-21	3730-3738	striatum	_	
19-22	3739-3742	and	_	
19-23	3743-3750	aspects	_	
19-24	3751-3753	of	_	
19-25	3754-3757	the	_	
19-26	3758-3768	prefrontal	_	
19-27	3769-3775	cortex	_	
19-28	3775-3776	,	_	
19-29	3777-3786	typically	_	
19-30	3787-3791	show	_	
19-31	3792-3802	activation	_	
19-32	3803-3813	reflective	_	
19-33	3814-3816	of	_	
19-34	3817-3819	an	_	
19-35	3820-3823	RPE	_	
19-36	3824-3832	response	_	
19-37	3832-3833	,	_	
19-38	3834-3836	in	_	
19-39	3837-3841	line	_	
19-40	3842-3846	with	_	
19-41	3847-3850	the	_	
19-42	3851-3857	notion	_	
19-43	3858-3862	that	_	
19-44	3863-3866	the	_	
19-45	3867-3872	blood	_	
19-46	3873-3879	oxygen	_	
19-47	3880-3885	level	_	
19-48	3886-3895	dependent	_	
19-49	3896-3897	(	_	
19-50	3897-3901	BOLD	_	
19-51	3901-3902	)	_	
19-52	3903-3909	signal	_	
19-53	3910-3916	likely	_	
19-54	3917-3925	reflects	_	
19-55	3926-3929	the	_	
19-56	3930-3941	information	_	
19-57	3942-3944	an	_	
19-58	3945-3949	area	_	
19-59	3950-3952	is	_	
19-60	3953-3962	receiving	_	
19-61	3963-3966	and	_	
19-62	3967-3977	processing	_	
19-63	3977-3978	.	_	

#Text=A recent meta-analysis of neuroimaging studies of prediction error during reinforcement learning confirmed robust prediction error activation in both ventral and dorsal aspects of the striatum as well as cortical regions including medial prefrontal, inferior and superior frontal, inferior parietal, and occipital cortex.
20-1	3979-3980	A	_	
20-2	3981-3987	recent	_	
20-3	3988-4001	meta-analysis	_	
20-4	4002-4004	of	_	
20-5	4005-4017	neuroimaging	_	
20-6	4018-4025	studies	_	
20-7	4026-4028	of	_	
20-8	4029-4039	prediction	_	
20-9	4040-4045	error	_	
20-10	4046-4052	during	_	
20-11	4053-4066	reinforcement	_	
20-12	4067-4075	learning	_	
20-13	4076-4085	confirmed	_	
20-14	4086-4092	robust	_	
20-15	4093-4103	prediction	_	
20-16	4104-4109	error	_	
20-17	4110-4120	activation	_	
20-18	4121-4123	in	_	
20-19	4124-4128	both	_	
20-20	4129-4136	ventral	_	
20-21	4137-4140	and	_	
20-22	4141-4147	dorsal	_	
20-23	4148-4155	aspects	_	
20-24	4156-4158	of	_	
20-25	4159-4162	the	_	
20-26	4163-4171	striatum	_	
20-27	4172-4174	as	_	
20-28	4175-4179	well	_	
20-29	4180-4182	as	_	
20-30	4183-4191	cortical	_	
20-31	4192-4199	regions	_	
20-32	4200-4209	including	_	
20-33	4210-4216	medial	_	
20-34	4217-4227	prefrontal	_	
20-35	4227-4228	,	_	
20-36	4229-4237	inferior	_	
20-37	4238-4241	and	_	
20-38	4242-4250	superior	_	
20-39	4251-4258	frontal	_	
20-40	4258-4259	,	_	
20-41	4260-4268	inferior	_	
20-42	4269-4277	parietal	_	
20-43	4277-4278	,	_	
20-44	4279-4282	and	_	
20-45	4283-4292	occipital	_	
20-46	4293-4299	cortex	_	
20-47	4299-4300	.	_	

#Text=Consistent with pathologically increased tonic striatal dopamine in schizophrenia, phasic RPE signaling in the striatum has been shown to be reduced in schizophrenia patients, a finding attributed to “drowning” of these phasic signals due to elevated presynaptic dopamine.
21-1	4301-4311	Consistent	_	
21-2	4312-4316	with	_	
21-3	4317-4331	pathologically	_	
21-4	4332-4341	increased	_	
21-5	4342-4347	tonic	_	
21-6	4348-4356	striatal	_	
21-7	4357-4365	dopamine	_	
21-8	4366-4368	in	_	
21-9	4369-4382	schizophrenia	_	
21-10	4382-4383	,	_	
21-11	4384-4390	phasic	_	
21-12	4391-4394	RPE	_	
21-13	4395-4404	signaling	_	
21-14	4405-4407	in	_	
21-15	4408-4411	the	_	
21-16	4412-4420	striatum	_	
21-17	4421-4424	has	_	
21-18	4425-4429	been	_	
21-19	4430-4435	shown	_	
21-20	4436-4438	to	_	
21-21	4439-4441	be	_	
21-22	4442-4449	reduced	_	
21-23	4450-4452	in	_	
21-24	4453-4466	schizophrenia	_	
21-25	4467-4475	patients	_	
21-26	4475-4476	,	_	
21-27	4477-4478	a	_	
21-28	4479-4486	finding	_	
21-29	4487-4497	attributed	_	
21-30	4498-4500	to	_	
21-31	4501-4502	“	_	
21-32	4502-4510	drowning	_	
21-33	4510-4511	”	_	
21-34	4512-4514	of	_	
21-35	4515-4520	these	_	
21-36	4521-4527	phasic	_	
21-37	4528-4535	signals	_	
21-38	4536-4539	due	_	
21-39	4540-4542	to	_	
21-40	4543-4551	elevated	_	
21-41	4552-4563	presynaptic	_	
21-42	4564-4572	dopamine	_	
21-43	4572-4573	.	_	

#Text=As the primary target of dopaminergic neurons, the ventral striatum has been a major region of interest for reinforcement learning studies in schizophrenia; however, impaired RPE signaling has also been detected in patients in additional areas such as prefrontal cortex, parietal cortex, thalamus, and cerebellum.
22-1	4574-4576	As	_	
22-2	4577-4580	the	_	
22-3	4581-4588	primary	_	
22-4	4589-4595	target	_	
22-5	4596-4598	of	_	
22-6	4599-4611	dopaminergic	_	
22-7	4612-4619	neurons	_	
22-8	4619-4620	,	_	
22-9	4621-4624	the	_	
22-10	4625-4632	ventral	_	
22-11	4633-4641	striatum	_	
22-12	4642-4645	has	_	
22-13	4646-4650	been	_	
22-14	4651-4652	a	_	
22-15	4653-4658	major	_	
22-16	4659-4665	region	_	
22-17	4666-4668	of	_	
22-18	4669-4677	interest	_	
22-19	4678-4681	for	_	
22-20	4682-4695	reinforcement	_	
22-21	4696-4704	learning	_	
22-22	4705-4712	studies	_	
22-23	4713-4715	in	_	
22-24	4716-4729	schizophrenia	_	
22-25	4729-4730	;	_	
22-26	4731-4738	however	_	
22-27	4738-4739	,	_	
22-28	4740-4748	impaired	_	
22-29	4749-4752	RPE	_	
22-30	4753-4762	signaling	_	
22-31	4763-4766	has	_	
22-32	4767-4771	also	_	
22-33	4772-4776	been	_	
22-34	4777-4785	detected	_	
22-35	4786-4788	in	_	
22-36	4789-4797	patients	_	
22-37	4798-4800	in	_	
22-38	4801-4811	additional	_	
22-39	4812-4817	areas	_	
22-40	4818-4822	such	_	
22-41	4823-4825	as	_	
22-42	4826-4836	prefrontal	_	
22-43	4837-4843	cortex	_	
22-44	4843-4844	,	_	
22-45	4845-4853	parietal	_	
22-46	4854-4860	cortex	_	
22-47	4860-4861	,	_	
22-48	4862-4870	thalamus	_	
22-49	4870-4871	,	_	
22-50	4872-4875	and	_	
22-51	4876-4886	cerebellum	_	
22-52	4886-4887	.	_	

#Text=Furthermore, there is evidence that reward feedback processing and RPE signaling in schizophrenia is selectively impaired for reward outcomes, but largely intact for loss outcomes, typically consisting of omission of expected reward.
23-1	4888-4899	Furthermore	_	
23-2	4899-4900	,	_	
23-3	4901-4906	there	_	
23-4	4907-4909	is	_	
23-5	4910-4918	evidence	_	
23-6	4919-4923	that	_	
23-7	4924-4930	reward	_	
23-8	4931-4939	feedback	_	
23-9	4940-4950	processing	_	
23-10	4951-4954	and	_	
23-11	4955-4958	RPE	_	
23-12	4959-4968	signaling	_	
23-13	4969-4971	in	_	
23-14	4972-4985	schizophrenia	_	
23-15	4986-4988	is	_	
23-16	4989-5000	selectively	_	
23-17	5001-5009	impaired	_	
23-18	5010-5013	for	_	
23-19	5014-5020	reward	_	
23-20	5021-5029	outcomes	_	
23-21	5029-5030	,	_	
23-22	5031-5034	but	_	
23-23	5035-5042	largely	_	
23-24	5043-5049	intact	_	
23-25	5050-5053	for	_	
23-26	5054-5058	loss	_	
23-27	5059-5067	outcomes	_	
23-28	5067-5068	,	_	
23-29	5069-5078	typically	_	
23-30	5079-5089	consisting	_	
23-31	5090-5092	of	_	
23-32	5093-5101	omission	_	
23-33	5102-5104	of	_	
23-34	5105-5113	expected	_	
23-35	5114-5120	reward	_	
23-36	5120-5121	.	_	

#Text=While meta-analytic findings have shown some overlap of neural regions processing reward and punishment in healthy individuals including in the striatum und medial frontal cortex, encoding of prediction errors during gain and loss outcomes appears to be spatially segregated in temporal and occipital regions.
24-1	5122-5127	While	_	
24-2	5128-5141	meta-analytic	_	
24-3	5142-5150	findings	_	
24-4	5151-5155	have	_	
24-5	5156-5161	shown	_	
24-6	5162-5166	some	_	
24-7	5167-5174	overlap	_	
24-8	5175-5177	of	_	
24-9	5178-5184	neural	_	
24-10	5185-5192	regions	_	
24-11	5193-5203	processing	_	
24-12	5204-5210	reward	_	
24-13	5211-5214	and	_	
24-14	5215-5225	punishment	_	
24-15	5226-5228	in	_	
24-16	5229-5236	healthy	_	
24-17	5237-5248	individuals	_	
24-18	5249-5258	including	_	
24-19	5259-5261	in	_	
24-20	5262-5265	the	_	
24-21	5266-5274	striatum	_	
24-22	5275-5278	und	_	
24-23	5279-5285	medial	_	
24-24	5286-5293	frontal	_	
24-25	5294-5300	cortex	_	
24-26	5300-5301	,	_	
24-27	5302-5310	encoding	_	
24-28	5311-5313	of	_	
24-29	5314-5324	prediction	_	
24-30	5325-5331	errors	_	
24-31	5332-5338	during	_	
24-32	5339-5343	gain	_	
24-33	5344-5347	and	_	
24-34	5348-5352	loss	_	
24-35	5353-5361	outcomes	_	
24-36	5362-5369	appears	_	
24-37	5370-5372	to	_	
24-38	5373-5375	be	_	
24-39	5376-5385	spatially	_	
24-40	5386-5396	segregated	_	
24-41	5397-5399	in	_	
24-42	5400-5408	temporal	_	
24-43	5409-5412	and	_	
24-44	5413-5422	occipital	_	
24-45	5423-5430	regions	_	
24-46	5430-5431	.	_	

#Text=This supports the possibility that the reward processing network could be selectively impaired in schizophrenia.
25-1	5432-5436	This	_	
25-2	5437-5445	supports	_	
25-3	5446-5449	the	_	
25-4	5450-5461	possibility	_	
25-5	5462-5466	that	_	
25-6	5467-5470	the	_	
25-7	5471-5477	reward	_	
25-8	5478-5488	processing	_	
25-9	5489-5496	network	_	
25-10	5497-5502	could	_	
25-11	5503-5505	be	_	
25-12	5506-5517	selectively	_	
25-13	5518-5526	impaired	_	
25-14	5527-5529	in	_	
25-15	5530-5543	schizophrenia	_	
25-16	5543-5544	.	_	

#Text=The question of whether a common dopaminergic abnormality underlies both treatment responsive and treatment resistant schizophrenia remains largely unresolved.
26-1	5545-5548	The	_	
26-2	5549-5557	question	_	
26-3	5558-5560	of	_	
26-4	5561-5568	whether	_	
26-5	5569-5570	a	_	
26-6	5571-5577	common	_	
26-7	5578-5590	dopaminergic	_	
26-8	5591-5602	abnormality	_	
26-9	5603-5612	underlies	_	
26-10	5613-5617	both	_	
26-11	5618-5627	treatment	_	
26-12	5628-5638	responsive	_	
26-13	5639-5642	and	_	
26-14	5643-5652	treatment	_	
26-15	5653-5662	resistant	_	
26-16	5663-5676	schizophrenia	_	
26-17	5677-5684	remains	_	
26-18	5685-5692	largely	_	
26-19	5693-5703	unresolved	_	
26-20	5703-5704	.	_	

#Text=Recent evidence suggests that elevated striatal dopamine synthesis capacity is specific to treatment responsive schizophrenia, whereas anterior cingulate glutamate levels may be selectively increased in TRS.
27-1	5705-5711	Recent	_	
27-2	5712-5720	evidence	_	
27-3	5721-5729	suggests	_	
27-4	5730-5734	that	_	
27-5	5735-5743	elevated	_	
27-6	5744-5752	striatal	_	
27-7	5753-5761	dopamine	_	
27-8	5762-5771	synthesis	_	
27-9	5772-5780	capacity	_	
27-10	5781-5783	is	_	
27-11	5784-5792	specific	_	
27-12	5793-5795	to	_	
27-13	5796-5805	treatment	_	
27-14	5806-5816	responsive	_	
27-15	5817-5830	schizophrenia	_	
27-16	5830-5831	,	_	
27-17	5832-5839	whereas	_	
27-18	5840-5848	anterior	_	
27-19	5849-5858	cingulate	_	
27-20	5859-5868	glutamate	_	
27-21	5869-5875	levels	_	
27-22	5876-5879	may	_	
27-23	5880-5882	be	_	
27-24	5883-5894	selectively	_	
27-25	5895-5904	increased	_	
27-26	5905-5907	in	_	
27-27	5908-5911	TRS	_	
27-28	5911-5912	.	_	

#Text=However, the neural activation associated with dopamine functioning in the context of reinforcement learning has not been explicitly compared between these patient groups.
28-1	5913-5920	However	_	
28-2	5920-5921	,	_	
28-3	5922-5925	the	_	
28-4	5926-5932	neural	_	
28-5	5933-5943	activation	_	
28-6	5944-5954	associated	_	
28-7	5955-5959	with	_	
28-8	5960-5968	dopamine	_	
28-9	5969-5980	functioning	_	
28-10	5981-5983	in	_	
28-11	5984-5987	the	_	
28-12	5988-5995	context	_	
28-13	5996-5998	of	_	
28-14	5999-6012	reinforcement	_	
28-15	6013-6021	learning	_	
28-16	6022-6025	has	_	
28-17	6026-6029	not	_	
28-18	6030-6034	been	_	
28-19	6035-6045	explicitly	_	
28-20	6046-6054	compared	_	
28-21	6055-6062	between	_	
28-22	6063-6068	these	_	
28-23	6069-6076	patient	_	
28-24	6077-6083	groups	_	
28-25	6083-6084	.	_	

#Text=Given the link between dopamine and RPE activation, a normal RPE signature would be expected in TRS if dopamine function is indeed unimpaired in this group.
29-1	6085-6090	Given	_	
29-2	6091-6094	the	_	
29-3	6095-6099	link	_	
29-4	6100-6107	between	_	
29-5	6108-6116	dopamine	_	
29-6	6117-6120	and	_	
29-7	6121-6124	RPE	_	
29-8	6125-6135	activation	_	
29-9	6135-6136	,	_	
29-10	6137-6138	a	_	
29-11	6139-6145	normal	_	
29-12	6146-6149	RPE	_	
29-13	6150-6159	signature	_	
29-14	6160-6165	would	_	
29-15	6166-6168	be	_	
29-16	6169-6177	expected	_	
29-17	6178-6180	in	_	
29-18	6181-6184	TRS	_	
29-19	6185-6187	if	_	
29-20	6188-6196	dopamine	_	
29-21	6197-6205	function	_	
29-22	6206-6208	is	_	
29-23	6209-6215	indeed	_	
29-24	6216-6226	unimpaired	_	
29-25	6227-6229	in	_	
29-26	6230-6234	this	_	
29-27	6235-6240	group	_	
29-28	6240-6241	.	_	

#Text=In contrast, treatment responsive patients would be expected to exhibit the abnormal RPE activation typically associated with schizophrenia.
30-1	6242-6244	In	_	
30-2	6245-6253	contrast	_	
30-3	6253-6254	,	_	
30-4	6255-6264	treatment	_	
30-5	6265-6275	responsive	_	
30-6	6276-6284	patients	_	
30-7	6285-6290	would	_	
30-8	6291-6293	be	_	
30-9	6294-6302	expected	_	
30-10	6303-6305	to	_	
30-11	6306-6313	exhibit	_	
30-12	6314-6317	the	_	
30-13	6318-6326	abnormal	_	
30-14	6327-6330	RPE	_	
30-15	6331-6341	activation	_	
30-16	6342-6351	typically	_	
30-17	6352-6362	associated	_	
30-18	6363-6367	with	_	
30-19	6368-6381	schizophrenia	_	
30-20	6381-6382	.	_	

#Text=Note that behavior may be similarly impaired in the two groups if distinct nodes of the same reward network are differentially impaired.
31-1	6383-6387	Note	_	
31-2	6388-6392	that	_	
31-3	6393-6401	behavior	_	
31-4	6402-6405	may	_	
31-5	6406-6408	be	_	
31-6	6409-6418	similarly	_	
31-7	6419-6427	impaired	_	
31-8	6428-6430	in	_	
31-9	6431-6434	the	_	
31-10	6435-6438	two	_	
31-11	6439-6445	groups	_	
31-12	6446-6448	if	_	
31-13	6449-6457	distinct	_	
31-14	6458-6463	nodes	_	
31-15	6464-6466	of	_	
31-16	6467-6470	the	_	
31-17	6471-6475	same	_	
31-18	6476-6482	reward	_	
31-19	6483-6490	network	_	
31-20	6491-6494	are	_	
31-21	6495-6509	differentially	_	
31-22	6510-6518	impaired	_	
31-23	6518-6519	.	_	

#Text=Reinforcement learning relies not only on striatal dopamine function, but also on complex fronto-striatal interactions regulating related processes such as cognitive control, goal maintenance and planning, as well as action value and effort computations.
32-1	6520-6533	Reinforcement	_	
32-2	6534-6542	learning	_	
32-3	6543-6549	relies	_	
32-4	6550-6553	not	_	
32-5	6554-6558	only	_	
32-6	6559-6561	on	_	
32-7	6562-6570	striatal	_	
32-8	6571-6579	dopamine	_	
32-9	6580-6588	function	_	
32-10	6588-6589	,	_	
32-11	6590-6593	but	_	
32-12	6594-6598	also	_	
32-13	6599-6601	on	_	
32-14	6602-6609	complex	_	
32-15	6610-6625	fronto-striatal	_	
32-16	6626-6638	interactions	_	
32-17	6639-6649	regulating	_	
32-18	6650-6657	related	_	
32-19	6658-6667	processes	_	
32-20	6668-6672	such	_	
32-21	6673-6675	as	_	
32-22	6676-6685	cognitive	_	
32-23	6686-6693	control	_	
32-24	6693-6694	,	_	
32-25	6695-6699	goal	_	
32-26	6700-6711	maintenance	_	
32-27	6712-6715	and	_	
32-28	6716-6724	planning	_	
32-29	6724-6725	,	_	
32-30	6726-6728	as	_	
32-31	6729-6733	well	_	
32-32	6734-6736	as	_	
32-33	6737-6743	action	_	
32-34	6744-6749	value	_	
32-35	6750-6753	and	_	
32-36	6754-6760	effort	_	
32-37	6761-6773	computations	_	
32-38	6773-6774	.	_	

#Text=As bottom-up learning signals are utilized to update a model of the surrounding environment, it is necessary to exert top-down cognitive control-particularly in the presence of persistent cognitive or behavioral bias-in order to optimise task focused learning.
33-1	6775-6777	As	_	
33-2	6778-6787	bottom-up	_	
33-3	6788-6796	learning	_	
33-4	6797-6804	signals	_	
33-5	6805-6808	are	_	
33-6	6809-6817	utilized	_	
33-7	6818-6820	to	_	
33-8	6821-6827	update	_	
33-9	6828-6829	a	_	
33-10	6830-6835	model	_	
33-11	6836-6838	of	_	
33-12	6839-6842	the	_	
33-13	6843-6854	surrounding	_	
33-14	6855-6866	environment	_	
33-15	6866-6867	,	_	
33-16	6868-6870	it	_	
33-17	6871-6873	is	_	
33-18	6874-6883	necessary	_	
33-19	6884-6886	to	_	
33-20	6887-6892	exert	_	
33-21	6893-6901	top-down	_	
33-22	6902-6911	cognitive	_	
33-23	6912-6932	control-particularly	_	
33-24	6933-6935	in	_	
33-25	6936-6939	the	_	
33-26	6940-6948	presence	_	
33-27	6949-6951	of	_	
33-28	6952-6962	persistent	_	
33-29	6963-6972	cognitive	_	
33-30	6973-6975	or	_	
33-31	6976-6986	behavioral	_	
33-32	6987-6994	bias-in	_	
33-33	6995-7000	order	_	
33-34	7001-7003	to	_	
33-35	7004-7012	optimise	_	
33-36	7013-7017	task	_	
33-37	7018-7025	focused	_	
33-38	7026-7034	learning	_	
33-39	7034-7035	.	_	

#Text=As such, it is possible that even with intact RPE signaling, a lack of cognitive control modulating learning processes could lead to a disruption of reinforcement learning.
34-1	7036-7038	As	_	
34-2	7039-7043	such	_	
34-3	7043-7044	,	_	
34-4	7045-7047	it	_	
34-5	7048-7050	is	_	
34-6	7051-7059	possible	_	
34-7	7060-7064	that	_	
34-8	7065-7069	even	_	
34-9	7070-7074	with	_	
34-10	7075-7081	intact	_	
34-11	7082-7085	RPE	_	
34-12	7086-7095	signaling	_	
34-13	7095-7096	,	_	
34-14	7097-7098	a	_	
34-15	7099-7103	lack	_	
34-16	7104-7106	of	_	
34-17	7107-7116	cognitive	_	
34-18	7117-7124	control	_	
34-19	7125-7135	modulating	_	
34-20	7136-7144	learning	_	
34-21	7145-7154	processes	_	
34-22	7155-7160	could	_	
34-23	7161-7165	lead	_	
34-24	7166-7168	to	_	
34-25	7169-7170	a	_	
34-26	7171-7181	disruption	_	
34-27	7182-7184	of	_	
34-28	7185-7198	reinforcement	_	
34-29	7199-7207	learning	_	
34-30	7207-7208	.	_	

#Text=Notably, glutamatergic dysfunction may be associated with these cognitive control deficits in schizophrenia, providing a useful explanatory mechanisms for potential deficits in TRS.
35-1	7209-7216	Notably	_	
35-2	7216-7217	,	_	
35-3	7218-7231	glutamatergic	_	
35-4	7232-7243	dysfunction	_	
35-5	7244-7247	may	_	
35-6	7248-7250	be	_	
35-7	7251-7261	associated	_	
35-8	7262-7266	with	_	
35-9	7267-7272	these	_	
35-10	7273-7282	cognitive	_	
35-11	7283-7290	control	_	
35-12	7291-7299	deficits	_	
35-13	7300-7302	in	_	
35-14	7303-7316	schizophrenia	_	
35-15	7316-7317	,	_	
35-16	7318-7327	providing	_	
35-17	7328-7329	a	_	
35-18	7330-7336	useful	_	
35-19	7337-7348	explanatory	_	
35-20	7349-7359	mechanisms	_	
35-21	7360-7363	for	_	
35-22	7364-7373	potential	_	
35-23	7374-7382	deficits	_	
35-24	7383-7385	in	_	
35-25	7386-7389	TRS	_	
35-26	7389-7390	.	_	

#Text=In this study, we aimed to tap into these processes by quantifying cognitive bias in a reinforcement learning task and observing its modulation of RPE signaling.
36-1	7391-7393	In	_	
36-2	7394-7398	this	_	
36-3	7399-7404	study	_	
36-4	7404-7405	,	_	
36-5	7406-7408	we	_	
36-6	7409-7414	aimed	_	
36-7	7415-7417	to	_	
36-8	7418-7421	tap	_	
36-9	7422-7426	into	_	
36-10	7427-7432	these	_	
36-11	7433-7442	processes	_	
36-12	7443-7445	by	_	
36-13	7446-7457	quantifying	_	
36-14	7458-7467	cognitive	_	
36-15	7468-7472	bias	_	
36-16	7473-7475	in	_	
36-17	7476-7477	a	_	
36-18	7478-7491	reinforcement	_	
36-19	7492-7500	learning	_	
36-20	7501-7505	task	_	
36-21	7506-7509	and	_	
36-22	7510-7519	observing	_	
36-23	7520-7523	its	_	
36-24	7524-7534	modulation	_	
36-25	7535-7537	of	_	
36-26	7538-7541	RPE	_	
36-27	7542-7551	signaling	_	
36-28	7551-7552	.	_	

#Text=We compared treatment resistant and treatment responsive patients with a diagnosis of schizophrenia using fMRI while investigating 1) neural correlates of RPEs during wins and losses and 2) the association of cognitive bias with these learning signals.
37-1	7553-7555	We	_	
37-2	7556-7564	compared	_	
37-3	7565-7574	treatment	_	
37-4	7575-7584	resistant	_	
37-5	7585-7588	and	_	
37-6	7589-7598	treatment	_	
37-7	7599-7609	responsive	_	
37-8	7610-7618	patients	_	
37-9	7619-7623	with	_	
37-10	7624-7625	a	_	
37-11	7626-7635	diagnosis	_	
37-12	7636-7638	of	_	
37-13	7639-7652	schizophrenia	_	
37-14	7653-7658	using	_	
37-15	7659-7663	fMRI	_	
37-16	7664-7669	while	_	
37-17	7670-7683	investigating	_	
37-18	7684-7685	1	_	
37-19	7685-7686	)	_	
37-20	7687-7693	neural	_	
37-21	7694-7704	correlates	_	
37-22	7705-7707	of	_	
37-23	7708-7712	RPEs	_	
37-24	7713-7719	during	_	
37-25	7720-7724	wins	_	
37-26	7725-7728	and	_	
37-27	7729-7735	losses	_	
37-28	7736-7739	and	_	
37-29	7740-7741	2	_	
37-30	7741-7742	)	_	
37-31	7743-7746	the	_	
37-32	7747-7758	association	_	
37-33	7759-7761	of	_	
37-34	7762-7771	cognitive	_	
37-35	7772-7776	bias	_	
37-36	7777-7781	with	_	
37-37	7782-7787	these	_	
37-38	7788-7796	learning	_	
37-39	7797-7804	signals	_	
37-40	7804-7805	.	_	

#Text=Cognitive bias was induced with a probabilistic reinforcement learning task using faces with varying expressions, which is known to elicit a bias towards happy faces in both healthy controls and patients with schizophrenia.
38-1	7806-7815	Cognitive	_	
38-2	7816-7820	bias	_	
38-3	7821-7824	was	_	
38-4	7825-7832	induced	_	
38-5	7833-7837	with	_	
38-6	7838-7839	a	_	
38-7	7840-7853	probabilistic	_	
38-8	7854-7867	reinforcement	_	
38-9	7868-7876	learning	_	
38-10	7877-7881	task	_	
38-11	7882-7887	using	_	
38-12	7888-7893	faces	_	
38-13	7894-7898	with	_	
38-14	7899-7906	varying	_	
38-15	7907-7918	expressions	_	
38-16	7918-7919	,	_	
38-17	7920-7925	which	_	
38-18	7926-7928	is	_	
38-19	7929-7934	known	_	
38-20	7935-7937	to	_	
38-21	7938-7944	elicit	_	
38-22	7945-7946	a	_	
38-23	7947-7951	bias	_	
38-24	7952-7959	towards	_	
38-25	7960-7965	happy	_	
38-26	7966-7971	faces	_	
38-27	7972-7974	in	_	
38-28	7975-7979	both	_	
38-29	7980-7987	healthy	_	
38-30	7988-7996	controls	_	
38-31	7997-8000	and	_	
38-32	8001-8009	patients	_	
38-33	8010-8014	with	_	
38-34	8015-8028	schizophrenia	_	
38-35	8028-8029	.	_	

#Text=We examined RPE signaling separately for wins and losses on this task both because dissociable systems have been suggested for prediction error signaling of rewards and losses and due to evidence that reward and loss processing may be differentially impacted in schizophrenia.
39-1	8030-8032	We	_	
39-2	8033-8041	examined	_	
39-3	8042-8045	RPE	_	
39-4	8046-8055	signaling	_	
39-5	8056-8066	separately	_	
39-6	8067-8070	for	_	
39-7	8071-8075	wins	_	
39-8	8076-8079	and	_	
39-9	8080-8086	losses	_	
39-10	8087-8089	on	_	
39-11	8090-8094	this	_	
39-12	8095-8099	task	_	
39-13	8100-8104	both	_	
39-14	8105-8112	because	_	
39-15	8113-8124	dissociable	_	
39-16	8125-8132	systems	_	
39-17	8133-8137	have	_	
39-18	8138-8142	been	_	
39-19	8143-8152	suggested	_	
39-20	8153-8156	for	_	
39-21	8157-8167	prediction	_	
39-22	8168-8173	error	_	
39-23	8174-8183	signaling	_	
39-24	8184-8186	of	_	
39-25	8187-8194	rewards	_	
39-26	8195-8198	and	_	
39-27	8199-8205	losses	_	
39-28	8206-8209	and	_	
39-29	8210-8213	due	_	
39-30	8214-8216	to	_	
39-31	8217-8225	evidence	_	
39-32	8226-8230	that	_	
39-33	8231-8237	reward	_	
39-34	8238-8241	and	_	
39-35	8242-8246	loss	_	
39-36	8247-8257	processing	_	
39-37	8258-8261	may	_	
39-38	8262-8264	be	_	
39-39	8265-8279	differentially	_	
39-40	8280-8288	impacted	_	
39-41	8289-8291	in	_	
39-42	8292-8305	schizophrenia	_	
39-43	8305-8306	.	_	

#Text=In addition we anticipated that this would more closely reflect variabilities in prediction errors rather than effects of outcome itself.
40-1	8307-8309	In	_	
40-2	8310-8318	addition	_	
40-3	8319-8321	we	_	
40-4	8322-8333	anticipated	_	
40-5	8334-8338	that	_	
40-6	8339-8343	this	_	
40-7	8344-8349	would	_	
40-8	8350-8354	more	_	
40-9	8355-8362	closely	_	
40-10	8363-8370	reflect	_	
40-11	8371-8384	variabilities	_	
40-12	8385-8387	in	_	
40-13	8388-8398	prediction	_	
40-14	8399-8405	errors	_	
40-15	8406-8412	rather	_	
40-16	8413-8417	than	_	
40-17	8418-8425	effects	_	
40-18	8426-8428	of	_	
40-19	8429-8436	outcome	_	
40-20	8437-8443	itself	_	
40-21	8443-8444	.	_	

#Text=Based on the theory that treatment responsive schizophrenia, but not TRS, is characterized by an abnormal dopaminergic signature, we tested the hypothesis that responsive patients would show reduced RPE signaling compared to healthy controls and TRS patients.
41-1	8445-8450	Based	_	
41-2	8451-8453	on	_	
41-3	8454-8457	the	_	
41-4	8458-8464	theory	_	
41-5	8465-8469	that	_	
41-6	8470-8479	treatment	_	
41-7	8480-8490	responsive	_	
41-8	8491-8504	schizophrenia	_	
41-9	8504-8505	,	_	
41-10	8506-8509	but	_	
41-11	8510-8513	not	_	
41-12	8514-8517	TRS	_	
41-13	8517-8518	,	_	
41-14	8519-8521	is	_	
41-15	8522-8535	characterized	_	
41-16	8536-8538	by	_	
41-17	8539-8541	an	_	
41-18	8542-8550	abnormal	_	
41-19	8551-8563	dopaminergic	_	
41-20	8564-8573	signature	_	
41-21	8573-8574	,	_	
41-22	8575-8577	we	_	
41-23	8578-8584	tested	_	
41-24	8585-8588	the	_	
41-25	8589-8599	hypothesis	_	
41-26	8600-8604	that	_	
41-27	8605-8615	responsive	_	
41-28	8616-8624	patients	_	
41-29	8625-8630	would	_	
41-30	8631-8635	show	_	
41-31	8636-8643	reduced	_	
41-32	8644-8647	RPE	_	
41-33	8648-8657	signaling	_	
41-34	8658-8666	compared	_	
41-35	8667-8669	to	_	
41-36	8670-8677	healthy	_	
41-37	8678-8686	controls	_	
41-38	8687-8690	and	_	
41-39	8691-8694	TRS	_	
41-40	8695-8703	patients	_	
41-41	8703-8704	.	_	

#Text=This effect was expected to be particularly pronounced for win outcomes in areas typically associated with RPE signaling and dysfunctions in schizophrenia such as the striatum and thalamus.
42-1	8705-8709	This	_	
42-2	8710-8716	effect	_	
42-3	8717-8720	was	_	
42-4	8721-8729	expected	_	
42-5	8730-8732	to	_	
42-6	8733-8735	be	_	
42-7	8736-8748	particularly	_	
42-8	8749-8759	pronounced	_	
42-9	8760-8763	for	_	
42-10	8764-8767	win	_	
42-11	8768-8776	outcomes	_	
42-12	8777-8779	in	_	
42-13	8780-8785	areas	_	
42-14	8786-8795	typically	_	
42-15	8796-8806	associated	_	
42-16	8807-8811	with	_	
42-17	8812-8815	RPE	_	
42-18	8816-8825	signaling	_	
42-19	8826-8829	and	_	
42-20	8830-8842	dysfunctions	_	
42-21	8843-8845	in	_	
42-22	8846-8859	schizophrenia	_	
42-23	8860-8864	such	_	
42-24	8865-8867	as	_	
42-25	8868-8871	the	_	
42-26	8872-8880	striatum	_	
42-27	8881-8884	and	_	
42-28	8885-8893	thalamus	_	
42-29	8893-8894	.	_	

#Text=An additional exploratory analysis examined whether emotional bias would differentially modulate the neural RPE response in TRS patients compared with both responsive patients and controls.
43-1	8895-8897	An	_	
43-2	8898-8908	additional	_	
43-3	8909-8920	exploratory	_	
43-4	8921-8929	analysis	_	
43-5	8930-8938	examined	_	
43-6	8939-8946	whether	_	
43-7	8947-8956	emotional	_	
43-8	8957-8961	bias	_	
43-9	8962-8967	would	_	
43-10	8968-8982	differentially	_	
43-11	8983-8991	modulate	_	
43-12	8992-8995	the	_	
43-13	8996-9002	neural	_	
43-14	9003-9006	RPE	_	
43-15	9007-9015	response	_	
43-16	9016-9018	in	_	
43-17	9019-9022	TRS	_	
43-18	9023-9031	patients	_	
43-19	9032-9040	compared	_	
43-20	9041-9045	with	_	
43-21	9046-9050	both	_	
43-22	9051-9061	responsive	_	
43-23	9062-9070	patients	_	
43-24	9071-9074	and	_	
43-25	9075-9083	controls	_	
43-26	9083-9084	.	_	

#Text=Methods and materials
#Text=Participants
#Text=The study recruited 42 individuals with a diagnosis of schizophrenia (according to ICD-10 criteria) and 24 healthy controls matched for age, sex, and socioeconomic background consented to participate in this study.
44-1	9085-9092	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-2	9093-9096	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-3	9097-9106	materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-4	9107-9119	Participants	_	
44-5	9120-9123	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-6	9124-9129	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-7	9130-9139	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-8	9140-9142	42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-9	9143-9154	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-10	9155-9159	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-11	9160-9161	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-12	9162-9171	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-13	9172-9174	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-14	9175-9188	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
44-15	9189-9190	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-16	9190-9199	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-17	9200-9202	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-18	9203-9206	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-19	9206-9207	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-20	9207-9209	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-21	9210-9218	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-22	9218-9219	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-23	9220-9223	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-24	9224-9226	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-25	9227-9234	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
44-26	9235-9243	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
44-27	9244-9251	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-28	9252-9255	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-29	9256-9259	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-30	9259-9260	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-31	9261-9264	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-32	9264-9265	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-33	9266-9269	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-34	9270-9283	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-35	9284-9294	background	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-36	9295-9304	consented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-37	9305-9307	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-38	9308-9319	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-39	9320-9322	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-40	9323-9327	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-41	9328-9333	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-42	9333-9334	.	_	

#Text=The patient sample included 21 with treatment resistant schizophrenia (TRS), based on persistent psychotic symptoms as defined as a score of at least 4 (moderate) on at least two positive symptom items of the Positive and Negative Syndrome Scale (PANSS), at least two prior drug trials of 4–6 weeks duration with no clinical improvement, and persistence of illness for longer than five years with no period of good social or occupational functioning.
45-1	9335-9338	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-2	9339-9346	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-3	9347-9353	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-4	9354-9362	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-5	9363-9365	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-6	9366-9370	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-7	9371-9380	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-8	9381-9390	resistant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-9	9391-9404	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-10	9405-9406	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-11	9406-9409	TRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-12	9409-9410	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-13	9410-9411	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-14	9412-9417	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-15	9418-9420	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-16	9421-9431	persistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-17	9432-9441	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-18	9442-9450	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-19	9451-9453	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-20	9454-9461	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-21	9462-9464	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-22	9465-9466	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-23	9467-9472	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-24	9473-9475	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-25	9476-9478	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-26	9479-9484	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-27	9485-9486	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-28	9487-9488	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-29	9488-9496	moderate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-30	9496-9497	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-31	9498-9500	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-32	9501-9503	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-33	9504-9509	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-34	9510-9513	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-35	9514-9522	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-36	9523-9530	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-37	9531-9536	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-38	9537-9539	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-39	9540-9543	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-40	9544-9552	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-41	9553-9556	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-42	9557-9565	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-43	9566-9574	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-44	9575-9580	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-45	9581-9582	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-46	9582-9587	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-47	9587-9588	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[7]	
45-48	9588-9589	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-49	9590-9592	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-50	9593-9598	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-51	9599-9602	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-52	9603-9608	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-53	9609-9613	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-54	9614-9620	trials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-55	9621-9623	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-56	9624-9625	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-57	9625-9626	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-58	9626-9627	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-59	9628-9633	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-60	9634-9642	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-61	9643-9647	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-62	9648-9650	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-63	9651-9659	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-64	9660-9671	improvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-65	9671-9672	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-66	9673-9676	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-67	9677-9688	persistence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-68	9689-9691	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-69	9692-9699	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-70	9700-9703	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-71	9704-9710	longer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-72	9711-9715	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-73	9716-9720	five	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-74	9721-9726	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-75	9727-9731	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-76	9732-9734	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-77	9735-9741	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-78	9742-9744	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-79	9745-9749	good	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-80	9750-9756	social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-81	9757-9759	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-82	9760-9772	occupational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-83	9773-9784	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
45-84	9784-9785	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The latter two criteria were ascertained by reviewing patients’ medical records and self-report of occupational status.
46-1	9786-9789	The	_	
46-2	9790-9796	latter	_	
46-3	9797-9800	two	_	
46-4	9801-9809	criteria	_	
46-5	9810-9814	were	_	
46-6	9815-9826	ascertained	_	
46-7	9827-9829	by	_	
46-8	9830-9839	reviewing	_	
46-9	9840-9848	patients	_	
46-10	9848-9849	’	_	
46-11	9850-9857	medical	_	
46-12	9858-9865	records	_	
46-13	9866-9869	and	_	
46-14	9870-9881	self-report	_	
46-15	9882-9884	of	_	
46-16	9885-9897	occupational	_	
46-17	9898-9904	status	_	
46-18	9904-9905	.	_	

#Text=The remaining 21 patients (NTR) fulfilled criteria for being in symptomatic remission, as defined by a score of 3 or less on all items of the PANSS, these symptoms having been stable for at least 6 months and prescribed a stable dosage of antipsychotic for the previous 6 months.
47-1	9906-9909	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-2	9910-9919	remaining	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-3	9920-9922	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-4	9923-9931	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-5	9932-9933	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-6	9933-9936	NTR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-7	9936-9937	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-8	9938-9947	fulfilled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-9	9948-9956	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-10	9957-9960	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-11	9961-9966	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-12	9967-9969	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-13	9970-9981	symptomatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-14	9982-9991	remission	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-15	9991-9992	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-16	9993-9995	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-17	9996-10003	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-18	10004-10006	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-19	10007-10008	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-20	10009-10014	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-21	10015-10017	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-22	10018-10019	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-23	10020-10022	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-24	10023-10027	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-25	10028-10030	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-26	10031-10034	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-27	10035-10040	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-28	10041-10043	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-29	10044-10047	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-30	10048-10053	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[9]	
47-31	10053-10054	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-32	10055-10060	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-33	10061-10069	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-34	10070-10076	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-35	10077-10081	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-36	10082-10088	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-37	10089-10092	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-38	10093-10095	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-39	10096-10101	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-40	10102-10103	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-41	10104-10110	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-42	10111-10114	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-43	10115-10125	prescribed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-44	10126-10127	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-45	10128-10134	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-46	10135-10141	dosage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-47	10142-10144	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-48	10145-10158	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-49	10159-10162	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-50	10163-10166	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-51	10167-10175	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-52	10176-10177	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-53	10178-10184	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-54	10184-10185	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Current clozapine use was an exclusion criterion for all patients.
48-1	10186-10193	Current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-2	10194-10203	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-3	10204-10207	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-4	10208-10211	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-5	10212-10214	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-6	10215-10224	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-7	10225-10234	criterion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-8	10235-10238	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-9	10239-10242	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-10	10243-10251	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-11	10251-10252	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Exclusion criteria for all subjects were a history of neurological illness, current major physical illness, and drug dependency over the last six months.
49-1	10253-10262	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-2	10263-10271	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-3	10272-10275	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-4	10276-10279	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-5	10280-10288	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-6	10289-10293	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-7	10294-10295	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-8	10296-10303	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-9	10304-10306	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-10	10307-10319	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-11	10320-10327	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-12	10327-10328	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-13	10329-10336	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-14	10337-10342	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-15	10343-10351	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-16	10352-10359	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-17	10359-10360	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-18	10361-10364	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-19	10365-10369	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-20	10370-10380	dependency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-21	10381-10385	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-22	10386-10389	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-23	10390-10394	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-24	10395-10398	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-25	10399-10405	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-26	10405-10406	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Exclusion criteria for HC were a history of psychiatric illness and a first-degree relative having suffered from a psychotic illness.
50-1	10407-10416	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-2	10417-10425	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-3	10426-10429	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-4	10430-10432	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
50-5	10433-10437	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-6	10438-10439	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-7	10440-10447	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-8	10448-10450	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-9	10451-10462	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-10	10463-10470	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-11	10471-10474	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-12	10475-10476	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-13	10477-10489	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-14	10490-10498	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-15	10499-10505	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-16	10506-10514	suffered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-17	10515-10519	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-18	10520-10521	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-19	10522-10531	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-20	10532-10539	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-21	10539-10540	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=All subjects had normal hearing and normal or corrected-to-normal vision.
51-1	10541-10544	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-2	10545-10553	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-3	10554-10557	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-4	10558-10564	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-5	10565-10572	hearing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-6	10573-10576	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-7	10577-10583	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-8	10584-10586	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-9	10587-10606	corrected-to-normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-10	10607-10613	vision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
51-11	10613-10614	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=The two patient groups were matched for age, sex, duration of illness, medication type and dosage.
52-1	10615-10618	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-2	10619-10622	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-3	10623-10630	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-4	10631-10637	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-5	10638-10642	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-6	10643-10650	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-7	10651-10654	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-8	10655-10658	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-9	10658-10659	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-10	10660-10663	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-11	10663-10664	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-12	10665-10673	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-13	10674-10676	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-14	10677-10684	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-15	10684-10685	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-16	10686-10696	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-17	10697-10701	type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-18	10702-10705	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-19	10706-10712	dosage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
52-20	10712-10713	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Intelligence quotient was measured with the two-item Wechsler Abbreviated Scale of Intelligence (WASI).
53-1	10714-10726	Intelligence	_	
53-2	10727-10735	quotient	_	
53-3	10736-10739	was	_	
53-4	10740-10748	measured	_	
53-5	10749-10753	with	_	
53-6	10754-10757	the	_	
53-7	10758-10766	two-item	_	
53-8	10767-10775	Wechsler	_	
53-9	10776-10787	Abbreviated	_	
53-10	10788-10793	Scale	_	
53-11	10794-10796	of	_	
53-12	10797-10809	Intelligence	_	
53-13	10810-10811	(	_	
53-14	10811-10815	WASI	_	
53-15	10815-10816	)	_	
53-16	10816-10817	.	_	

#Text=Chlorpromazine (CPZ) equivalent doses of medications were calculated using conversion tables.
54-1	10818-10832	Chlorpromazine	_	
54-2	10833-10834	(	_	
54-3	10834-10837	CPZ	_	
54-4	10837-10838	)	_	
54-5	10839-10849	equivalent	_	
54-6	10850-10855	doses	_	
54-7	10856-10858	of	_	
54-8	10859-10870	medications	_	
54-9	10871-10875	were	_	
54-10	10876-10886	calculated	_	
54-11	10887-10892	using	_	
54-12	10893-10903	conversion	_	
54-13	10904-10910	tables	_	
54-14	10910-10911	.	_	

#Text=Ethical approval was provided by the London Camberwell St Giles Research and Ethics Committee.
55-1	10912-10919	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-2	10920-10928	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-3	10929-10932	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-4	10933-10941	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-5	10942-10944	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-6	10945-10948	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-7	10949-10955	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-8	10956-10966	Camberwell	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-9	10967-10969	St	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-10	10970-10975	Giles	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-11	10976-10984	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-12	10985-10988	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-13	10989-10995	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-14	10996-11005	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
55-15	11005-11006	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=All participants provided informed written consent and were compensated for their time and travel.
#Text=fMRI procedure
#Text=A schematic of a trial sequence is shown in Supplementary Figure 1.
56-1	11007-11010	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-2	11011-11023	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-3	11024-11032	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-4	11033-11041	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-5	11042-11049	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-6	11050-11057	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-7	11058-11061	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-8	11062-11066	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-9	11067-11078	compensated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-10	11079-11082	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-11	11083-11088	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-12	11089-11093	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-13	11094-11097	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-14	11098-11104	travel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
56-15	11104-11105	.	_	
56-16	11106-11110	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
56-17	11111-11120	procedure	_	
56-18	11121-11122	A	_	
56-19	11123-11132	schematic	_	
56-20	11133-11135	of	_	
56-21	11136-11137	a	_	
56-22	11138-11143	trial	_	
56-23	11144-11152	sequence	_	
56-24	11153-11155	is	_	
56-25	11156-11161	shown	_	
56-26	11162-11164	in	_	
56-27	11165-11178	Supplementary	_	
56-28	11179-11185	Figure	_	
56-29	11186-11187	1	_	
56-30	11187-11188	.	_	

#Text=Subjects underwent a reward learning paradigm consisting of choosing between two simultaneously presented faces, and over a series of iterative trials, learning to identify which of the faces was associated with a higher reward probability.
57-1	11189-11197	Subjects	_	
57-2	11198-11207	underwent	_	
57-3	11208-11209	a	_	
57-4	11210-11216	reward	_	
57-5	11217-11225	learning	_	
57-6	11226-11234	paradigm	_	
57-7	11235-11245	consisting	_	
57-8	11246-11248	of	_	
57-9	11249-11257	choosing	_	
57-10	11258-11265	between	_	
57-11	11266-11269	two	_	
57-12	11270-11284	simultaneously	_	
57-13	11285-11294	presented	_	
57-14	11295-11300	faces	_	
57-15	11300-11301	,	_	
57-16	11302-11305	and	_	
57-17	11306-11310	over	_	
57-18	11311-11312	a	_	
57-19	11313-11319	series	_	
57-20	11320-11322	of	_	
57-21	11323-11332	iterative	_	
57-22	11333-11339	trials	_	
57-23	11339-11340	,	_	
57-24	11341-11349	learning	_	
57-25	11350-11352	to	_	
57-26	11353-11361	identify	_	
57-27	11362-11367	which	_	
57-28	11368-11370	of	_	
57-29	11371-11374	the	_	
57-30	11375-11380	faces	_	
57-31	11381-11384	was	_	
57-32	11385-11395	associated	_	
57-33	11396-11400	with	_	
57-34	11401-11402	a	_	
57-35	11403-11409	higher	_	
57-36	11410-11416	reward	_	
57-37	11417-11428	probability	_	
57-38	11428-11429	.	_	

#Text=Subjects were given the task of maximizing the reward (10p per correct choice) achieved during the task.
58-1	11430-11438	Subjects	_	
58-2	11439-11443	were	_	
58-3	11444-11449	given	_	
58-4	11450-11453	the	_	
58-5	11454-11458	task	_	
58-6	11459-11461	of	_	
58-7	11462-11472	maximizing	_	
58-8	11473-11476	the	_	
58-9	11477-11483	reward	_	
58-10	11484-11485	(	_	
58-11	11485-11488	10p	_	
58-12	11489-11492	per	_	
58-13	11493-11500	correct	_	
58-14	11501-11507	choice	_	
58-15	11507-11508	)	_	
58-16	11509-11517	achieved	_	
58-17	11518-11524	during	_	
58-18	11525-11528	the	_	
58-19	11529-11533	task	_	
58-20	11533-11534	.	_	

#Text=The task screen was viewed via a head-mounted mirror inside the MRI scanner and response selection was via a button box operated by the right index and middle fingers.
59-1	11535-11538	The	_	
59-2	11539-11543	task	_	
59-3	11544-11550	screen	_	
59-4	11551-11554	was	_	
59-5	11555-11561	viewed	_	
59-6	11562-11565	via	_	
59-7	11566-11567	a	_	
59-8	11568-11580	head-mounted	_	
59-9	11581-11587	mirror	_	
59-10	11588-11594	inside	_	
59-11	11595-11598	the	_	
59-12	11599-11602	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
59-13	11603-11610	scanner	_	
59-14	11611-11614	and	_	
59-15	11615-11623	response	_	
59-16	11624-11633	selection	_	
59-17	11634-11637	was	_	
59-18	11638-11641	via	_	
59-19	11642-11643	a	_	
59-20	11644-11650	button	_	
59-21	11651-11654	box	_	
59-22	11655-11663	operated	_	
59-23	11664-11666	by	_	
59-24	11667-11670	the	_	
59-25	11671-11676	right	_	
59-26	11677-11682	index	_	
59-27	11683-11686	and	_	
59-28	11687-11693	middle	_	
59-29	11694-11701	fingers	_	
59-30	11701-11702	.	_	

#Text=The task consisted of four blocks of 30 trials each, during which two faces were presented side by side.
60-1	11703-11706	The	_	
60-2	11707-11711	task	_	
60-3	11712-11721	consisted	_	
60-4	11722-11724	of	_	
60-5	11725-11729	four	_	
60-6	11730-11736	blocks	_	
60-7	11737-11739	of	_	
60-8	11740-11742	30	_	
60-9	11743-11749	trials	_	
60-10	11750-11754	each	_	
60-11	11754-11755	,	_	
60-12	11756-11762	during	_	
60-13	11763-11768	which	_	
60-14	11769-11772	two	_	
60-15	11773-11778	faces	_	
60-16	11779-11783	were	_	
60-17	11784-11793	presented	_	
60-18	11794-11798	side	_	
60-19	11799-11801	by	_	
60-20	11802-11806	side	_	
60-21	11806-11807	.	_	

#Text=One face was associated with a 60% reward probability and the other with a 40% reward probability.
61-1	11808-11811	One	_	
61-2	11812-11816	face	_	
61-3	11817-11820	was	_	
61-4	11821-11831	associated	_	
61-5	11832-11836	with	_	
61-6	11837-11838	a	_	
61-7	11839-11842	60%	_	
61-8	11843-11849	reward	_	
61-9	11850-11861	probability	_	
61-10	11862-11865	and	_	
61-11	11866-11869	the	_	
61-12	11870-11875	other	_	
61-13	11876-11880	with	_	
61-14	11881-11882	a	_	
61-15	11883-11886	40%	_	
61-16	11887-11893	reward	_	
61-17	11894-11905	probability	_	
61-18	11905-11906	.	_	

#Text=Faces within a block differed either in emotional expression (blocks 1 and 3) or identity (blocks 2 and 4), as described previously.
62-1	11907-11912	Faces	_	
62-2	11913-11919	within	_	
62-3	11920-11921	a	_	
62-4	11922-11927	block	_	
62-5	11928-11936	differed	_	
62-6	11937-11943	either	_	
62-7	11944-11946	in	_	
62-8	11947-11956	emotional	_	
62-9	11957-11967	expression	_	
62-10	11968-11969	(	_	
62-11	11969-11975	blocks	_	
62-12	11976-11977	1	_	
62-13	11978-11981	and	_	
62-14	11982-11983	3	_	
62-15	11983-11984	)	_	
62-16	11985-11987	or	_	
62-17	11988-11996	identity	_	
62-18	11997-11998	(	_	
62-19	11998-12004	blocks	_	
62-20	12005-12006	2	_	
62-21	12007-12010	and	_	
62-22	12011-12012	4	_	
62-23	12012-12013	)	_	
62-24	12013-12014	,	_	
62-25	12015-12017	as	_	
62-26	12018-12027	described	_	
62-27	12028-12038	previously	_	
62-28	12038-12039	.	_	

#Text=In brief, emotional blocks consisted of one happy and one angry face with the same identity.
63-1	12040-12042	In	_	
63-2	12043-12048	brief	_	
63-3	12048-12049	,	_	
63-4	12050-12059	emotional	_	
63-5	12060-12066	blocks	_	
63-6	12067-12076	consisted	_	
63-7	12077-12079	of	_	
63-8	12080-12083	one	_	
63-9	12084-12089	happy	_	
63-10	12090-12093	and	_	
63-11	12094-12097	one	_	
63-12	12098-12103	angry	_	
63-13	12104-12108	face	_	
63-14	12109-12113	with	_	
63-15	12114-12117	the	_	
63-16	12118-12122	same	_	
63-17	12123-12131	identity	_	
63-18	12131-12132	.	_	

#Text=Neutral blocks consistent of two faces with different identities but with neutral expressions.
64-1	12133-12140	Neutral	_	
64-2	12141-12147	blocks	_	
64-3	12148-12158	consistent	_	
64-4	12159-12161	of	_	
64-5	12162-12165	two	_	
64-6	12166-12171	faces	_	
64-7	12172-12176	with	_	
64-8	12177-12186	different	_	
64-9	12187-12197	identities	_	
64-10	12198-12201	but	_	
64-11	12202-12206	with	_	
64-12	12207-12214	neutral	_	
64-13	12215-12226	expressions	_	
64-14	12226-12227	.	_	

#Text=Combinations of identities and reward contingencies were counterbalanced across blocks and subjects.
65-1	12228-12240	Combinations	_	
65-2	12241-12243	of	_	
65-3	12244-12254	identities	_	
65-4	12255-12258	and	_	
65-5	12259-12265	reward	_	
65-6	12266-12279	contingencies	_	
65-7	12280-12284	were	_	
65-8	12285-12300	counterbalanced	_	
65-9	12301-12307	across	_	
65-10	12308-12314	blocks	_	
65-11	12315-12318	and	_	
65-12	12319-12327	subjects	_	
65-13	12327-12328	.	_	

#Text=Each trial began with a period of 1000 ms during which a white central fixation cross was presented against a dark background.
66-1	12329-12333	Each	_	
66-2	12334-12339	trial	_	
66-3	12340-12345	began	_	
66-4	12346-12350	with	_	
66-5	12351-12352	a	_	
66-6	12353-12359	period	_	
66-7	12360-12362	of	_	
66-8	12363-12367	1000	_	
66-9	12368-12370	ms	_	
66-10	12371-12377	during	_	
66-11	12378-12383	which	_	
66-12	12384-12385	a	_	
66-13	12386-12391	white	_	
66-14	12392-12399	central	_	
66-15	12400-12408	fixation	_	
66-16	12409-12414	cross	_	
66-17	12415-12418	was	_	
66-18	12419-12428	presented	_	
66-19	12429-12436	against	_	
66-20	12437-12438	a	_	
66-21	12439-12443	dark	_	
66-22	12444-12454	background	_	
66-23	12454-12455	.	_	

#Text=This was followed by two faces being presented to the right and left of the fixation cross for 4500 ms.
67-1	12456-12460	This	_	
67-2	12461-12464	was	_	
67-3	12465-12473	followed	_	
67-4	12474-12476	by	_	
67-5	12477-12480	two	_	
67-6	12481-12486	faces	_	
67-7	12487-12492	being	_	
67-8	12493-12502	presented	_	
67-9	12503-12505	to	_	
67-10	12506-12509	the	_	
67-11	12510-12515	right	_	
67-12	12516-12519	and	_	
67-13	12520-12524	left	_	
67-14	12525-12527	of	_	
67-15	12528-12531	the	_	
67-16	12532-12540	fixation	_	
67-17	12541-12546	cross	_	
67-18	12547-12550	for	_	
67-19	12551-12555	4500	_	
67-20	12556-12558	ms	_	
67-21	12558-12559	.	_	

#Text=Within this time window subjects were required to select one of the faces by pressing the corresponding button with their right hand.
68-1	12560-12566	Within	_	
68-2	12567-12571	this	_	
68-3	12572-12576	time	_	
68-4	12577-12583	window	_	
68-5	12584-12592	subjects	_	
68-6	12593-12597	were	_	
68-7	12598-12606	required	_	
68-8	12607-12609	to	_	
68-9	12610-12616	select	_	
68-10	12617-12620	one	_	
68-11	12621-12623	of	_	
68-12	12624-12627	the	_	
68-13	12628-12633	faces	_	
68-14	12634-12636	by	_	
68-15	12637-12645	pressing	_	
68-16	12646-12649	the	_	
68-17	12650-12663	corresponding	_	
68-18	12664-12670	button	_	
68-19	12671-12675	with	_	
68-20	12676-12681	their	_	
68-21	12682-12687	right	_	
68-22	12688-12692	hand	_	
68-23	12692-12693	.	_	

#Text=The selected face was highlighted by a yellow square surrounding it.
69-1	12694-12697	The	_	
69-2	12698-12706	selected	_	
69-3	12707-12711	face	_	
69-4	12712-12715	was	_	
69-5	12716-12727	highlighted	_	
69-6	12728-12730	by	_	
69-7	12731-12732	a	_	
69-8	12733-12739	yellow	_	
69-9	12740-12746	square	_	
69-10	12747-12758	surrounding	_	
69-11	12759-12761	it	_	
69-12	12761-12762	.	_	

#Text=Feedback was then presented on the screen for 1500 ms.
70-1	12763-12771	Feedback	_	
70-2	12772-12775	was	_	
70-3	12776-12780	then	_	
70-4	12781-12790	presented	_	
70-5	12791-12793	on	_	
70-6	12794-12797	the	_	
70-7	12798-12804	screen	_	
70-8	12805-12808	for	_	
70-9	12809-12813	1500	_	
70-10	12814-12816	ms	_	
70-11	12816-12817	.	_	

#Text=The task had a total duration of approximately 15 minutes.
71-1	12818-12821	The	_	
71-2	12822-12826	task	_	
71-3	12827-12830	had	_	
71-4	12831-12832	a	_	
71-5	12833-12838	total	_	
71-6	12839-12847	duration	_	
71-7	12848-12850	of	_	
71-8	12851-12864	approximately	_	
71-9	12865-12867	15	_	
71-10	12868-12875	minutes	_	
71-11	12875-12876	.	_	

#Text=Scanning parameters
#Text=Functional scans were acquired using a T2* echo planar sequence (430 volumes, TR=2000 ms, TE=35 ms, field of view = 24 cm, slice thickness = 3 mm, matrix = 64 × 64, flip angle = 75°) sensitive to blood oxygenation level-dependent (BOLD) contrast on a 3T GE Excite II MR scanner (GE Healthcare, USA).
72-1	12877-12885	Scanning	_	
72-2	12886-12896	parameters	_	
72-3	12897-12907	Functional	_	
72-4	12908-12913	scans	_	
72-5	12914-12918	were	_	
72-6	12919-12927	acquired	_	
72-7	12928-12933	using	_	
72-8	12934-12935	a	_	
72-9	12936-12938	T2	_	
72-10	12938-12939	*	_	
72-11	12940-12944	echo	_	
72-12	12945-12951	planar	_	
72-13	12952-12960	sequence	_	
72-14	12961-12962	(	_	
72-15	12962-12965	430	_	
72-16	12966-12973	volumes	_	
72-17	12973-12974	,	_	
72-18	12975-12977	TR	_	
72-19	12977-12978	=	_	
72-20	12978-12982	2000	_	
72-21	12983-12985	ms	_	
72-22	12985-12986	,	_	
72-23	12987-12989	TE	_	
72-24	12989-12990	=	_	
72-25	12990-12992	35	_	
72-26	12993-12995	ms	_	
72-27	12995-12996	,	_	
72-28	12997-13002	field	_	
72-29	13003-13005	of	_	
72-30	13006-13010	view	_	
72-31	13011-13012	=	_	
72-32	13013-13015	24	_	
72-33	13016-13018	cm	_	
72-34	13018-13019	,	_	
72-35	13020-13025	slice	_	
72-36	13026-13035	thickness	_	
72-37	13036-13037	=	_	
72-38	13038-13039	3	_	
72-39	13040-13042	mm	_	
72-40	13042-13043	,	_	
72-41	13044-13050	matrix	_	
72-42	13051-13052	=	_	
72-43	13053-13055	64	_	
72-44	13056-13057	×	_	
72-45	13058-13060	64	_	
72-46	13060-13061	,	_	
72-47	13062-13066	flip	_	
72-48	13067-13072	angle	_	
72-49	13073-13074	=	_	
72-50	13075-13077	75	_	
72-51	13077-13078	°	_	
72-52	13078-13079	)	_	
72-53	13080-13089	sensitive	_	
72-54	13090-13092	to	_	
72-55	13093-13098	blood	_	
72-56	13099-13110	oxygenation	_	
72-57	13111-13126	level-dependent	_	
72-58	13127-13128	(	_	
72-59	13128-13132	BOLD	_	
72-60	13132-13133	)	_	
72-61	13134-13142	contrast	_	
72-62	13143-13145	on	_	
72-63	13146-13147	a	_	
72-64	13148-13150	3T	_	
72-65	13151-13153	GE	_	
72-66	13154-13160	Excite	_	
72-67	13161-13163	II	_	
72-68	13164-13166	MR	_	
72-69	13167-13174	scanner	_	
72-70	13175-13176	(	_	
72-71	13176-13178	GE	_	
72-72	13179-13189	Healthcare	_	
72-73	13189-13190	,	_	
72-74	13191-13194	USA	_	
72-75	13194-13195	)	_	
72-76	13195-13196	.	_	

#Text=A structural image was acquired for each subject with a T1-weighted magnetization prepared rapid acquisition gradient echo (MP RAGE) sequence (TR=7321 ms, TE=3 ms, TI = 400 ms, field of view = 240, slice thickness = 1.2 mm, 196 slices).
73-1	13197-13198	A	_	
73-2	13199-13209	structural	_	
73-3	13210-13215	image	_	
73-4	13216-13219	was	_	
73-5	13220-13228	acquired	_	
73-6	13229-13232	for	_	
73-7	13233-13237	each	_	
73-8	13238-13245	subject	_	
73-9	13246-13250	with	_	
73-10	13251-13252	a	_	
73-11	13253-13255	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
73-12	13255-13256	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
73-13	13256-13264	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]	
73-14	13265-13278	magnetization	_	
73-15	13279-13287	prepared	_	
73-16	13288-13293	rapid	_	
73-17	13294-13305	acquisition	_	
73-18	13306-13314	gradient	_	
73-19	13315-13319	echo	_	
73-20	13320-13321	(	_	
73-21	13321-13323	MP	_	
73-22	13324-13328	RAGE	_	
73-23	13328-13329	)	_	
73-24	13330-13338	sequence	_	
73-25	13339-13340	(	_	
73-26	13340-13342	TR	_	
73-27	13342-13343	=	_	
73-28	13343-13347	7321	_	
73-29	13348-13350	ms	_	
73-30	13350-13351	,	_	
73-31	13352-13354	TE	_	
73-32	13354-13355	=	_	
73-33	13355-13356	3	_	
73-34	13357-13359	ms	_	
73-35	13359-13360	,	_	
73-36	13361-13363	TI	_	
73-37	13364-13365	=	_	
73-38	13366-13369	400	_	
73-39	13370-13372	ms	_	
73-40	13372-13373	,	_	
73-41	13374-13379	field	_	
73-42	13380-13382	of	_	
73-43	13383-13387	view	_	
73-44	13388-13389	=	_	
73-45	13390-13393	240	_	
73-46	13393-13394	,	_	
73-47	13395-13400	slice	_	
73-48	13401-13410	thickness	_	
73-49	13411-13412	=	_	
73-50	13413-13416	1.2	_	
73-51	13417-13419	mm	_	
73-52	13419-13420	,	_	
73-53	13421-13424	196	_	
73-54	13425-13431	slices	_	
73-55	13431-13432	)	_	
73-56	13432-13433	.	_	

#Text=Reinforcement learning model
#Text=The behavioural data was modelled using a “double update” reinforcement learning model.
74-1	13434-13447	Reinforcement	_	
74-2	13448-13456	learning	_	
74-3	13457-13462	model	_	
74-4	13463-13466	The	_	
74-5	13467-13478	behavioural	_	
74-6	13479-13483	data	_	
74-7	13484-13487	was	_	
74-8	13488-13496	modelled	_	
74-9	13497-13502	using	_	
74-10	13503-13504	a	_	
74-11	13505-13506	“	_	
74-12	13506-13512	double	_	
74-13	13513-13519	update	_	
74-14	13519-13520	”	_	
74-15	13521-13534	reinforcement	_	
74-16	13535-13543	learning	_	
74-17	13544-13549	model	_	
74-18	13549-13550	.	_	

#Text=Choice probability for choosing option 1 on trial t was computed on each trial using the softmax function  where the inverse temperature β determines the randomness of the subject’s choice, and Q1(t) denotes the action value, or expected reward, for choice 1 on trial t.
75-1	13551-13557	Choice	_	
75-2	13558-13569	probability	_	
75-3	13570-13573	for	_	
75-4	13574-13582	choosing	_	
75-5	13583-13589	option	_	
75-6	13590-13591	1	_	
75-7	13592-13594	on	_	
75-8	13595-13600	trial	_	
75-9	13601-13602	t	_	
75-10	13603-13606	was	_	
75-11	13607-13615	computed	_	
75-12	13616-13618	on	_	
75-13	13619-13623	each	_	
75-14	13624-13629	trial	_	
75-15	13630-13635	using	_	
75-16	13636-13639	the	_	
75-17	13640-13647	softmax	_	
75-18	13648-13656	function	_	
75-19	13658-13663	where	_	
75-20	13664-13667	the	_	
75-21	13668-13675	inverse	_	
75-22	13676-13687	temperature	_	
75-23	13688-13689	β	_	
75-24	13690-13700	determines	_	
75-25	13701-13704	the	_	
75-26	13705-13715	randomness	_	
75-27	13716-13718	of	_	
75-28	13719-13722	the	_	
75-29	13723-13730	subject	_	
75-30	13730-13731	’	_	
75-31	13731-13732	s	_	
75-32	13733-13739	choice	_	
75-33	13739-13740	,	_	
75-34	13741-13744	and	_	
75-35	13745-13747	Q1	_	
75-36	13747-13748	(	_	
75-37	13748-13749	t	_	
75-38	13749-13750	)	_	
75-39	13751-13758	denotes	_	
75-40	13759-13762	the	_	
75-41	13763-13769	action	_	
75-42	13770-13775	value	_	
75-43	13775-13776	,	_	
75-44	13777-13779	or	_	
75-45	13780-13788	expected	_	
75-46	13789-13795	reward	_	
75-47	13795-13796	,	_	
75-48	13797-13800	for	_	
75-49	13801-13807	choice	_	
75-50	13808-13809	1	_	
75-51	13810-13812	on	_	
75-52	13813-13818	trial	_	
75-53	13819-13820	t	_	
75-54	13820-13821	.	_	

#Text=The action value for the chosen option is updated on a trial-by-trial basis using the reward prediction error, defined as the difference between the expected reward Q and obtained reward R on trial t, scaled by the learning rate parameter α.
76-1	13822-13825	The	_	
76-2	13826-13832	action	_	
76-3	13833-13838	value	_	
76-4	13839-13842	for	_	
76-5	13843-13846	the	_	
76-6	13847-13853	chosen	_	
76-7	13854-13860	option	_	
76-8	13861-13863	is	_	
76-9	13864-13871	updated	_	
76-10	13872-13874	on	_	
76-11	13875-13876	a	_	
76-12	13877-13891	trial-by-trial	_	
76-13	13892-13897	basis	_	
76-14	13898-13903	using	_	
76-15	13904-13907	the	_	
76-16	13908-13914	reward	_	
76-17	13915-13925	prediction	_	
76-18	13926-13931	error	_	
76-19	13931-13932	,	_	
76-20	13933-13940	defined	_	
76-21	13941-13943	as	_	
76-22	13944-13947	the	_	
76-23	13948-13958	difference	_	
76-24	13959-13966	between	_	
76-25	13967-13970	the	_	
76-26	13971-13979	expected	_	
76-27	13980-13986	reward	_	
76-28	13987-13988	Q	_	
76-29	13989-13992	and	_	
76-30	13993-14001	obtained	_	
76-31	14002-14008	reward	_	
76-32	14009-14010	R	_	
76-33	14011-14013	on	_	
76-34	14014-14019	trial	_	
76-35	14020-14021	t	_	
76-36	14021-14022	,	_	
76-37	14023-14029	scaled	_	
76-38	14030-14032	by	_	
76-39	14033-14036	the	_	
76-40	14037-14045	learning	_	
76-41	14046-14050	rate	_	
76-42	14051-14060	parameter	_	
76-43	14061-14062	α	_	
76-44	14062-14063	.	_	

#Text=The action value for the unchosen option 2 was additionally updated on each trial, using the inverse reward value and identical learning rate parameter: 
#Text=This model reflects the symmetry of choice outcomes, whereby feedback associated with a chosen option is also informative of the unchosen option (e.g., if stimulus 1 lost, stimulus 2 would have won).
77-1	14064-14067	The	_	
77-2	14068-14074	action	_	
77-3	14075-14080	value	_	
77-4	14081-14084	for	_	
77-5	14085-14088	the	_	
77-6	14089-14097	unchosen	_	
77-7	14098-14104	option	_	
77-8	14105-14106	2	_	
77-9	14107-14110	was	_	
77-10	14111-14123	additionally	_	
77-11	14124-14131	updated	_	
77-12	14132-14134	on	_	
77-13	14135-14139	each	_	
77-14	14140-14145	trial	_	
77-15	14145-14146	,	_	
77-16	14147-14152	using	_	
77-17	14153-14156	the	_	
77-18	14157-14164	inverse	_	
77-19	14165-14171	reward	_	
77-20	14172-14177	value	_	
77-21	14178-14181	and	_	
77-22	14182-14191	identical	_	
77-23	14192-14200	learning	_	
77-24	14201-14205	rate	_	
77-25	14206-14215	parameter	_	
77-26	14215-14216	:	_	
77-27	14218-14222	This	_	
77-28	14223-14228	model	_	
77-29	14229-14237	reflects	_	
77-30	14238-14241	the	_	
77-31	14242-14250	symmetry	_	
77-32	14251-14253	of	_	
77-33	14254-14260	choice	_	
77-34	14261-14269	outcomes	_	
77-35	14269-14270	,	_	
77-36	14271-14278	whereby	_	
77-37	14279-14287	feedback	_	
77-38	14288-14298	associated	_	
77-39	14299-14303	with	_	
77-40	14304-14305	a	_	
77-41	14306-14312	chosen	_	
77-42	14313-14319	option	_	
77-43	14320-14322	is	_	
77-44	14323-14327	also	_	
77-45	14328-14339	informative	_	
77-46	14340-14342	of	_	
77-47	14343-14346	the	_	
77-48	14347-14355	unchosen	_	
77-49	14356-14362	option	_	
77-50	14363-14364	(	_	
77-51	14364-14367	e.g	_	
77-52	14367-14368	.	_	
77-53	14368-14369	,	_	
77-54	14370-14372	if	_	
77-55	14373-14381	stimulus	_	
77-56	14382-14383	1	_	
77-57	14384-14388	lost	_	
77-58	14388-14389	,	_	
77-59	14390-14398	stimulus	_	
77-60	14399-14400	2	_	
77-61	14401-14406	would	_	
77-62	14407-14411	have	_	
77-63	14412-14415	won	_	
77-64	14415-14416	)	_	
77-65	14416-14417	.	_	

#Text=The two free parameters β and α were estimated for each group separately by minimizing the negative log likelihood of the observed data pooled across all subjects within the group.
78-1	14418-14421	The	_	
78-2	14422-14425	two	_	
78-3	14426-14430	free	_	
78-4	14431-14441	parameters	_	
78-5	14442-14443	β	_	
78-6	14444-14447	and	_	
78-7	14448-14449	α	_	
78-8	14450-14454	were	_	
78-9	14455-14464	estimated	_	
78-10	14465-14468	for	_	
78-11	14469-14473	each	_	
78-12	14474-14479	group	_	
78-13	14480-14490	separately	_	
78-14	14491-14493	by	_	
78-15	14494-14504	minimizing	_	
78-16	14505-14508	the	_	
78-17	14509-14517	negative	_	
78-18	14518-14521	log	_	
78-19	14522-14532	likelihood	_	
78-20	14533-14535	of	_	
78-21	14536-14539	the	_	
78-22	14540-14548	observed	_	
78-23	14549-14553	data	_	
78-24	14554-14560	pooled	_	
78-25	14561-14567	across	_	
78-26	14568-14571	all	_	
78-27	14572-14580	subjects	_	
78-28	14581-14587	within	_	
78-29	14588-14591	the	_	
78-30	14592-14597	group	_	
78-31	14597-14598	.	_	

#Text=Behavioural analysis
#Text=Choices were defined as ideal if the action value (computed by the model) of the chosen option was greater than that of the unchosen option.
79-1	14599-14610	Behavioural	_	
79-2	14611-14619	analysis	_	
79-3	14620-14627	Choices	_	
79-4	14628-14632	were	_	
79-5	14633-14640	defined	_	
79-6	14641-14643	as	_	
79-7	14644-14649	ideal	_	
79-8	14650-14652	if	_	
79-9	14653-14656	the	_	
79-10	14657-14663	action	_	
79-11	14664-14669	value	_	
79-12	14670-14671	(	_	
79-13	14671-14679	computed	_	
79-14	14680-14682	by	_	
79-15	14683-14686	the	_	
79-16	14687-14692	model	_	
79-17	14692-14693	)	_	
79-18	14694-14696	of	_	
79-19	14697-14700	the	_	
79-20	14701-14707	chosen	_	
79-21	14708-14714	option	_	
79-22	14715-14718	was	_	
79-23	14719-14726	greater	_	
79-24	14727-14731	than	_	
79-25	14732-14736	that	_	
79-26	14737-14739	of	_	
79-27	14740-14743	the	_	
79-28	14744-14752	unchosen	_	
79-29	14753-14759	option	_	
79-30	14759-14760	.	_	

#Text=Subjects’ proportions of ideal choices were analysed using a linear mixed effects model including the predictors group (HC vs.
80-1	14761-14769	Subjects	_	
80-2	14769-14770	’	_	
80-3	14771-14782	proportions	_	
80-4	14783-14785	of	_	
80-5	14786-14791	ideal	_	
80-6	14792-14799	choices	_	
80-7	14800-14804	were	_	
80-8	14805-14813	analysed	_	
80-9	14814-14819	using	_	
80-10	14820-14821	a	_	
80-11	14822-14828	linear	_	
80-12	14829-14834	mixed	_	
80-13	14835-14842	effects	_	
80-14	14843-14848	model	_	
80-15	14849-14858	including	_	
80-16	14859-14862	the	_	
80-17	14863-14873	predictors	_	
80-18	14874-14879	group	_	
80-19	14880-14881	(	_	
80-20	14881-14883	HC	_	
80-21	14884-14886	vs	_	
80-22	14886-14887	.	_	

#Text=NTR vs.
81-1	14888-14891	NTR	_	
81-2	14892-14894	vs	_	
81-3	14894-14895	.	_	

#Text=TRS) and condition (emotional vs. neutral)
#Text=Emotional bias was defined as the difference between the proportion of choices for the happy face when the angry face would have been an ideal choice, and proportion of choices for the angry face when the happy face would have been the ideal choice.
82-1	14896-14899	TRS	_	
82-2	14899-14900	)	_	
82-3	14901-14904	and	_	
82-4	14905-14914	condition	_	
82-5	14915-14916	(	_	
82-6	14916-14925	emotional	_	
82-7	14926-14928	vs	_	
82-8	14928-14929	.	_	
82-9	14930-14937	neutral	_	
82-10	14937-14938	)	_	
82-11	14939-14948	Emotional	_	
82-12	14949-14953	bias	_	
82-13	14954-14957	was	_	
82-14	14958-14965	defined	_	
82-15	14966-14968	as	_	
82-16	14969-14972	the	_	
82-17	14973-14983	difference	_	
82-18	14984-14991	between	_	
82-19	14992-14995	the	_	
82-20	14996-15006	proportion	_	
82-21	15007-15009	of	_	
82-22	15010-15017	choices	_	
82-23	15018-15021	for	_	
82-24	15022-15025	the	_	
82-25	15026-15031	happy	_	
82-26	15032-15036	face	_	
82-27	15037-15041	when	_	
82-28	15042-15045	the	_	
82-29	15046-15051	angry	_	
82-30	15052-15056	face	_	
82-31	15057-15062	would	_	
82-32	15063-15067	have	_	
82-33	15068-15072	been	_	
82-34	15073-15075	an	_	
82-35	15076-15081	ideal	_	
82-36	15082-15088	choice	_	
82-37	15088-15089	,	_	
82-38	15090-15093	and	_	
82-39	15094-15104	proportion	_	
82-40	15105-15107	of	_	
82-41	15108-15115	choices	_	
82-42	15116-15119	for	_	
82-43	15120-15123	the	_	
82-44	15124-15129	angry	_	
82-45	15130-15134	face	_	
82-46	15135-15139	when	_	
82-47	15140-15143	the	_	
82-48	15144-15149	happy	_	
82-49	15150-15154	face	_	
82-50	15155-15160	would	_	
82-51	15161-15165	have	_	
82-52	15166-15170	been	_	
82-53	15171-15174	the	_	
82-54	15175-15180	ideal	_	
82-55	15181-15187	choice	_	
82-56	15187-15188	.	_	

#Text=Emotional bias was compared between groups using one-way ANOVA.
#Text=fMRI preprocessing and analysis
#Text=The fMRI data were preprocessed and analyzed using the FEAT tool from the FMRIB Software Library (FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/,).
83-1	15189-15198	Emotional	_	
83-2	15199-15203	bias	_	
83-3	15204-15207	was	_	
83-4	15208-15216	compared	_	
83-5	15217-15224	between	_	
83-6	15225-15231	groups	_	
83-7	15232-15237	using	_	
83-8	15238-15245	one-way	_	
83-9	15246-15251	ANOVA	_	
83-10	15251-15252	.	_	
83-11	15253-15257	fMRI	_	
83-12	15258-15271	preprocessing	_	
83-13	15272-15275	and	_	
83-14	15276-15284	analysis	_	
83-15	15285-15288	The	_	
83-16	15289-15293	fMRI	_	
83-17	15294-15298	data	_	
83-18	15299-15303	were	_	
83-19	15304-15316	preprocessed	_	
83-20	15317-15320	and	_	
83-21	15321-15329	analyzed	_	
83-22	15330-15335	using	_	
83-23	15336-15339	the	_	
83-24	15340-15344	FEAT	_	
83-25	15345-15349	tool	_	
83-26	15350-15354	from	_	
83-27	15355-15358	the	_	
83-28	15359-15364	FMRIB	_	
83-29	15365-15373	Software	_	
83-30	15374-15381	Library	_	
83-31	15382-15383	(	_	
83-32	15383-15386	FSL	_	
83-33	15386-15387	,	_	
83-34	15388-15392	http	_	
83-35	15392-15393	:	_	
83-36	15393-15394	/	_	
83-37	15394-15395	/	_	
83-38	15395-15413	fsl.fmrib.ox.ac.uk	_	
83-39	15413-15414	/	_	
83-40	15414-15417	fsl	_	
83-41	15417-15418	/	_	
83-42	15418-15425	fslwiki	_	
83-43	15425-15426	/	_	
83-44	15426-15427	,	_	
83-45	15427-15428	)	_	
83-46	15428-15429	.	_	

#Text=Functional and structural brain images were extracted from non-brain tissue using FSL’s brain extraction tool (BET), and EPI images were realigned using MCFLIRT to correct effects of head motion.
84-1	15430-15440	Functional	_	
84-2	15441-15444	and	_	
84-3	15445-15455	structural	_	
84-4	15456-15461	brain	_	
84-5	15462-15468	images	_	
84-6	15469-15473	were	_	
84-7	15474-15483	extracted	_	
84-8	15484-15488	from	_	
84-9	15489-15498	non-brain	_	
84-10	15499-15505	tissue	_	
84-11	15506-15511	using	_	
84-12	15512-15515	FSL	_	
84-13	15515-15516	’	_	
84-14	15516-15517	s	_	
84-15	15518-15523	brain	_	
84-16	15524-15534	extraction	_	
84-17	15535-15539	tool	_	
84-18	15540-15541	(	_	
84-19	15541-15544	BET	_	
84-20	15544-15545	)	_	
84-21	15545-15546	,	_	
84-22	15547-15550	and	_	
84-23	15551-15554	EPI	_	
84-24	15555-15561	images	_	
84-25	15562-15566	were	_	
84-26	15567-15576	realigned	_	
84-27	15577-15582	using	_	
84-28	15583-15590	MCFLIRT	_	
84-29	15591-15593	to	_	
84-30	15594-15601	correct	_	
84-31	15602-15609	effects	_	
84-32	15610-15612	of	_	
84-33	15613-15617	head	_	
84-34	15618-15624	motion	_	
84-35	15624-15625	.	_	

#Text=A 100-s temporal high-pass filter was applied and data were spatially smoothed using a Gaussian kernel of 5mm FWHM.
85-1	15626-15627	A	_	
85-2	15628-15631	100	_	
85-3	15631-15632	-	_	
85-4	15632-15633	s	_	
85-5	15634-15642	temporal	_	
85-6	15643-15652	high-pass	_	
85-7	15653-15659	filter	_	
85-8	15660-15663	was	_	
85-9	15664-15671	applied	_	
85-10	15672-15675	and	_	
85-11	15676-15680	data	_	
85-12	15681-15685	were	_	
85-13	15686-15695	spatially	_	
85-14	15696-15704	smoothed	_	
85-15	15705-15710	using	_	
85-16	15711-15712	a	_	
85-17	15713-15721	Gaussian	_	
85-18	15722-15728	kernel	_	
85-19	15729-15731	of	_	
85-20	15732-15735	5mm	_	
85-21	15736-15740	FWHM	_	
85-22	15740-15741	.	_	

#Text=The functional MRI data were analyzed using the general linear model as implemented in FSL FEAT.
86-1	15742-15745	The	_	
86-2	15746-15756	functional	_	
86-3	15757-15760	MRI	_	
86-4	15761-15765	data	_	
86-5	15766-15770	were	_	
86-6	15771-15779	analyzed	_	
86-7	15780-15785	using	_	
86-8	15786-15789	the	_	
86-9	15790-15797	general	_	
86-10	15798-15804	linear	_	
86-11	15805-15810	model	_	
86-12	15811-15813	as	_	
86-13	15814-15825	implemented	_	
86-14	15826-15828	in	_	
86-15	15829-15832	FSL	_	
86-16	15833-15837	FEAT	_	
86-17	15837-15838	.	_	

#Text=For the first level analysis, the phases of the task (face presentation, choice, win outcome, and loss outcome) were modelled separately for emotional and neutral trials, resulting in eight unmodulated regressors.
87-1	15839-15842	For	_	
87-2	15843-15846	the	_	
87-3	15847-15852	first	_	
87-4	15853-15858	level	_	
87-5	15859-15867	analysis	_	
87-6	15867-15868	,	_	
87-7	15869-15872	the	_	
87-8	15873-15879	phases	_	
87-9	15880-15882	of	_	
87-10	15883-15886	the	_	
87-11	15887-15891	task	_	
87-12	15892-15893	(	_	
87-13	15893-15897	face	_	
87-14	15898-15910	presentation	_	
87-15	15910-15911	,	_	
87-16	15912-15918	choice	_	
87-17	15918-15919	,	_	
87-18	15920-15923	win	_	
87-19	15924-15931	outcome	_	
87-20	15931-15932	,	_	
87-21	15933-15936	and	_	
87-22	15937-15941	loss	_	
87-23	15942-15949	outcome	_	
87-24	15949-15950	)	_	
87-25	15951-15955	were	_	
87-26	15956-15964	modelled	_	
87-27	15965-15975	separately	_	
87-28	15976-15979	for	_	
87-29	15980-15989	emotional	_	
87-30	15990-15993	and	_	
87-31	15994-16001	neutral	_	
87-32	16002-16008	trials	_	
87-33	16008-16009	,	_	
87-34	16010-16019	resulting	_	
87-35	16020-16022	in	_	
87-36	16023-16028	eight	_	
87-37	16029-16040	unmodulated	_	
87-38	16041-16051	regressors	_	
87-39	16051-16052	.	_	

#Text=In addition, the win outcome and loss outcome phases were parametrically modulated with the trial-by-trial RPE values, again separately for emotional and neutral trials, resulting in four additional parametric regressors.
88-1	16053-16055	In	_	
88-2	16056-16064	addition	_	
88-3	16064-16065	,	_	
88-4	16066-16069	the	_	
88-5	16070-16073	win	_	
88-6	16074-16081	outcome	_	
88-7	16082-16085	and	_	
88-8	16086-16090	loss	_	
88-9	16091-16098	outcome	_	
88-10	16099-16105	phases	_	
88-11	16106-16110	were	_	
88-12	16111-16125	parametrically	_	
88-13	16126-16135	modulated	_	
88-14	16136-16140	with	_	
88-15	16141-16144	the	_	
88-16	16145-16159	trial-by-trial	_	
88-17	16160-16163	RPE	_	
88-18	16164-16170	values	_	
88-19	16170-16171	,	_	
88-20	16172-16177	again	_	
88-21	16178-16188	separately	_	
88-22	16189-16192	for	_	
88-23	16193-16202	emotional	_	
88-24	16203-16206	and	_	
88-25	16207-16214	neutral	_	
88-26	16215-16221	trials	_	
88-27	16221-16222	,	_	
88-28	16223-16232	resulting	_	
88-29	16233-16235	in	_	
88-30	16236-16240	four	_	
88-31	16241-16251	additional	_	
88-32	16252-16262	parametric	_	
88-33	16263-16273	regressors	_	
88-34	16273-16274	.	_	

#Text=Each regressor was modelled with a delta function of zero duration and convolved with a canonical hemodynamic response function and its temporal derivative.
89-1	16275-16279	Each	_	
89-2	16280-16289	regressor	_	
89-3	16290-16293	was	_	
89-4	16294-16302	modelled	_	
89-5	16303-16307	with	_	
89-6	16308-16309	a	_	
89-7	16310-16315	delta	_	
89-8	16316-16324	function	_	
89-9	16325-16327	of	_	
89-10	16328-16332	zero	_	
89-11	16333-16341	duration	_	
89-12	16342-16345	and	_	
89-13	16346-16355	convolved	_	
89-14	16356-16360	with	_	
89-15	16361-16362	a	_	
89-16	16363-16372	canonical	_	
89-17	16373-16384	hemodynamic	_	
89-18	16385-16393	response	_	
89-19	16394-16402	function	_	
89-20	16403-16406	and	_	
89-21	16407-16410	its	_	
89-22	16411-16419	temporal	_	
89-23	16420-16430	derivative	_	
89-24	16430-16431	.	_	

#Text=Six standard motion parameters as well as a motion artefact confound matrix, which identified motion-corrupted volumes, were added as regressors of no interest.
90-1	16432-16435	Six	_	
90-2	16436-16444	standard	_	
90-3	16445-16451	motion	_	
90-4	16452-16462	parameters	_	
90-5	16463-16465	as	_	
90-6	16466-16470	well	_	
90-7	16471-16473	as	_	
90-8	16474-16475	a	_	
90-9	16476-16482	motion	_	
90-10	16483-16491	artefact	_	
90-11	16492-16500	confound	_	
90-12	16501-16507	matrix	_	
90-13	16507-16508	,	_	
90-14	16509-16514	which	_	
90-15	16515-16525	identified	_	
90-16	16526-16542	motion-corrupted	_	
90-17	16543-16550	volumes	_	
90-18	16550-16551	,	_	
90-19	16552-16556	were	_	
90-20	16557-16562	added	_	
90-21	16563-16565	as	_	
90-22	16566-16576	regressors	_	
90-23	16577-16579	of	_	
90-24	16580-16582	no	_	
90-25	16583-16591	interest	_	
90-26	16591-16592	.	_	

#Text=Volumes detected as corrupted were calculated by DVARS as implemented by FSL Motion Outliers.
91-1	16593-16600	Volumes	_	
91-2	16601-16609	detected	_	
91-3	16610-16612	as	_	
91-4	16613-16622	corrupted	_	
91-5	16623-16627	were	_	
91-6	16628-16638	calculated	_	
91-7	16639-16641	by	_	
91-8	16642-16647	DVARS	_	
91-9	16648-16650	as	_	
91-10	16651-16662	implemented	_	
91-11	16663-16665	by	_	
91-12	16666-16669	FSL	_	
91-13	16670-16676	Motion	_	
91-14	16677-16685	Outliers	_	
91-15	16685-16686	.	_	

#Text=Percentage of corrupted volumes did not differ between groups, F(2,60) = 0.166, p > .848 (HC: N = 24; M = 0.4%, SD = 0.2%; NTR: N = 21; M = 0.4%, SD = 0.2%; TRS: N = 18; M = 0.4%, SD = 0.3%).
92-1	16687-16697	Percentage	_	
92-2	16698-16700	of	_	
92-3	16701-16710	corrupted	_	
92-4	16711-16718	volumes	_	
92-5	16719-16722	did	_	
92-6	16723-16726	not	_	
92-7	16727-16733	differ	_	
92-8	16734-16741	between	_	
92-9	16742-16748	groups	_	
92-10	16748-16749	,	_	
92-11	16750-16751	F	_	
92-12	16751-16752	(	_	
92-13	16752-16756	2,60	_	
92-14	16756-16757	)	_	
92-15	16758-16759	=	_	
92-16	16760-16765	0.166	_	
92-17	16765-16766	,	_	
92-18	16767-16768	p	_	
92-19	16769-16770	>	_	
92-20	16771-16775	.848	_	
92-21	16776-16777	(	_	
92-22	16777-16779	HC	_	
92-23	16779-16780	:	_	
92-24	16781-16782	N	_	
92-25	16783-16784	=	_	
92-26	16785-16787	24	_	
92-27	16787-16788	;	_	
92-28	16789-16790	M	_	
92-29	16791-16792	=	_	
92-30	16793-16797	0.4%	_	
92-31	16797-16798	,	_	
92-32	16799-16801	SD	_	
92-33	16802-16803	=	_	
92-34	16804-16808	0.2%	_	
92-35	16808-16809	;	_	
92-36	16810-16813	NTR	_	
92-37	16813-16814	:	_	
92-38	16815-16816	N	_	
92-39	16817-16818	=	_	
92-40	16819-16821	21	_	
92-41	16821-16822	;	_	
92-42	16823-16824	M	_	
92-43	16825-16826	=	_	
92-44	16827-16831	0.4%	_	
92-45	16831-16832	,	_	
92-46	16833-16835	SD	_	
92-47	16836-16837	=	_	
92-48	16838-16842	0.2%	_	
92-49	16842-16843	;	_	
92-50	16844-16847	TRS	_	
92-51	16847-16848	:	_	
92-52	16849-16850	N	_	
92-53	16851-16852	=	_	
92-54	16853-16855	18	_	
92-55	16855-16856	;	_	
92-56	16857-16858	M	_	
92-57	16859-16860	=	_	
92-58	16861-16865	0.4%	_	
92-59	16865-16866	,	_	
92-60	16867-16869	SD	_	
92-61	16870-16871	=	_	
92-62	16872-16876	0.3%	_	
92-63	16876-16877	)	_	
92-64	16877-16878	.	_	

#Text=Contrasts of interest were constructed using the RPE regressors of win and loss outcomes separately.
93-1	16879-16888	Contrasts	_	
93-2	16889-16891	of	_	
93-3	16892-16900	interest	_	
93-4	16901-16905	were	_	
93-5	16906-16917	constructed	_	
93-6	16918-16923	using	_	
93-7	16924-16927	the	_	
93-8	16928-16931	RPE	_	
93-9	16932-16942	regressors	_	
93-10	16943-16945	of	_	
93-11	16946-16949	win	_	
93-12	16950-16953	and	_	
93-13	16954-16958	loss	_	
93-14	16959-16967	outcomes	_	
93-15	16968-16978	separately	_	
93-16	16978-16979	.	_	

#Text=The first two contrasts averaged across the emotional and neutral conditions, resulting in the contrasts of interest: 1) win RPE and 2) loss RPE.
94-1	16980-16983	The	_	
94-2	16984-16989	first	_	
94-3	16990-16993	two	_	
94-4	16994-17003	contrasts	_	
94-5	17004-17012	averaged	_	
94-6	17013-17019	across	_	
94-7	17020-17023	the	_	
94-8	17024-17033	emotional	_	
94-9	17034-17037	and	_	
94-10	17038-17045	neutral	_	
94-11	17046-17056	conditions	_	
94-12	17056-17057	,	_	
94-13	17058-17067	resulting	_	
94-14	17068-17070	in	_	
94-15	17071-17074	the	_	
94-16	17075-17084	contrasts	_	
94-17	17085-17087	of	_	
94-18	17088-17096	interest	_	
94-19	17096-17097	:	_	
94-20	17098-17099	1	_	
94-21	17099-17100	)	_	
94-22	17101-17104	win	_	
94-23	17105-17108	RPE	_	
94-24	17109-17112	and	_	
94-25	17113-17114	2	_	
94-26	17114-17115	)	_	
94-27	17116-17120	loss	_	
94-28	17121-17124	RPE	_	
94-29	17124-17125	.	_	

#Text=The following two contrasts were constructed to detect activation which was greater in the emotional condition compared to the neutral condition: 3) win RPE [emotional > neutral] and 4) loss RPE [emotional > neutral].
95-1	17126-17129	The	_	
95-2	17130-17139	following	_	
95-3	17140-17143	two	_	
95-4	17144-17153	contrasts	_	
95-5	17154-17158	were	_	
95-6	17159-17170	constructed	_	
95-7	17171-17173	to	_	
95-8	17174-17180	detect	_	
95-9	17181-17191	activation	_	
95-10	17192-17197	which	_	
95-11	17198-17201	was	_	
95-12	17202-17209	greater	_	
95-13	17210-17212	in	_	
95-14	17213-17216	the	_	
95-15	17217-17226	emotional	_	
95-16	17227-17236	condition	_	
95-17	17237-17245	compared	_	
95-18	17246-17248	to	_	
95-19	17249-17252	the	_	
95-20	17253-17260	neutral	_	
95-21	17261-17270	condition	_	
95-22	17270-17271	:	_	
95-23	17272-17273	3	_	
95-24	17273-17274	)	_	
95-25	17275-17278	win	_	
95-26	17279-17282	RPE	_	
95-27	17283-17284	[	_	
95-28	17284-17293	emotional	_	
95-29	17294-17295	>	_	
95-30	17296-17303	neutral	_	
95-31	17303-17304	]	_	
95-32	17305-17308	and	_	
95-33	17309-17310	4	_	
95-34	17310-17311	)	_	
95-35	17312-17316	loss	_	
95-36	17317-17320	RPE	_	
95-37	17321-17322	[	_	
95-38	17322-17331	emotional	_	
95-39	17332-17333	>	_	
95-40	17334-17341	neutral	_	
95-41	17341-17342	]	_	
95-42	17342-17343	.	_	

#Text=At the group level, contrasts were submitted to separate mixed effects analyses (FLAME1), modelling the effect of group (HC, NTR, or TRS) on BOLD signal.
96-1	17344-17346	At	_	
96-2	17347-17350	the	_	
96-3	17351-17356	group	_	
96-4	17357-17362	level	_	
96-5	17362-17363	,	_	
96-6	17364-17373	contrasts	_	
96-7	17374-17378	were	_	
96-8	17379-17388	submitted	_	
96-9	17389-17391	to	_	
96-10	17392-17400	separate	_	
96-11	17401-17406	mixed	_	
96-12	17407-17414	effects	_	
96-13	17415-17423	analyses	_	
96-14	17424-17425	(	_	
96-15	17425-17431	FLAME1	_	
96-16	17431-17432	)	_	
96-17	17432-17433	,	_	
96-18	17434-17443	modelling	_	
96-19	17444-17447	the	_	
96-20	17448-17454	effect	_	
96-21	17455-17457	of	_	
96-22	17458-17463	group	_	
96-23	17464-17465	(	_	
96-24	17465-17467	HC	_	
96-25	17467-17468	,	_	
96-26	17469-17472	NTR	_	
96-27	17472-17473	,	_	
96-28	17474-17476	or	_	
96-29	17477-17480	TRS	_	
96-30	17480-17481	)	_	
96-31	17482-17484	on	_	
96-32	17485-17489	BOLD	_	
96-33	17490-17496	signal	_	
96-34	17496-17497	.	_	

#Text=Whole-brain activation differences between groups were tested for win RPE and loss RPE.
97-1	17498-17509	Whole-brain	_	
97-2	17510-17520	activation	_	
97-3	17521-17532	differences	_	
97-4	17533-17540	between	_	
97-5	17541-17547	groups	_	
97-6	17548-17552	were	_	
97-7	17553-17559	tested	_	
97-8	17560-17563	for	_	
97-9	17564-17567	win	_	
97-10	17568-17571	RPE	_	
97-11	17572-17575	and	_	
97-12	17576-17580	loss	_	
97-13	17581-17584	RPE	_	
97-14	17584-17585	.	_	

#Text=In order to detect subcortical RPE activation we conducted an ROI analysis using a binary subcortical mask consisting of the bilateral striatum and thalamus (anatomically defined from the probabilistic Harvard Oxford Subcortical Structural Atlas thresholded at 30%).
98-1	17586-17588	In	_	
98-2	17589-17594	order	_	
98-3	17595-17597	to	_	
98-4	17598-17604	detect	_	
98-5	17605-17616	subcortical	_	
98-6	17617-17620	RPE	_	
98-7	17621-17631	activation	_	
98-8	17632-17634	we	_	
98-9	17635-17644	conducted	_	
98-10	17645-17647	an	_	
98-11	17648-17651	ROI	_	
98-12	17652-17660	analysis	_	
98-13	17661-17666	using	_	
98-14	17667-17668	a	_	
98-15	17669-17675	binary	_	
98-16	17676-17687	subcortical	_	
98-17	17688-17692	mask	_	
98-18	17693-17703	consisting	_	
98-19	17704-17706	of	_	
98-20	17707-17710	the	_	
98-21	17711-17720	bilateral	_	
98-22	17721-17729	striatum	_	
98-23	17730-17733	and	_	
98-24	17734-17742	thalamus	_	
98-25	17743-17744	(	_	
98-26	17744-17756	anatomically	_	
98-27	17757-17764	defined	_	
98-28	17765-17769	from	_	
98-29	17770-17773	the	_	
98-30	17774-17787	probabilistic	_	
98-31	17788-17795	Harvard	_	
98-32	17796-17802	Oxford	_	
98-33	17803-17814	Subcortical	_	
98-34	17815-17825	Structural	_	
98-35	17826-17831	Atlas	_	
98-36	17832-17843	thresholded	_	
98-37	17844-17846	at	_	
98-38	17847-17850	30%	_	
98-39	17850-17851	)	_	
98-40	17851-17852	.	_	

#Text=Broad inclusion of all structures of the striatum as well as the thalamus was based on the fact that subcortical RPE signaling was detected in each of these regions in a meta-analysis and dysfunctions in schizophrenia have also been observed in both striatum and thalamus.
99-1	17853-17858	Broad	_	
99-2	17859-17868	inclusion	_	
99-3	17869-17871	of	_	
99-4	17872-17875	all	_	
99-5	17876-17886	structures	_	
99-6	17887-17889	of	_	
99-7	17890-17893	the	_	
99-8	17894-17902	striatum	_	
99-9	17903-17905	as	_	
99-10	17906-17910	well	_	
99-11	17911-17913	as	_	
99-12	17914-17917	the	_	
99-13	17918-17926	thalamus	_	
99-14	17927-17930	was	_	
99-15	17931-17936	based	_	
99-16	17937-17939	on	_	
99-17	17940-17943	the	_	
99-18	17944-17948	fact	_	
99-19	17949-17953	that	_	
99-20	17954-17965	subcortical	_	
99-21	17966-17969	RPE	_	
99-22	17970-17979	signaling	_	
99-23	17980-17983	was	_	
99-24	17984-17992	detected	_	
99-25	17993-17995	in	_	
99-26	17996-18000	each	_	
99-27	18001-18003	of	_	
99-28	18004-18009	these	_	
99-29	18010-18017	regions	_	
99-30	18018-18020	in	_	
99-31	18021-18022	a	_	
99-32	18023-18036	meta-analysis	_	
99-33	18037-18040	and	_	
99-34	18041-18053	dysfunctions	_	
99-35	18054-18056	in	_	
99-36	18057-18070	schizophrenia	_	
99-37	18071-18075	have	_	
99-38	18076-18080	also	_	
99-39	18081-18085	been	_	
99-40	18086-18094	observed	_	
99-41	18095-18097	in	_	
99-42	18098-18102	both	_	
99-43	18103-18111	striatum	_	
99-44	18112-18115	and	_	
99-45	18116-18124	thalamus	_	
99-46	18124-18125	.	_	

#Text=In order to assess the differential effect of emotional bias on RPE-related signal, analyses of the win RPE [emotional > neutral] and loss RPE [emotional > neutral] contrasts included emotional bias as a covariate, and group × bias interaction effects were assessed.
100-1	18126-18128	In	_	
100-2	18129-18134	order	_	
100-3	18135-18137	to	_	
100-4	18138-18144	assess	_	
100-5	18145-18148	the	_	
100-6	18149-18161	differential	_	
100-7	18162-18168	effect	_	
100-8	18169-18171	of	_	
100-9	18172-18181	emotional	_	
100-10	18182-18186	bias	_	
100-11	18187-18189	on	_	
100-12	18190-18201	RPE-related	_	
100-13	18202-18208	signal	_	
100-14	18208-18209	,	_	
100-15	18210-18218	analyses	_	
100-16	18219-18221	of	_	
100-17	18222-18225	the	_	
100-18	18226-18229	win	_	
100-19	18230-18233	RPE	_	
100-20	18234-18235	[	_	
100-21	18235-18244	emotional	_	
100-22	18245-18246	>	_	
100-23	18247-18254	neutral	_	
100-24	18254-18255	]	_	
100-25	18256-18259	and	_	
100-26	18260-18264	loss	_	
100-27	18265-18268	RPE	_	
100-28	18269-18270	[	_	
100-29	18270-18279	emotional	_	
100-30	18280-18281	>	_	
100-31	18282-18289	neutral	_	
100-32	18289-18290	]	_	
100-33	18291-18300	contrasts	_	
100-34	18301-18309	included	_	
100-35	18310-18319	emotional	_	
100-36	18320-18324	bias	_	
100-37	18325-18327	as	_	
100-38	18328-18329	a	_	
100-39	18330-18339	covariate	_	
100-40	18339-18340	,	_	
100-41	18341-18344	and	_	
100-42	18345-18350	group	_	
100-43	18351-18352	×	_	
100-44	18353-18357	bias	_	
100-45	18358-18369	interaction	_	
100-46	18370-18377	effects	_	
100-47	18378-18382	were	_	
100-48	18383-18391	assessed	_	
100-49	18391-18392	.	_	

#Text=Significant clusters were determined by a voxelwise z-threshold of 2.3 and a cluster significance threshold of p=0.05 (whole-brain family wise error corrected for multiple comparisons).
101-1	18393-18404	Significant	_	
101-2	18405-18413	clusters	_	
101-3	18414-18418	were	_	
101-4	18419-18429	determined	_	
101-5	18430-18432	by	_	
101-6	18433-18434	a	_	
101-7	18435-18444	voxelwise	_	
101-8	18445-18456	z-threshold	_	
101-9	18457-18459	of	_	
101-10	18460-18463	2.3	_	
101-11	18464-18467	and	_	
101-12	18468-18469	a	_	
101-13	18470-18477	cluster	_	
101-14	18478-18490	significance	_	
101-15	18491-18500	threshold	_	
101-16	18501-18503	of	_	
101-17	18504-18505	p	_	
101-18	18505-18506	=	_	
101-19	18506-18510	0.05	_	
101-20	18511-18512	(	_	
101-21	18512-18523	whole-brain	_	
101-22	18524-18530	family	_	
101-23	18531-18535	wise	_	
101-24	18536-18541	error	_	
101-25	18542-18551	corrected	_	
101-26	18552-18555	for	_	
101-27	18556-18564	multiple	_	
101-28	18565-18576	comparisons	_	
101-29	18576-18577	)	_	
101-30	18577-18578	.	_	

#Text=Correlation analyses were conducted between key positive symptoms (delusion and hallucinations) and significant clusters of RPE-related activation detected in the subcortical ROI analysis, and are reported where significant.
102-1	18579-18590	Correlation	_	
102-2	18591-18599	analyses	_	
102-3	18600-18604	were	_	
102-4	18605-18614	conducted	_	
102-5	18615-18622	between	_	
102-6	18623-18626	key	_	
102-7	18627-18635	positive	_	
102-8	18636-18644	symptoms	_	
102-9	18645-18646	(	_	
102-10	18646-18654	delusion	_	
102-11	18655-18658	and	_	
102-12	18659-18673	hallucinations	_	
102-13	18673-18674	)	_	
102-14	18675-18678	and	_	
102-15	18679-18690	significant	_	
102-16	18691-18699	clusters	_	
102-17	18700-18702	of	_	
102-18	18703-18714	RPE-related	_	
102-19	18715-18725	activation	_	
102-20	18726-18734	detected	_	
102-21	18735-18737	in	_	
102-22	18738-18741	the	_	
102-23	18742-18753	subcortical	_	
102-24	18754-18757	ROI	_	
102-25	18758-18766	analysis	_	
102-26	18766-18767	,	_	
102-27	18768-18771	and	_	
102-28	18772-18775	are	_	
102-29	18776-18784	reported	_	
102-30	18785-18790	where	_	
102-31	18791-18802	significant	_	
102-32	18802-18803	.	_	

#Text=Results
#Text=Demographic characteristics the studied samples are presented in Table 1.
103-1	18804-18811	Results	_	
103-2	18812-18823	Demographic	_	
103-3	18824-18839	characteristics	_	
103-4	18840-18843	the	_	
103-5	18844-18851	studied	_	
103-6	18852-18859	samples	_	
103-7	18860-18863	are	_	
103-8	18864-18873	presented	_	
103-9	18874-18876	in	_	
103-10	18877-18882	Table	_	
103-11	18883-18884	1	_	
103-12	18884-18885	.	_	

#Text=The TRS patients showed higher scores on all PANSS symptom dimensions compared to NTR patients.
104-1	18886-18889	The	_	
104-2	18890-18893	TRS	_	
104-3	18894-18902	patients	_	
104-4	18903-18909	showed	_	
104-5	18910-18916	higher	_	
104-6	18917-18923	scores	_	
104-7	18924-18926	on	_	
104-8	18927-18930	all	_	
104-9	18931-18936	PANSS	_	
104-10	18937-18944	symptom	_	
104-11	18945-18955	dimensions	_	
104-12	18956-18964	compared	_	
104-13	18965-18967	to	_	
104-14	18968-18971	NTR	_	
104-15	18972-18980	patients	_	
104-16	18980-18981	.	_	

#Text=Behavioural results
#Text=The proportion of ideal choices differed significantly between the three groups, F(2,63) = 3.69, p = .031, with HC (M = 0.63, SD = 0.13) making significantly more ideal choices compared to NTR patients (M = 0.55, SD = 0.13), p = .037, and marginally more compared to TRS patients (M = 0.57, SD = 0.11), p = .062.
105-1	18982-18993	Behavioural	_	
105-2	18994-19001	results	_	
105-3	19002-19005	The	_	
105-4	19006-19016	proportion	_	
105-5	19017-19019	of	_	
105-6	19020-19025	ideal	_	
105-7	19026-19033	choices	_	
105-8	19034-19042	differed	_	
105-9	19043-19056	significantly	_	
105-10	19057-19064	between	_	
105-11	19065-19068	the	_	
105-12	19069-19074	three	_	
105-13	19075-19081	groups	_	
105-14	19081-19082	,	_	
105-15	19083-19084	F	_	
105-16	19084-19085	(	_	
105-17	19085-19089	2,63	_	
105-18	19089-19090	)	_	
105-19	19091-19092	=	_	
105-20	19093-19097	3.69	_	
105-21	19097-19098	,	_	
105-22	19099-19100	p	_	
105-23	19101-19102	=	_	
105-24	19103-19107	.031	_	
105-25	19107-19108	,	_	
105-26	19109-19113	with	_	
105-27	19114-19116	HC	_	
105-28	19117-19118	(	_	
105-29	19118-19119	M	_	
105-30	19120-19121	=	_	
105-31	19122-19126	0.63	_	
105-32	19126-19127	,	_	
105-33	19128-19130	SD	_	
105-34	19131-19132	=	_	
105-35	19133-19137	0.13	_	
105-36	19137-19138	)	_	
105-37	19139-19145	making	_	
105-38	19146-19159	significantly	_	
105-39	19160-19164	more	_	
105-40	19165-19170	ideal	_	
105-41	19171-19178	choices	_	
105-42	19179-19187	compared	_	
105-43	19188-19190	to	_	
105-44	19191-19194	NTR	_	
105-45	19195-19203	patients	_	
105-46	19204-19205	(	_	
105-47	19205-19206	M	_	
105-48	19207-19208	=	_	
105-49	19209-19213	0.55	_	
105-50	19213-19214	,	_	
105-51	19215-19217	SD	_	
105-52	19218-19219	=	_	
105-53	19220-19224	0.13	_	
105-54	19224-19225	)	_	
105-55	19225-19226	,	_	
105-56	19227-19228	p	_	
105-57	19229-19230	=	_	
105-58	19231-19235	.037	_	
105-59	19235-19236	,	_	
105-60	19237-19240	and	_	
105-61	19241-19251	marginally	_	
105-62	19252-19256	more	_	
105-63	19257-19265	compared	_	
105-64	19266-19268	to	_	
105-65	19269-19272	TRS	_	
105-66	19273-19281	patients	_	
105-67	19282-19283	(	_	
105-68	19283-19284	M	_	
105-69	19285-19286	=	_	
105-70	19287-19291	0.57	_	
105-71	19291-19292	,	_	
105-72	19293-19295	SD	_	
105-73	19296-19297	=	_	
105-74	19298-19302	0.11	_	
105-75	19302-19303	)	_	
105-76	19303-19304	,	_	
105-77	19305-19306	p	_	
105-78	19307-19308	=	_	
105-79	19309-19313	.062	_	
105-80	19313-19314	.	_	

#Text=There was no significant main effect of (emotional vs. neutral) condition, and no group × condition interaction.
106-1	19315-19320	There	_	
106-2	19321-19324	was	_	
106-3	19325-19327	no	_	
106-4	19328-19339	significant	_	
106-5	19340-19344	main	_	
106-6	19345-19351	effect	_	
106-7	19352-19354	of	_	
106-8	19355-19356	(	_	
106-9	19356-19365	emotional	_	
106-10	19366-19368	vs	_	
106-11	19368-19369	.	_	
106-12	19370-19377	neutral	_	
106-13	19377-19378	)	_	
106-14	19379-19388	condition	_	
106-15	19388-19389	,	_	
106-16	19390-19393	and	_	
106-17	19394-19396	no	_	
106-18	19397-19402	group	_	
106-19	19403-19404	×	_	
106-20	19405-19414	condition	_	
106-21	19415-19426	interaction	_	
106-22	19426-19427	.	_	

#Text=All groups showed an emotional bias towards choosing the happy over the angry face, which did not differ significantly between groups, p > .05 (HC: M = 0.06, SD = 0.13; NTR: M = 0.13, SD = 0.22; TRS: M = 0.04, SD = 0.16).
107-1	19428-19431	All	_	
107-2	19432-19438	groups	_	
107-3	19439-19445	showed	_	
107-4	19446-19448	an	_	
107-5	19449-19458	emotional	_	
107-6	19459-19463	bias	_	
107-7	19464-19471	towards	_	
107-8	19472-19480	choosing	_	
107-9	19481-19484	the	_	
107-10	19485-19490	happy	_	
107-11	19491-19495	over	_	
107-12	19496-19499	the	_	
107-13	19500-19505	angry	_	
107-14	19506-19510	face	_	
107-15	19510-19511	,	_	
107-16	19512-19517	which	_	
107-17	19518-19521	did	_	
107-18	19522-19525	not	_	
107-19	19526-19532	differ	_	
107-20	19533-19546	significantly	_	
107-21	19547-19554	between	_	
107-22	19555-19561	groups	_	
107-23	19561-19562	,	_	
107-24	19563-19564	p	_	
107-25	19565-19566	>	_	
107-26	19567-19570	.05	_	
107-27	19571-19572	(	_	
107-28	19572-19574	HC	_	
107-29	19574-19575	:	_	
107-30	19576-19577	M	_	
107-31	19578-19579	=	_	
107-32	19580-19584	0.06	_	
107-33	19584-19585	,	_	
107-34	19586-19588	SD	_	
107-35	19589-19590	=	_	
107-36	19591-19595	0.13	_	
107-37	19595-19596	;	_	
107-38	19597-19600	NTR	_	
107-39	19600-19601	:	_	
107-40	19602-19603	M	_	
107-41	19604-19605	=	_	
107-42	19606-19610	0.13	_	
107-43	19610-19611	,	_	
107-44	19612-19614	SD	_	
107-45	19615-19616	=	_	
107-46	19617-19621	0.22	_	
107-47	19621-19622	;	_	
107-48	19623-19626	TRS	_	
107-49	19626-19627	:	_	
107-50	19628-19629	M	_	
107-51	19630-19631	=	_	
107-52	19632-19636	0.04	_	
107-53	19636-19637	,	_	
107-54	19638-19640	SD	_	
107-55	19641-19642	=	_	
107-56	19643-19647	0.16	_	
107-57	19647-19648	)	_	
107-58	19648-19649	.	_	

#Text=Neuroimaging results
#Text=RPE signaling for wins and losses
#Text=HC showed RPE-related activation in response to win outcomes of the bilateral dorsolateral prefrontal cortices, superior frontal cortex, parietal cortices and visual cortex as well as cerebellum (see Figure 1A).
108-1	19650-19662	Neuroimaging	_	
108-2	19663-19670	results	_	
108-3	19671-19674	RPE	_	
108-4	19675-19684	signaling	_	
108-5	19685-19688	for	_	
108-6	19689-19693	wins	_	
108-7	19694-19697	and	_	
108-8	19698-19704	losses	_	
108-9	19705-19707	HC	_	
108-10	19708-19714	showed	_	
108-11	19715-19726	RPE-related	_	
108-12	19727-19737	activation	_	
108-13	19738-19740	in	_	
108-14	19741-19749	response	_	
108-15	19750-19752	to	_	
108-16	19753-19756	win	_	
108-17	19757-19765	outcomes	_	
108-18	19766-19768	of	_	
108-19	19769-19772	the	_	
108-20	19773-19782	bilateral	_	
108-21	19783-19795	dorsolateral	_	
108-22	19796-19806	prefrontal	_	
108-23	19807-19815	cortices	_	
108-24	19815-19816	,	_	
108-25	19817-19825	superior	_	
108-26	19826-19833	frontal	_	
108-27	19834-19840	cortex	_	
108-28	19840-19841	,	_	
108-29	19842-19850	parietal	_	
108-30	19851-19859	cortices	_	
108-31	19860-19863	and	_	
108-32	19864-19870	visual	_	
108-33	19871-19877	cortex	_	
108-34	19878-19880	as	_	
108-35	19881-19885	well	_	
108-36	19886-19888	as	_	
108-37	19889-19899	cerebellum	_	
108-38	19900-19901	(	_	
108-39	19901-19904	see	_	
108-40	19905-19911	Figure	_	
108-41	19912-19914	1A	_	
108-42	19914-19915	)	_	
108-43	19915-19916	.	_	

#Text=TRS patients showed a similar activation pattern (Figure 1C).
109-1	19917-19920	TRS	_	
109-2	19921-19929	patients	_	
109-3	19930-19936	showed	_	
109-4	19937-19938	a	_	
109-5	19939-19946	similar	_	
109-6	19947-19957	activation	_	
109-7	19958-19965	pattern	_	
109-8	19966-19967	(	_	
109-9	19967-19973	Figure	_	
109-10	19974-19976	1C	_	
109-11	19976-19977	)	_	
109-12	19977-19978	.	_	

#Text=In contrast, NTR patients showed no supra-threshold RPE-related activation.
110-1	19979-19981	In	_	
110-2	19982-19990	contrast	_	
110-3	19990-19991	,	_	
110-4	19992-19995	NTR	_	
110-5	19996-20004	patients	_	
110-6	20005-20011	showed	_	
110-7	20012-20014	no	_	
110-8	20015-20030	supra-threshold	_	
110-9	20031-20042	RPE-related	_	
110-10	20043-20053	activation	_	
110-11	20053-20054	.	_	

#Text=Group comparisons showed that NTR patients had significantly reduced RPE-related activation in precentral gyrus compared to TRS, in angular gyrus compared to HC, as well as in cerebellum compared to both HC and TRS (Figure 2, Supplementary Table 1).
111-1	20055-20060	Group	_	
111-2	20061-20072	comparisons	_	
111-3	20073-20079	showed	_	
111-4	20080-20084	that	_	
111-5	20085-20088	NTR	_	
111-6	20089-20097	patients	_	
111-7	20098-20101	had	_	
111-8	20102-20115	significantly	_	
111-9	20116-20123	reduced	_	
111-10	20124-20135	RPE-related	_	
111-11	20136-20146	activation	_	
111-12	20147-20149	in	_	
111-13	20150-20160	precentral	_	
111-14	20161-20166	gyrus	_	
111-15	20167-20175	compared	_	
111-16	20176-20178	to	_	
111-17	20179-20182	TRS	_	
111-18	20182-20183	,	_	
111-19	20184-20186	in	_	
111-20	20187-20194	angular	_	
111-21	20195-20200	gyrus	_	
111-22	20201-20209	compared	_	
111-23	20210-20212	to	_	
111-24	20213-20215	HC	_	
111-25	20215-20216	,	_	
111-26	20217-20219	as	_	
111-27	20220-20224	well	_	
111-28	20225-20227	as	_	
111-29	20228-20230	in	_	
111-30	20231-20241	cerebellum	_	
111-31	20242-20250	compared	_	
111-32	20251-20253	to	_	
111-33	20254-20258	both	_	
111-34	20259-20261	HC	_	
111-35	20262-20265	and	_	
111-36	20266-20269	TRS	_	
111-37	20270-20271	(	_	
111-38	20271-20277	Figure	_	
111-39	20278-20279	2	_	
111-40	20279-20280	,	_	
111-41	20281-20294	Supplementary	_	
111-42	20295-20300	Table	_	
111-43	20301-20302	1	_	
111-44	20302-20303	)	_	
111-45	20303-20304	.	_	

#Text=The subcortical ROI analysis revealed a significant effect of group (p < .05 uncorrected), with NTR patients showing reduced RPE-related activation in bilateral thalamus and caudate head compared to both HC and TRS (Figure 3A).
112-1	20305-20308	The	_	
112-2	20309-20320	subcortical	_	
112-3	20321-20324	ROI	_	
112-4	20325-20333	analysis	_	
112-5	20334-20342	revealed	_	
112-6	20343-20344	a	_	
112-7	20345-20356	significant	_	
112-8	20357-20363	effect	_	
112-9	20364-20366	of	_	
112-10	20367-20372	group	_	
112-11	20373-20374	(	_	
112-12	20374-20375	p	_	
112-13	20376-20377	<	_	
112-14	20378-20381	.05	_	
112-15	20382-20393	uncorrected	_	
112-16	20393-20394	)	_	
112-17	20394-20395	,	_	
112-18	20396-20400	with	_	
112-19	20401-20404	NTR	_	
112-20	20405-20413	patients	_	
112-21	20414-20421	showing	_	
112-22	20422-20429	reduced	_	
112-23	20430-20441	RPE-related	_	
112-24	20442-20452	activation	_	
112-25	20453-20455	in	_	
112-26	20456-20465	bilateral	_	
112-27	20466-20474	thalamus	_	
112-28	20475-20478	and	_	
112-29	20479-20486	caudate	_	
112-30	20487-20491	head	_	
112-31	20492-20500	compared	_	
112-32	20501-20503	to	_	
112-33	20504-20508	both	_	
112-34	20509-20511	HC	_	
112-35	20512-20515	and	_	
112-36	20516-20519	TRS	_	
112-37	20520-20521	(	_	
112-38	20521-20527	Figure	_	
112-39	20528-20530	3A	_	
112-40	20530-20531	)	_	
112-41	20531-20532	.	_	

#Text=Loss-related RPE response was observed in a widespread network in both HC and TRS, similar to that during win outcomes (Figures 1B and 1D).
113-1	20533-20545	Loss-related	_	
113-2	20546-20549	RPE	_	
113-3	20550-20558	response	_	
113-4	20559-20562	was	_	
113-5	20563-20571	observed	_	
113-6	20572-20574	in	_	
113-7	20575-20576	a	_	
113-8	20577-20587	widespread	_	
113-9	20588-20595	network	_	
113-10	20596-20598	in	_	
113-11	20599-20603	both	_	
113-12	20604-20606	HC	_	
113-13	20607-20610	and	_	
113-14	20611-20614	TRS	_	
113-15	20614-20615	,	_	
113-16	20616-20623	similar	_	
113-17	20624-20626	to	_	
113-18	20627-20631	that	_	
113-19	20632-20638	during	_	
113-20	20639-20642	win	_	
113-21	20643-20651	outcomes	_	
113-22	20652-20653	(	_	
113-23	20653-20660	Figures	_	
113-24	20661-20663	1B	_	
113-25	20664-20667	and	_	
113-26	20668-20670	1D	_	
113-27	20670-20671	)	_	
113-28	20671-20672	.	_	

#Text=Due to the negative sign of loss-related RPE, this signal reflects a negative RPE signal, with greater prediction errors resulting in greater deactivation in these areas.
114-1	20673-20676	Due	_	
114-2	20677-20679	to	_	
114-3	20680-20683	the	_	
114-4	20684-20692	negative	_	
114-5	20693-20697	sign	_	
114-6	20698-20700	of	_	
114-7	20701-20713	loss-related	_	
114-8	20714-20717	RPE	_	
114-9	20717-20718	,	_	
114-10	20719-20723	this	_	
114-11	20724-20730	signal	_	
114-12	20731-20739	reflects	_	
114-13	20740-20741	a	_	
114-14	20742-20750	negative	_	
114-15	20751-20754	RPE	_	
114-16	20755-20761	signal	_	
114-17	20761-20762	,	_	
114-18	20763-20767	with	_	
114-19	20768-20775	greater	_	
114-20	20776-20786	prediction	_	
114-21	20787-20793	errors	_	
114-22	20794-20803	resulting	_	
114-23	20804-20806	in	_	
114-24	20807-20814	greater	_	
114-25	20815-20827	deactivation	_	
114-26	20828-20830	in	_	
114-27	20831-20836	these	_	
114-28	20837-20842	areas	_	
114-29	20842-20843	.	_	

#Text=The NTR group showed no significant supra-threshold RPE related signal, with no significant group differences at whole-brain level.
115-1	20844-20847	The	_	
115-2	20848-20851	NTR	_	
115-3	20852-20857	group	_	
115-4	20858-20864	showed	_	
115-5	20865-20867	no	_	
115-6	20868-20879	significant	_	
115-7	20880-20895	supra-threshold	_	
115-8	20896-20899	RPE	_	
115-9	20900-20907	related	_	
115-10	20908-20914	signal	_	
115-11	20914-20915	,	_	
115-12	20916-20920	with	_	
115-13	20921-20923	no	_	
115-14	20924-20935	significant	_	
115-15	20936-20941	group	_	
115-16	20942-20953	differences	_	
115-17	20954-20956	at	_	
115-18	20957-20968	whole-brain	_	
115-19	20969-20974	level	_	
115-20	20974-20975	.	_	

#Text=The subcortical ROI analysis revealed reduced RPE-related signal in bilateral pallidum and caudate in NTR compared to HC (p < .05 uncorrected) and no significant difference between TRS and either of the other two groups (Figure 3B).
116-1	20976-20979	The	_	
116-2	20980-20991	subcortical	_	
116-3	20992-20995	ROI	_	
116-4	20996-21004	analysis	_	
116-5	21005-21013	revealed	_	
116-6	21014-21021	reduced	_	
116-7	21022-21033	RPE-related	_	
116-8	21034-21040	signal	_	
116-9	21041-21043	in	_	
116-10	21044-21053	bilateral	_	
116-11	21054-21062	pallidum	_	
116-12	21063-21066	and	_	
116-13	21067-21074	caudate	_	
116-14	21075-21077	in	_	
116-15	21078-21081	NTR	_	
116-16	21082-21090	compared	_	
116-17	21091-21093	to	_	
116-18	21094-21096	HC	_	
116-19	21097-21098	(	_	
116-20	21098-21099	p	_	
116-21	21100-21101	<	_	
116-22	21102-21105	.05	_	
116-23	21106-21117	uncorrected	_	
116-24	21117-21118	)	_	
116-25	21119-21122	and	_	
116-26	21123-21125	no	_	
116-27	21126-21137	significant	_	
116-28	21138-21148	difference	_	
116-29	21149-21156	between	_	
116-30	21157-21160	TRS	_	
116-31	21161-21164	and	_	
116-32	21165-21171	either	_	
116-33	21172-21174	of	_	
116-34	21175-21178	the	_	
116-35	21179-21184	other	_	
116-36	21185-21188	two	_	
116-37	21189-21195	groups	_	
116-38	21196-21197	(	_	
116-39	21197-21203	Figure	_	
116-40	21204-21206	3B	_	
116-41	21206-21207	)	_	
116-42	21207-21208	.	_	

#Text=Emotional bias × group interaction on RPE signal
#Text=During the emotional (versus neutral) loss trials, the whole-brain analysis showed a significant group × emotional bias interaction on RPE signal in bilateral thalamus and caudate nucleus, indicating a differential correlation in TRS and NTR patients (Figure 4, Supplementary Table 2).
117-1	21209-21218	Emotional	_	
117-2	21219-21223	bias	_	
117-3	21224-21225	×	_	
117-4	21226-21231	group	_	
117-5	21232-21243	interaction	_	
117-6	21244-21246	on	_	
117-7	21247-21250	RPE	_	
117-8	21251-21257	signal	_	
117-9	21258-21264	During	_	
117-10	21265-21268	the	_	
117-11	21269-21278	emotional	_	
117-12	21279-21280	(	_	
117-13	21280-21286	versus	_	
117-14	21287-21294	neutral	_	
117-15	21294-21295	)	_	
117-16	21296-21300	loss	_	
117-17	21301-21307	trials	_	
117-18	21307-21308	,	_	
117-19	21309-21312	the	_	
117-20	21313-21324	whole-brain	_	
117-21	21325-21333	analysis	_	
117-22	21334-21340	showed	_	
117-23	21341-21342	a	_	
117-24	21343-21354	significant	_	
117-25	21355-21360	group	_	
117-26	21361-21362	×	_	
117-27	21363-21372	emotional	_	
117-28	21373-21377	bias	_	
117-29	21378-21389	interaction	_	
117-30	21390-21392	on	_	
117-31	21393-21396	RPE	_	
117-32	21397-21403	signal	_	
117-33	21404-21406	in	_	
117-34	21407-21416	bilateral	_	
117-35	21417-21425	thalamus	_	
117-36	21426-21429	and	_	
117-37	21430-21437	caudate	_	
117-38	21438-21445	nucleus	_	
117-39	21445-21446	,	_	
117-40	21447-21457	indicating	_	
117-41	21458-21459	a	_	
117-42	21460-21472	differential	_	
117-43	21473-21484	correlation	_	
117-44	21485-21487	in	_	
117-45	21488-21491	TRS	_	
117-46	21492-21495	and	_	
117-47	21496-21499	NTR	_	
117-48	21500-21508	patients	_	
117-49	21509-21510	(	_	
117-50	21510-21516	Figure	_	
117-51	21517-21518	4	_	
117-52	21518-21519	,	_	
117-53	21520-21533	Supplementary	_	
117-54	21534-21539	Table	_	
117-55	21540-21541	2	_	
117-56	21541-21542	)	_	
117-57	21542-21543	.	_	

#Text=In TRS patients, a stronger emotional bias was associated with increased RPE signal in this region (R = 0.58, p = .006).
118-1	21544-21546	In	_	
118-2	21547-21550	TRS	_	
118-3	21551-21559	patients	_	
118-4	21559-21560	,	_	
118-5	21561-21562	a	_	
118-6	21563-21571	stronger	_	
118-7	21572-21581	emotional	_	
118-8	21582-21586	bias	_	
118-9	21587-21590	was	_	
118-10	21591-21601	associated	_	
118-11	21602-21606	with	_	
118-12	21607-21616	increased	_	
118-13	21617-21620	RPE	_	
118-14	21621-21627	signal	_	
118-15	21628-21630	in	_	
118-16	21631-21635	this	_	
118-17	21636-21642	region	_	
118-18	21643-21644	(	_	
118-19	21644-21645	R	_	
118-20	21646-21647	=	_	
118-21	21648-21652	0.58	_	
118-22	21652-21653	,	_	
118-23	21654-21655	p	_	
118-24	21656-21657	=	_	
118-25	21658-21662	.006	_	
118-26	21662-21663	)	_	
118-27	21663-21664	.	_	

#Text=In contrast, in NTR patients, the opposite was the case (R = −0.56, p = .008).
119-1	21665-21667	In	_	
119-2	21668-21676	contrast	_	
119-3	21676-21677	,	_	
119-4	21678-21680	in	_	
119-5	21681-21684	NTR	_	
119-6	21685-21693	patients	_	
119-7	21693-21694	,	_	
119-8	21695-21698	the	_	
119-9	21699-21707	opposite	_	
119-10	21708-21711	was	_	
119-11	21712-21715	the	_	
119-12	21716-21720	case	_	
119-13	21721-21722	(	_	
119-14	21722-21723	R	_	
119-15	21724-21725	=	_	
119-16	21726-21727	−	_	
119-17	21727-21731	0.56	_	
119-18	21731-21732	,	_	
119-19	21733-21734	p	_	
119-20	21735-21736	=	_	
119-21	21737-21741	.008	_	
119-22	21741-21742	)	_	
119-23	21742-21743	.	_	

#Text=This negative correlation in NTR was no longer significant after excluding one outlier, however the difference between correlation coefficients in the two groups remained significant (Fisher’s R to Z = 2.69, two-tailed p = .007).
120-1	21744-21748	This	_	
120-2	21749-21757	negative	_	
120-3	21758-21769	correlation	_	
120-4	21770-21772	in	_	
120-5	21773-21776	NTR	_	
120-6	21777-21780	was	_	
120-7	21781-21783	no	_	
120-8	21784-21790	longer	_	
120-9	21791-21802	significant	_	
120-10	21803-21808	after	_	
120-11	21809-21818	excluding	_	
120-12	21819-21822	one	_	
120-13	21823-21830	outlier	_	
120-14	21830-21831	,	_	
120-15	21832-21839	however	_	
120-16	21840-21843	the	_	
120-17	21844-21854	difference	_	
120-18	21855-21862	between	_	
120-19	21863-21874	correlation	_	
120-20	21875-21887	coefficients	_	
120-21	21888-21890	in	_	
120-22	21891-21894	the	_	
120-23	21895-21898	two	_	
120-24	21899-21905	groups	_	
120-25	21906-21914	remained	_	
120-26	21915-21926	significant	_	
120-27	21927-21928	(	_	
120-28	21928-21934	Fisher	_	
120-29	21934-21935	’	_	
120-30	21935-21936	s	_	
120-31	21937-21938	R	_	
120-32	21939-21941	to	_	
120-33	21942-21943	Z	_	
120-34	21944-21945	=	_	
120-35	21946-21950	2.69	_	
120-36	21950-21951	,	_	
120-37	21952-21962	two-tailed	_	
120-38	21963-21964	p	_	
120-39	21965-21966	=	_	
120-40	21967-21971	.007	_	
120-41	21971-21972	)	_	
120-42	21972-21973	.	_	

#Text=Interestingly, RPE signal in this region was significantly correlated with delusion severity in TRS patients, with stronger RPE signaling associated with more severe symptoms of delusions (R = 0.48, p = .027).
121-1	21974-21987	Interestingly	_	
121-2	21987-21988	,	_	
121-3	21989-21992	RPE	_	
121-4	21993-21999	signal	_	
121-5	22000-22002	in	_	
121-6	22003-22007	this	_	
121-7	22008-22014	region	_	
121-8	22015-22018	was	_	
121-9	22019-22032	significantly	_	
121-10	22033-22043	correlated	_	
121-11	22044-22048	with	_	
121-12	22049-22057	delusion	_	
121-13	22058-22066	severity	_	
121-14	22067-22069	in	_	
121-15	22070-22073	TRS	_	
121-16	22074-22082	patients	_	
121-17	22082-22083	,	_	
121-18	22084-22088	with	_	
121-19	22089-22097	stronger	_	
121-20	22098-22101	RPE	_	
121-21	22102-22111	signaling	_	
121-22	22112-22122	associated	_	
121-23	22123-22127	with	_	
121-24	22128-22132	more	_	
121-25	22133-22139	severe	_	
121-26	22140-22148	symptoms	_	
121-27	22149-22151	of	_	
121-28	22152-22161	delusions	_	
121-29	22162-22163	(	_	
121-30	22163-22164	R	_	
121-31	22165-22166	=	_	
121-32	22167-22171	0.48	_	
121-33	22171-22172	,	_	
121-34	22173-22174	p	_	
121-35	22175-22176	=	_	
121-36	22177-22181	.027	_	
121-37	22181-22182	)	_	
121-38	22182-22183	.	_	

#Text=This interaction was not evident in the emotional (versus neutral) win trials.
122-1	22184-22188	This	_	
122-2	22189-22200	interaction	_	
122-3	22201-22204	was	_	
122-4	22205-22208	not	_	
122-5	22209-22216	evident	_	
122-6	22217-22219	in	_	
122-7	22220-22223	the	_	
122-8	22224-22233	emotional	_	
122-9	22234-22235	(	_	
122-10	22235-22241	versus	_	
122-11	22242-22249	neutral	_	
122-12	22249-22250	)	_	
122-13	22251-22254	win	_	
122-14	22255-22261	trials	_	
122-15	22261-22262	.	_	

#Text=Discussion
#Text=We used a probabilistic reward learning task to assess differences in neural mechanisms underlying reinforcement learning in patients with schizophrenia who were either treatment resistant (TRS) or non-treatment resistant (NTR), relative to a healthy control (HC) group.
123-1	22263-22273	Discussion	_	
123-2	22274-22276	We	_	
123-3	22277-22281	used	_	
123-4	22282-22283	a	_	
123-5	22284-22297	probabilistic	_	
123-6	22298-22304	reward	_	
123-7	22305-22313	learning	_	
123-8	22314-22318	task	_	
123-9	22319-22321	to	_	
123-10	22322-22328	assess	_	
123-11	22329-22340	differences	_	
123-12	22341-22343	in	_	
123-13	22344-22350	neural	_	
123-14	22351-22361	mechanisms	_	
123-15	22362-22372	underlying	_	
123-16	22373-22386	reinforcement	_	
123-17	22387-22395	learning	_	
123-18	22396-22398	in	_	
123-19	22399-22407	patients	_	
123-20	22408-22412	with	_	
123-21	22413-22426	schizophrenia	_	
123-22	22427-22430	who	_	
123-23	22431-22435	were	_	
123-24	22436-22442	either	_	
123-25	22443-22452	treatment	_	
123-26	22453-22462	resistant	_	
123-27	22463-22464	(	_	
123-28	22464-22467	TRS	_	
123-29	22467-22468	)	_	
123-30	22469-22471	or	_	
123-31	22472-22485	non-treatment	_	
123-32	22486-22495	resistant	_	
123-33	22496-22497	(	_	
123-34	22497-22500	NTR	_	
123-35	22500-22501	)	_	
123-36	22501-22502	,	_	
123-37	22503-22511	relative	_	
123-38	22512-22514	to	_	
123-39	22515-22516	a	_	
123-40	22517-22524	healthy	_	
123-41	22525-22532	control	_	
123-42	22533-22534	(	_	
123-43	22534-22536	HC	_	
123-44	22536-22537	)	_	
123-45	22538-22543	group	_	
123-46	22543-22544	.	_	

#Text=Our findings support the hypothesis that NTR patients show abnormal prediction error related activation compared to both HC and TRS, consistent with the theory that this patient group is characterized by a greater disruption of dopaminergic functioning.
124-1	22545-22548	Our	_	
124-2	22549-22557	findings	_	
124-3	22558-22565	support	_	
124-4	22566-22569	the	_	
124-5	22570-22580	hypothesis	_	
124-6	22581-22585	that	_	
124-7	22586-22589	NTR	_	
124-8	22590-22598	patients	_	
124-9	22599-22603	show	_	
124-10	22604-22612	abnormal	_	
124-11	22613-22623	prediction	_	
124-12	22624-22629	error	_	
124-13	22630-22637	related	_	
124-14	22638-22648	activation	_	
124-15	22649-22657	compared	_	
124-16	22658-22660	to	_	
124-17	22661-22665	both	_	
124-18	22666-22668	HC	_	
124-19	22669-22672	and	_	
124-20	22673-22676	TRS	_	
124-21	22676-22677	,	_	
124-22	22678-22688	consistent	_	
124-23	22689-22693	with	_	
124-24	22694-22697	the	_	
124-25	22698-22704	theory	_	
124-26	22705-22709	that	_	
124-27	22710-22714	this	_	
124-28	22715-22722	patient	_	
124-29	22723-22728	group	_	
124-30	22729-22731	is	_	
124-31	22732-22745	characterized	_	
124-32	22746-22748	by	_	
124-33	22749-22750	a	_	
124-34	22751-22758	greater	_	
124-35	22759-22769	disruption	_	
124-36	22770-22772	of	_	
124-37	22773-22785	dopaminergic	_	
124-38	22786-22797	functioning	_	
124-39	22797-22798	.	_	

#Text=We also found that underlying cognitive bias differentially modulated learning processes in the two patient groups.
125-1	22799-22801	We	_	
125-2	22802-22806	also	_	
125-3	22807-22812	found	_	
125-4	22813-22817	that	_	
125-5	22818-22828	underlying	_	
125-6	22829-22838	cognitive	_	
125-7	22839-22843	bias	_	
125-8	22844-22858	differentially	_	
125-9	22859-22868	modulated	_	
125-10	22869-22877	learning	_	
125-11	22878-22887	processes	_	
125-12	22888-22890	in	_	
125-13	22891-22894	the	_	
125-14	22895-22898	two	_	
125-15	22899-22906	patient	_	
125-16	22907-22913	groups	_	
125-17	22913-22914	.	_	

#Text=We found that HC and TRS patients showed similar patterns of prediction error signaling both during wins and losses.
126-1	22915-22917	We	_	
126-2	22918-22923	found	_	
126-3	22924-22928	that	_	
126-4	22929-22931	HC	_	
126-5	22932-22935	and	_	
126-6	22936-22939	TRS	_	
126-7	22940-22948	patients	_	
126-8	22949-22955	showed	_	
126-9	22956-22963	similar	_	
126-10	22964-22972	patterns	_	
126-11	22973-22975	of	_	
126-12	22976-22986	prediction	_	
126-13	22987-22992	error	_	
126-14	22993-23002	signaling	_	
126-15	23003-23007	both	_	
126-16	23008-23014	during	_	
126-17	23015-23019	wins	_	
126-18	23020-23023	and	_	
126-19	23024-23030	losses	_	
126-20	23030-23031	.	_	

#Text=RPE activation was evident in a widespread network in these groups, consistent with the notion that reward processing is almost ubiquitous in the brain.
127-1	23032-23035	RPE	_	
127-2	23036-23046	activation	_	
127-3	23047-23050	was	_	
127-4	23051-23058	evident	_	
127-5	23059-23061	in	_	
127-6	23062-23063	a	_	
127-7	23064-23074	widespread	_	
127-8	23075-23082	network	_	
127-9	23083-23085	in	_	
127-10	23086-23091	these	_	
127-11	23092-23098	groups	_	
127-12	23098-23099	,	_	
127-13	23100-23110	consistent	_	
127-14	23111-23115	with	_	
127-15	23116-23119	the	_	
127-16	23120-23126	notion	_	
127-17	23127-23131	that	_	
127-18	23132-23138	reward	_	
127-19	23139-23149	processing	_	
127-20	23150-23152	is	_	
127-21	23153-23159	almost	_	
127-22	23160-23170	ubiquitous	_	
127-23	23171-23173	in	_	
127-24	23174-23177	the	_	
127-25	23178-23183	brain	_	
127-26	23183-23184	.	_	

#Text=The observed regions of activation, including medial, superior and dorsolateral frontal cortex as well as visual areas and parietal cortex, are largely in line with the human cortical substrate of prediction error reported elsewhere.
128-1	23185-23188	The	_	
128-2	23189-23197	observed	_	
128-3	23198-23205	regions	_	
128-4	23206-23208	of	_	
128-5	23209-23219	activation	_	
128-6	23219-23220	,	_	
128-7	23221-23230	including	_	
128-8	23231-23237	medial	_	
128-9	23237-23238	,	_	
128-10	23239-23247	superior	_	
128-11	23248-23251	and	_	
128-12	23252-23264	dorsolateral	_	
128-13	23265-23272	frontal	_	
128-14	23273-23279	cortex	_	
128-15	23280-23282	as	_	
128-16	23283-23287	well	_	
128-17	23288-23290	as	_	
128-18	23291-23297	visual	_	
128-19	23298-23303	areas	_	
128-20	23304-23307	and	_	
128-21	23308-23316	parietal	_	
128-22	23317-23323	cortex	_	
128-23	23323-23324	,	_	
128-24	23325-23328	are	_	
128-25	23329-23336	largely	_	
128-26	23337-23339	in	_	
128-27	23340-23344	line	_	
128-28	23345-23349	with	_	
128-29	23350-23353	the	_	
128-30	23354-23359	human	_	
128-31	23360-23368	cortical	_	
128-32	23369-23378	substrate	_	
128-33	23379-23381	of	_	
128-34	23382-23392	prediction	_	
128-35	23393-23398	error	_	
128-36	23399-23407	reported	_	
128-37	23408-23417	elsewhere	_	
128-38	23417-23418	.	_	

#Text=In contrast, NTR patients did not exhibit the same activation pattern.
129-1	23419-23421	In	_	
129-2	23422-23430	contrast	_	
129-3	23430-23431	,	_	
129-4	23432-23435	NTR	_	
129-5	23436-23444	patients	_	
129-6	23445-23448	did	_	
129-7	23449-23452	not	_	
129-8	23453-23460	exhibit	_	
129-9	23461-23464	the	_	
129-10	23465-23469	same	_	
129-11	23470-23480	activation	_	
129-12	23481-23488	pattern	_	
129-13	23488-23489	.	_	

#Text=During receipt of rewarding outcomes, a whole-brain analysis showed reduced activation in the cerebellum in NTR compared to both HC and TRS patients; in parietal cortex compared to HC; and precentral gyrus compared to TRS.
130-1	23490-23496	During	_	
130-2	23497-23504	receipt	_	
130-3	23505-23507	of	_	
130-4	23508-23517	rewarding	_	
130-5	23518-23526	outcomes	_	
130-6	23526-23527	,	_	
130-7	23528-23529	a	_	
130-8	23530-23541	whole-brain	_	
130-9	23542-23550	analysis	_	
130-10	23551-23557	showed	_	
130-11	23558-23565	reduced	_	
130-12	23566-23576	activation	_	
130-13	23577-23579	in	_	
130-14	23580-23583	the	_	
130-15	23584-23594	cerebellum	_	
130-16	23595-23597	in	_	
130-17	23598-23601	NTR	_	
130-18	23602-23610	compared	_	
130-19	23611-23613	to	_	
130-20	23614-23618	both	_	
130-21	23619-23621	HC	_	
130-22	23622-23625	and	_	
130-23	23626-23629	TRS	_	
130-24	23630-23638	patients	_	
130-25	23638-23639	;	_	
130-26	23640-23642	in	_	
130-27	23643-23651	parietal	_	
130-28	23652-23658	cortex	_	
130-29	23659-23667	compared	_	
130-30	23668-23670	to	_	
130-31	23671-23673	HC	_	
130-32	23673-23674	;	_	
130-33	23675-23678	and	_	
130-34	23679-23689	precentral	_	
130-35	23690-23695	gyrus	_	
130-36	23696-23704	compared	_	
130-37	23705-23707	to	_	
130-38	23708-23711	TRS	_	
130-39	23711-23712	.	_	

#Text=An ROI analysis revealed reduced activation in NTR in the thalamus and caudate compared to both HC and TRS.
131-1	23713-23715	An	_	
131-2	23716-23719	ROI	_	
131-3	23720-23728	analysis	_	
131-4	23729-23737	revealed	_	
131-5	23738-23745	reduced	_	
131-6	23746-23756	activation	_	
131-7	23757-23759	in	_	
131-8	23760-23763	NTR	_	
131-9	23764-23766	in	_	
131-10	23767-23770	the	_	
131-11	23771-23779	thalamus	_	
131-12	23780-23783	and	_	
131-13	23784-23791	caudate	_	
131-14	23792-23800	compared	_	
131-15	23801-23803	to	_	
131-16	23804-23808	both	_	
131-17	23809-23811	HC	_	
131-18	23812-23815	and	_	
131-19	23816-23819	TRS	_	
131-20	23819-23820	.	_	

#Text=Reduced RPE-related activation in the thalamus and caudate in schizophrenia patients has been previously reported and linked with dopaminergic dysfunction.
132-1	23821-23828	Reduced	_	
132-2	23829-23840	RPE-related	_	
132-3	23841-23851	activation	_	
132-4	23852-23854	in	_	
132-5	23855-23858	the	_	
132-6	23859-23867	thalamus	_	
132-7	23868-23871	and	_	
132-8	23872-23879	caudate	_	
132-9	23880-23882	in	_	
132-10	23883-23896	schizophrenia	_	
132-11	23897-23905	patients	_	
132-12	23906-23909	has	_	
132-13	23910-23914	been	_	
132-14	23915-23925	previously	_	
132-15	23926-23934	reported	_	
132-16	23935-23938	and	_	
132-17	23939-23945	linked	_	
132-18	23946-23950	with	_	
132-19	23951-23963	dopaminergic	_	
132-20	23964-23975	dysfunction	_	
132-21	23975-23976	.	_	

#Text=Moreover, a further study found attenuated responses to unexpected reward, but intact responses to omission of expected reward, in several overlapping regions including the striatum, precentral gyrus, parietal cortex and cerebellum in schizophrenia.
133-1	23977-23985	Moreover	_	
133-2	23985-23986	,	_	
133-3	23987-23988	a	_	
133-4	23989-23996	further	_	
133-5	23997-24002	study	_	
133-6	24003-24008	found	_	
133-7	24009-24019	attenuated	_	
133-8	24020-24029	responses	_	
133-9	24030-24032	to	_	
133-10	24033-24043	unexpected	_	
133-11	24044-24050	reward	_	
133-12	24050-24051	,	_	
133-13	24052-24055	but	_	
133-14	24056-24062	intact	_	
133-15	24063-24072	responses	_	
133-16	24073-24075	to	_	
133-17	24076-24084	omission	_	
133-18	24085-24087	of	_	
133-19	24088-24096	expected	_	
133-20	24097-24103	reward	_	
133-21	24103-24104	,	_	
133-22	24105-24107	in	_	
133-23	24108-24115	several	_	
133-24	24116-24127	overlapping	_	
133-25	24128-24135	regions	_	
133-26	24136-24145	including	_	
133-27	24146-24149	the	_	
133-28	24150-24158	striatum	_	
133-29	24158-24159	,	_	
133-30	24160-24170	precentral	_	
133-31	24171-24176	gyrus	_	
133-32	24176-24177	,	_	
133-33	24178-24186	parietal	_	
133-34	24187-24193	cortex	_	
133-35	24194-24197	and	_	
133-36	24198-24208	cerebellum	_	
133-37	24209-24211	in	_	
133-38	24212-24225	schizophrenia	_	
133-39	24225-24226	.	_	

#Text=In line with this, group differences with respect to loss outcomes in our study were less widespread, with NTR patients showing attenuated RPE signaling only in the pallidum and caudate compared to HC.
134-1	24227-24229	In	_	
134-2	24230-24234	line	_	
134-3	24235-24239	with	_	
134-4	24240-24244	this	_	
134-5	24244-24245	,	_	
134-6	24246-24251	group	_	
134-7	24252-24263	differences	_	
134-8	24264-24268	with	_	
134-9	24269-24276	respect	_	
134-10	24277-24279	to	_	
134-11	24280-24284	loss	_	
134-12	24285-24293	outcomes	_	
134-13	24294-24296	in	_	
134-14	24297-24300	our	_	
134-15	24301-24306	study	_	
134-16	24307-24311	were	_	
134-17	24312-24316	less	_	
134-18	24317-24327	widespread	_	
134-19	24327-24328	,	_	
134-20	24329-24333	with	_	
134-21	24334-24337	NTR	_	
134-22	24338-24346	patients	_	
134-23	24347-24354	showing	_	
134-24	24355-24365	attenuated	_	
134-25	24366-24369	RPE	_	
134-26	24370-24379	signaling	_	
134-27	24380-24384	only	_	
134-28	24385-24387	in	_	
134-29	24388-24391	the	_	
134-30	24392-24400	pallidum	_	
134-31	24401-24404	and	_	
134-32	24405-24412	caudate	_	
134-33	24413-24421	compared	_	
134-34	24422-24424	to	_	
134-35	24425-24427	HC	_	
134-36	24427-24428	.	_	

#Text=The findings support previous suggestions that prediction error related reinforcement learning deficits in schizophrenia stem primarily from abnormal processing of rewarding, rather than aversive, outcomes.
135-1	24429-24432	The	_	
135-2	24433-24441	findings	_	
135-3	24442-24449	support	_	
135-4	24450-24458	previous	_	
135-5	24459-24470	suggestions	_	
135-6	24471-24475	that	_	
135-7	24476-24486	prediction	_	
135-8	24487-24492	error	_	
135-9	24493-24500	related	_	
135-10	24501-24514	reinforcement	_	
135-11	24515-24523	learning	_	
135-12	24524-24532	deficits	_	
135-13	24533-24535	in	_	
135-14	24536-24549	schizophrenia	_	
135-15	24550-24554	stem	_	
135-16	24555-24564	primarily	_	
135-17	24565-24569	from	_	
135-18	24570-24578	abnormal	_	
135-19	24579-24589	processing	_	
135-20	24590-24592	of	_	
135-21	24593-24602	rewarding	_	
135-22	24602-24603	,	_	
135-23	24604-24610	rather	_	
135-24	24611-24615	than	_	
135-25	24616-24624	aversive	_	
135-26	24624-24625	,	_	
135-27	24626-24634	outcomes	_	
135-28	24634-24635	.	_	

#Text=Encoding of prediction errors during reinforcement learning is extensively driven by dopaminergic function.
136-1	24636-24644	Encoding	_	
136-2	24645-24647	of	_	
136-3	24648-24658	prediction	_	
136-4	24659-24665	errors	_	
136-5	24666-24672	during	_	
136-6	24673-24686	reinforcement	_	
136-7	24687-24695	learning	_	
136-8	24696-24698	is	_	
136-9	24699-24710	extensively	_	
136-10	24711-24717	driven	_	
136-11	24718-24720	by	_	
136-12	24721-24733	dopaminergic	_	
136-13	24734-24742	function	_	
136-14	24742-24743	.	_	

#Text=Although not all the regions found to encode prediction error in our study are densely innervated by dopaminergic projections, it is possible that a “global reinforcement signal” which is elicited by firing of dopamine neurons and broadcast through other regions of the brain indirectly modulates activation of structures with fewer direct connections to the dopamine system.
137-1	24744-24752	Although	_	
137-2	24753-24756	not	_	
137-3	24757-24760	all	_	
137-4	24761-24764	the	_	
137-5	24765-24772	regions	_	
137-6	24773-24778	found	_	
137-7	24779-24781	to	_	
137-8	24782-24788	encode	_	
137-9	24789-24799	prediction	_	
137-10	24800-24805	error	_	
137-11	24806-24808	in	_	
137-12	24809-24812	our	_	
137-13	24813-24818	study	_	
137-14	24819-24822	are	_	
137-15	24823-24830	densely	_	
137-16	24831-24841	innervated	_	
137-17	24842-24844	by	_	
137-18	24845-24857	dopaminergic	_	
137-19	24858-24869	projections	_	
137-20	24869-24870	,	_	
137-21	24871-24873	it	_	
137-22	24874-24876	is	_	
137-23	24877-24885	possible	_	
137-24	24886-24890	that	_	
137-25	24891-24892	a	_	
137-26	24893-24894	“	_	
137-27	24894-24900	global	_	
137-28	24901-24914	reinforcement	_	
137-29	24915-24921	signal	_	
137-30	24921-24922	”	_	
137-31	24923-24928	which	_	
137-32	24929-24931	is	_	
137-33	24932-24940	elicited	_	
137-34	24941-24943	by	_	
137-35	24944-24950	firing	_	
137-36	24951-24953	of	_	
137-37	24954-24962	dopamine	_	
137-38	24963-24970	neurons	_	
137-39	24971-24974	and	_	
137-40	24975-24984	broadcast	_	
137-41	24985-24992	through	_	
137-42	24993-24998	other	_	
137-43	24999-25006	regions	_	
137-44	25007-25009	of	_	
137-45	25010-25013	the	_	
137-46	25014-25019	brain	_	
137-47	25020-25030	indirectly	_	
137-48	25031-25040	modulates	_	
137-49	25041-25051	activation	_	
137-50	25052-25054	of	_	
137-51	25055-25065	structures	_	
137-52	25066-25070	with	_	
137-53	25071-25076	fewer	_	
137-54	25077-25083	direct	_	
137-55	25084-25095	connections	_	
137-56	25096-25098	to	_	
137-57	25099-25102	the	_	
137-58	25103-25111	dopamine	_	
137-59	25112-25118	system	_	
137-60	25118-25119	.	_	

#Text=An important criterion determining whether prediction error activation might reflect dopaminergic activity is a sign change for negative outcomes, which was indeed observed in this study.
138-1	25120-25122	An	_	
138-2	25123-25132	important	_	
138-3	25133-25142	criterion	_	
138-4	25143-25154	determining	_	
138-5	25155-25162	whether	_	
138-6	25163-25173	prediction	_	
138-7	25174-25179	error	_	
138-8	25180-25190	activation	_	
138-9	25191-25196	might	_	
138-10	25197-25204	reflect	_	
138-11	25205-25217	dopaminergic	_	
138-12	25218-25226	activity	_	
138-13	25227-25229	is	_	
138-14	25230-25231	a	_	
138-15	25232-25236	sign	_	
138-16	25237-25243	change	_	
138-17	25244-25247	for	_	
138-18	25248-25256	negative	_	
138-19	25257-25265	outcomes	_	
138-20	25265-25266	,	_	
138-21	25267-25272	which	_	
138-22	25273-25276	was	_	
138-23	25277-25283	indeed	_	
138-24	25284-25292	observed	_	
138-25	25293-25295	in	_	
138-26	25296-25300	this	_	
138-27	25301-25306	study	_	
138-28	25306-25307	.	_	

#Text=The observed activation is therefore unlikely to reflect simple attentional or surprise processing.
139-1	25308-25311	The	_	
139-2	25312-25320	observed	_	
139-3	25321-25331	activation	_	
139-4	25332-25334	is	_	
139-5	25335-25344	therefore	_	
139-6	25345-25353	unlikely	_	
139-7	25354-25356	to	_	
139-8	25357-25364	reflect	_	
139-9	25365-25371	simple	_	
139-10	25372-25383	attentional	_	
139-11	25384-25386	or	_	
139-12	25387-25395	surprise	_	
139-13	25396-25406	processing	_	
139-14	25406-25407	.	_	

#Text=Group differences observed in the ROI analyses are highly likely to reflect dopaminergic functioning, given that the striatum and thalamus receive dense dopamine projections from the midbrain.
140-1	25408-25413	Group	_	
140-2	25414-25425	differences	_	
140-3	25426-25434	observed	_	
140-4	25435-25437	in	_	
140-5	25438-25441	the	_	
140-6	25442-25445	ROI	_	
140-7	25446-25454	analyses	_	
140-8	25455-25458	are	_	
140-9	25459-25465	highly	_	
140-10	25466-25472	likely	_	
140-11	25473-25475	to	_	
140-12	25476-25483	reflect	_	
140-13	25484-25496	dopaminergic	_	
140-14	25497-25508	functioning	_	
140-15	25508-25509	,	_	
140-16	25510-25515	given	_	
140-17	25516-25520	that	_	
140-18	25521-25524	the	_	
140-19	25525-25533	striatum	_	
140-20	25534-25537	and	_	
140-21	25538-25546	thalamus	_	
140-22	25547-25554	receive	_	
140-23	25555-25560	dense	_	
140-24	25561-25569	dopamine	_	
140-25	25570-25581	projections	_	
140-26	25582-25586	from	_	
140-27	25587-25590	the	_	
140-28	25591-25599	midbrain	_	
140-29	25599-25600	.	_	

#Text=Our findings thus imply that putatively dopamine-driven mechanisms underlying reinforcement learning in response to reward feedback are selectively disrupted in NTR.
141-1	25601-25604	Our	_	
141-2	25605-25613	findings	_	
141-3	25614-25618	thus	_	
141-4	25619-25624	imply	_	
141-5	25625-25629	that	_	
141-6	25630-25640	putatively	_	
141-7	25641-25656	dopamine-driven	_	
141-8	25657-25667	mechanisms	_	
141-9	25668-25678	underlying	_	
141-10	25679-25692	reinforcement	_	
141-11	25693-25701	learning	_	
141-12	25702-25704	in	_	
141-13	25705-25713	response	_	
141-14	25714-25716	to	_	
141-15	25717-25723	reward	_	
141-16	25724-25732	feedback	_	
141-17	25733-25736	are	_	
141-18	25737-25748	selectively	_	
141-19	25749-25758	disrupted	_	
141-20	25759-25761	in	_	
141-21	25762-25765	NTR	_	
141-22	25765-25766	.	_	

#Text=In contrast, the similar RPE-related activation pattern in TRS patients and HC suggests that reinforcement learning deficits in this patient group do not stem from dopaminergically driven RPE signaling dysfunctions.
142-1	25767-25769	In	_	
142-2	25770-25778	contrast	_	
142-3	25778-25779	,	_	
142-4	25780-25783	the	_	
142-5	25784-25791	similar	_	
142-6	25792-25803	RPE-related	_	
142-7	25804-25814	activation	_	
142-8	25815-25822	pattern	_	
142-9	25823-25825	in	_	
142-10	25826-25829	TRS	_	
142-11	25830-25838	patients	_	
142-12	25839-25842	and	_	
142-13	25843-25845	HC	_	
142-14	25846-25854	suggests	_	
142-15	25855-25859	that	_	
142-16	25860-25873	reinforcement	_	
142-17	25874-25882	learning	_	
142-18	25883-25891	deficits	_	
142-19	25892-25894	in	_	
142-20	25895-25899	this	_	
142-21	25900-25907	patient	_	
142-22	25908-25913	group	_	
142-23	25914-25916	do	_	
142-24	25917-25920	not	_	
142-25	25921-25925	stem	_	
142-26	25926-25930	from	_	
142-27	25931-25947	dopaminergically	_	
142-28	25948-25954	driven	_	
142-29	25955-25958	RPE	_	
142-30	25959-25968	signaling	_	
142-31	25969-25981	dysfunctions	_	
142-32	25981-25982	.	_	

#Text=The data are consistent with the notion that TRS patients do not respond to dopaminergic antipsychotic medication because a dopaminergic abnormality is not the primary cause of symptoms in this subgroup.
143-1	25983-25986	The	_	
143-2	25987-25991	data	_	
143-3	25992-25995	are	_	
143-4	25996-26006	consistent	_	
143-5	26007-26011	with	_	
143-6	26012-26015	the	_	
143-7	26016-26022	notion	_	
143-8	26023-26027	that	_	
143-9	26028-26031	TRS	_	
143-10	26032-26040	patients	_	
143-11	26041-26043	do	_	
143-12	26044-26047	not	_	
143-13	26048-26055	respond	_	
143-14	26056-26058	to	_	
143-15	26059-26071	dopaminergic	_	
143-16	26072-26085	antipsychotic	_	
143-17	26086-26096	medication	_	
143-18	26097-26104	because	_	
143-19	26105-26106	a	_	
143-20	26107-26119	dopaminergic	_	
143-21	26120-26131	abnormality	_	
143-22	26132-26134	is	_	
143-23	26135-26138	not	_	
143-24	26139-26142	the	_	
143-25	26143-26150	primary	_	
143-26	26151-26156	cause	_	
143-27	26157-26159	of	_	
143-28	26160-26168	symptoms	_	
143-29	26169-26171	in	_	
143-30	26172-26176	this	_	
143-31	26177-26185	subgroup	_	
143-32	26185-26186	.	_	

#Text=Importantly, medication dosage did not significantly differ between the two patient groups in our sample.
144-1	26187-26198	Importantly	_	
144-2	26198-26199	,	_	
144-3	26200-26210	medication	_	
144-4	26211-26217	dosage	_	
144-5	26218-26221	did	_	
144-6	26222-26225	not	_	
144-7	26226-26239	significantly	_	
144-8	26240-26246	differ	_	
144-9	26247-26254	between	_	
144-10	26255-26258	the	_	
144-11	26259-26262	two	_	
144-12	26263-26270	patient	_	
144-13	26271-26277	groups	_	
144-14	26278-26280	in	_	
144-15	26281-26284	our	_	
144-16	26285-26291	sample	_	
144-17	26291-26292	.	_	

#Text=Non-response to medication in the TRS group is unlikely to arise from a lower prescribed medication dosage compared to NTR patients as CPZ equivalent dosages were descriptively higher in the TRS group.
145-1	26293-26305	Non-response	_	
145-2	26306-26308	to	_	
145-3	26309-26319	medication	_	
145-4	26320-26322	in	_	
145-5	26323-26326	the	_	
145-6	26327-26330	TRS	_	
145-7	26331-26336	group	_	
145-8	26337-26339	is	_	
145-9	26340-26348	unlikely	_	
145-10	26349-26351	to	_	
145-11	26352-26357	arise	_	
145-12	26358-26362	from	_	
145-13	26363-26364	a	_	
145-14	26365-26370	lower	_	
145-15	26371-26381	prescribed	_	
145-16	26382-26392	medication	_	
145-17	26393-26399	dosage	_	
145-18	26400-26408	compared	_	
145-19	26409-26411	to	_	
145-20	26412-26415	NTR	_	
145-21	26416-26424	patients	_	
145-22	26425-26427	as	_	
145-23	26428-26431	CPZ	_	
145-24	26432-26442	equivalent	_	
145-25	26443-26450	dosages	_	
145-26	26451-26455	were	_	
145-27	26456-26469	descriptively	_	
145-28	26470-26476	higher	_	
145-29	26477-26479	in	_	
145-30	26480-26483	the	_	
145-31	26484-26487	TRS	_	
145-32	26488-26493	group	_	
145-33	26493-26494	.	_	

#Text=However, due to the illness chronicity of patients included in our sample it was not possible to exhaustively ascertain the exact dosage and duration of all previous medication trials, thus cumulative medication exposure remains as a potential confound in this study.
146-1	26495-26502	However	_	
146-2	26502-26503	,	_	
146-3	26504-26507	due	_	
146-4	26508-26510	to	_	
146-5	26511-26514	the	_	
146-6	26515-26522	illness	_	
146-7	26523-26533	chronicity	_	
146-8	26534-26536	of	_	
146-9	26537-26545	patients	_	
146-10	26546-26554	included	_	
146-11	26555-26557	in	_	
146-12	26558-26561	our	_	
146-13	26562-26568	sample	_	
146-14	26569-26571	it	_	
146-15	26572-26575	was	_	
146-16	26576-26579	not	_	
146-17	26580-26588	possible	_	
146-18	26589-26591	to	_	
146-19	26592-26604	exhaustively	_	
146-20	26605-26614	ascertain	_	
146-21	26615-26618	the	_	
146-22	26619-26624	exact	_	
146-23	26625-26631	dosage	_	
146-24	26632-26635	and	_	
146-25	26636-26644	duration	_	
146-26	26645-26647	of	_	
146-27	26648-26651	all	_	
146-28	26652-26660	previous	_	
146-29	26661-26671	medication	_	
146-30	26672-26678	trials	_	
146-31	26678-26679	,	_	
146-32	26680-26684	thus	_	
146-33	26685-26695	cumulative	_	
146-34	26696-26706	medication	_	
146-35	26707-26715	exposure	_	
146-36	26716-26723	remains	_	
146-37	26724-26726	as	_	
146-38	26727-26728	a	_	
146-39	26729-26738	potential	_	
146-40	26739-26747	confound	_	
146-41	26748-26750	in	_	
146-42	26751-26755	this	_	
146-43	26756-26761	study	_	
146-44	26761-26762	.	_	

#Text=Interestingly, groups did not differ in terms of their bias towards choosing the happy face over the angry face on emotional trials.
147-1	26763-26776	Interestingly	_	
147-2	26776-26777	,	_	
147-3	26778-26784	groups	_	
147-4	26785-26788	did	_	
147-5	26789-26792	not	_	
147-6	26793-26799	differ	_	
147-7	26800-26802	in	_	
147-8	26803-26808	terms	_	
147-9	26809-26811	of	_	
147-10	26812-26817	their	_	
147-11	26818-26822	bias	_	
147-12	26823-26830	towards	_	
147-13	26831-26839	choosing	_	
147-14	26840-26843	the	_	
147-15	26844-26849	happy	_	
147-16	26850-26854	face	_	
147-17	26855-26859	over	_	
147-18	26860-26863	the	_	
147-19	26864-26869	angry	_	
147-20	26870-26874	face	_	
147-21	26875-26877	on	_	
147-22	26878-26887	emotional	_	
147-23	26888-26894	trials	_	
147-24	26894-26895	.	_	

#Text=However, there was a significant difference between TRS and NTR patients in how this bias was associated with RPE signal in the thalamus and caudate during loss processing.
148-1	26896-26903	However	_	
148-2	26903-26904	,	_	
148-3	26905-26910	there	_	
148-4	26911-26914	was	_	
148-5	26915-26916	a	_	
148-6	26917-26928	significant	_	
148-7	26929-26939	difference	_	
148-8	26940-26947	between	_	
148-9	26948-26951	TRS	_	
148-10	26952-26955	and	_	
148-11	26956-26959	NTR	_	
148-12	26960-26968	patients	_	
148-13	26969-26971	in	_	
148-14	26972-26975	how	_	
148-15	26976-26980	this	_	
148-16	26981-26985	bias	_	
148-17	26986-26989	was	_	
148-18	26990-27000	associated	_	
148-19	27001-27005	with	_	
148-20	27006-27009	RPE	_	
148-21	27010-27016	signal	_	
148-22	27017-27019	in	_	
148-23	27020-27023	the	_	
148-24	27024-27032	thalamus	_	
148-25	27033-27036	and	_	
148-26	27037-27044	caudate	_	
148-27	27045-27051	during	_	
148-28	27052-27056	loss	_	
148-29	27057-27067	processing	_	
148-30	27067-27068	.	_	

#Text=In NTR patients, a strong emotional bias was associated with further attenuation of the RPE signal.
149-1	27069-27071	In	_	
149-2	27072-27075	NTR	_	
149-3	27076-27084	patients	_	
149-4	27084-27085	,	_	
149-5	27086-27087	a	_	
149-6	27088-27094	strong	_	
149-7	27095-27104	emotional	_	
149-8	27105-27109	bias	_	
149-9	27110-27113	was	_	
149-10	27114-27124	associated	_	
149-11	27125-27129	with	_	
149-12	27130-27137	further	_	
149-13	27138-27149	attenuation	_	
149-14	27150-27152	of	_	
149-15	27153-27156	the	_	
149-16	27157-27160	RPE	_	
149-17	27161-27167	signal	_	
149-18	27167-27168	.	_	

#Text=By comparison, emotional bias in TRS was associated with an increased RPE signal.
150-1	27169-27171	By	_	
150-2	27172-27182	comparison	_	
150-3	27182-27183	,	_	
150-4	27184-27193	emotional	_	
150-5	27194-27198	bias	_	
150-6	27199-27201	in	_	
150-7	27202-27205	TRS	_	
150-8	27206-27209	was	_	
150-9	27210-27220	associated	_	
150-10	27221-27225	with	_	
150-11	27226-27228	an	_	
150-12	27229-27238	increased	_	
150-13	27239-27242	RPE	_	
150-14	27243-27249	signal	_	
150-15	27249-27250	.	_	

#Text=In turn, RPE signal in this region was positively related to delusional symptom severity specifically in the TRS group.
151-1	27251-27253	In	_	
151-2	27254-27258	turn	_	
151-3	27258-27259	,	_	
151-4	27260-27263	RPE	_	
151-5	27264-27270	signal	_	
151-6	27271-27273	in	_	
151-7	27274-27278	this	_	
151-8	27279-27285	region	_	
151-9	27286-27289	was	_	
151-10	27290-27300	positively	_	
151-11	27301-27308	related	_	
151-12	27309-27311	to	_	
151-13	27312-27322	delusional	_	
151-14	27323-27330	symptom	_	
151-15	27331-27339	severity	_	
151-16	27340-27352	specifically	_	
151-17	27353-27355	in	_	
151-18	27356-27359	the	_	
151-19	27360-27363	TRS	_	
151-20	27364-27369	group	_	
151-21	27369-27370	.	_	

#Text=This is surprising as striatal RPE signal has previously been reported to be negatively linked with symptom severity in schizophrenia; in line with the view that hyperdopaminergia-reflected in reduced RPE signaling-drives psychosis.
152-1	27371-27375	This	_	
152-2	27376-27378	is	_	
152-3	27379-27389	surprising	_	
152-4	27390-27392	as	_	
152-5	27393-27401	striatal	_	
152-6	27402-27405	RPE	_	
152-7	27406-27412	signal	_	
152-8	27413-27416	has	_	
152-9	27417-27427	previously	_	
152-10	27428-27432	been	_	
152-11	27433-27441	reported	_	
152-12	27442-27444	to	_	
152-13	27445-27447	be	_	
152-14	27448-27458	negatively	_	
152-15	27459-27465	linked	_	
152-16	27466-27470	with	_	
152-17	27471-27478	symptom	_	
152-18	27479-27487	severity	_	
152-19	27488-27490	in	_	
152-20	27491-27504	schizophrenia	_	
152-21	27504-27505	;	_	
152-22	27506-27508	in	_	
152-23	27509-27513	line	_	
152-24	27514-27518	with	_	
152-25	27519-27522	the	_	
152-26	27523-27527	view	_	
152-27	27528-27532	that	_	
152-28	27533-27560	hyperdopaminergia-reflected	_	
152-29	27561-27563	in	_	
152-30	27564-27571	reduced	_	
152-31	27572-27575	RPE	_	
152-32	27576-27592	signaling-drives	_	
152-33	27593-27602	psychosis	_	
152-34	27602-27603	.	_	

#Text=Our findings suggest that this relationship may be inverted in TRS patients in the thalamus and caudate.
153-1	27604-27607	Our	_	
153-2	27608-27616	findings	_	
153-3	27617-27624	suggest	_	
153-4	27625-27629	that	_	
153-5	27630-27634	this	_	
153-6	27635-27647	relationship	_	
153-7	27648-27651	may	_	
153-8	27652-27654	be	_	
153-9	27655-27663	inverted	_	
153-10	27664-27666	in	_	
153-11	27667-27670	TRS	_	
153-12	27671-27679	patients	_	
153-13	27680-27682	in	_	
153-14	27683-27686	the	_	
153-15	27687-27695	thalamus	_	
153-16	27696-27699	and	_	
153-17	27700-27707	caudate	_	
153-18	27707-27708	.	_	

#Text=Increased RPE signaling specifically on loss trials may reflect less accurate predictions, resulting in greater prediction errors when the outcome is negative.
154-1	27709-27718	Increased	_	
154-2	27719-27722	RPE	_	
154-3	27723-27732	signaling	_	
154-4	27733-27745	specifically	_	
154-5	27746-27748	on	_	
154-6	27749-27753	loss	_	
154-7	27754-27760	trials	_	
154-8	27761-27764	may	_	
154-9	27765-27772	reflect	_	
154-10	27773-27777	less	_	
154-11	27778-27786	accurate	_	
154-12	27787-27798	predictions	_	
154-13	27798-27799	,	_	
154-14	27800-27809	resulting	_	
154-15	27810-27812	in	_	
154-16	27813-27820	greater	_	
154-17	27821-27831	prediction	_	
154-18	27832-27838	errors	_	
154-19	27839-27843	when	_	
154-20	27844-27847	the	_	
154-21	27848-27855	outcome	_	
154-22	27856-27858	is	_	
154-23	27859-27867	negative	_	
154-24	27867-27868	.	_	

#Text=As such, a strong social bias in TRS may lead to worse predictions about outcomes but an intact subcortical response to prediction error, which in turn is not adequately utilized to update predictions.
155-1	27869-27871	As	_	
155-2	27872-27876	such	_	
155-3	27876-27877	,	_	
155-4	27878-27879	a	_	
155-5	27880-27886	strong	_	
155-6	27887-27893	social	_	
155-7	27894-27898	bias	_	
155-8	27899-27901	in	_	
155-9	27902-27905	TRS	_	
155-10	27906-27909	may	_	
155-11	27910-27914	lead	_	
155-12	27915-27917	to	_	
155-13	27918-27923	worse	_	
155-14	27924-27935	predictions	_	
155-15	27936-27941	about	_	
155-16	27942-27950	outcomes	_	
155-17	27951-27954	but	_	
155-18	27955-27957	an	_	
155-19	27958-27964	intact	_	
155-20	27965-27976	subcortical	_	
155-21	27977-27985	response	_	
155-22	27986-27988	to	_	
155-23	27989-27999	prediction	_	
155-24	28000-28005	error	_	
155-25	28005-28006	,	_	
155-26	28007-28012	which	_	
155-27	28013-28015	in	_	
155-28	28016-28020	turn	_	
155-29	28021-28023	is	_	
155-30	28024-28027	not	_	
155-31	28028-28038	adequately	_	
155-32	28039-28047	utilized	_	
155-33	28048-28050	to	_	
155-34	28051-28057	update	_	
155-35	28058-28069	predictions	_	
155-36	28069-28070	.	_	

#Text=In contrast, in NTR the prediction error response itself seems to be impaired, an effect which is further augmented in the presence of cognitive bias.
156-1	28071-28073	In	_	
156-2	28074-28082	contrast	_	
156-3	28082-28083	,	_	
156-4	28084-28086	in	_	
156-5	28087-28090	NTR	_	
156-6	28091-28094	the	_	
156-7	28095-28105	prediction	_	
156-8	28106-28111	error	_	
156-9	28112-28120	response	_	
156-10	28121-28127	itself	_	
156-11	28128-28133	seems	_	
156-12	28134-28136	to	_	
156-13	28137-28139	be	_	
156-14	28140-28148	impaired	_	
156-15	28148-28149	,	_	
156-16	28150-28152	an	_	
156-17	28153-28159	effect	_	
156-18	28160-28165	which	_	
156-19	28166-28168	is	_	
156-20	28169-28176	further	_	
156-21	28177-28186	augmented	_	
156-22	28187-28189	in	_	
156-23	28190-28193	the	_	
156-24	28194-28202	presence	_	
156-25	28203-28205	of	_	
156-26	28206-28215	cognitive	_	
156-27	28216-28220	bias	_	
156-28	28220-28221	.	_	

#Text=These data support a putative model of TRS whereby the central dysfunction lies not in the subcortical dopamine system itself, but in the implementation of cognitive control mechanisms interacting with this system.
157-1	28222-28227	These	_	
157-2	28228-28232	data	_	
157-3	28233-28240	support	_	
157-4	28241-28242	a	_	
157-5	28243-28251	putative	_	
157-6	28252-28257	model	_	
157-7	28258-28260	of	_	
157-8	28261-28264	TRS	_	
157-9	28265-28272	whereby	_	
157-10	28273-28276	the	_	
157-11	28277-28284	central	_	
157-12	28285-28296	dysfunction	_	
157-13	28297-28301	lies	_	
157-14	28302-28305	not	_	
157-15	28306-28308	in	_	
157-16	28309-28312	the	_	
157-17	28313-28324	subcortical	_	
157-18	28325-28333	dopamine	_	
157-19	28334-28340	system	_	
157-20	28341-28347	itself	_	
157-21	28347-28348	,	_	
157-22	28349-28352	but	_	
157-23	28353-28355	in	_	
157-24	28356-28359	the	_	
157-25	28360-28374	implementation	_	
157-26	28375-28377	of	_	
157-27	28378-28387	cognitive	_	
157-28	28388-28395	control	_	
157-29	28396-28406	mechanisms	_	
157-30	28407-28418	interacting	_	
157-31	28419-28423	with	_	
157-32	28424-28428	this	_	
157-33	28429-28435	system	_	
157-34	28435-28436	.	_	

#Text=This control could be contributed to by glutamatergic mechanisms.
158-1	28437-28441	This	_	
158-2	28442-28449	control	_	
158-3	28450-28455	could	_	
158-4	28456-28458	be	_	
158-5	28459-28470	contributed	_	
158-6	28471-28473	to	_	
158-7	28474-28476	by	_	
158-8	28477-28490	glutamatergic	_	
158-9	28491-28501	mechanisms	_	
158-10	28501-28502	.	_	

#Text=The striatum and cortex are interconnected by multiple partially overlapping circuits subserving learning and flexible cognition.
159-1	28503-28506	The	_	
159-2	28507-28515	striatum	_	
159-3	28516-28519	and	_	
159-4	28520-28526	cortex	_	
159-5	28527-28530	are	_	
159-6	28531-28545	interconnected	_	
159-7	28546-28548	by	_	
159-8	28549-28557	multiple	_	
159-9	28558-28567	partially	_	
159-10	28568-28579	overlapping	_	
159-11	28580-28588	circuits	_	
159-12	28589-28599	subserving	_	
159-13	28600-28608	learning	_	
159-14	28609-28612	and	_	
159-15	28613-28621	flexible	_	
159-16	28622-28631	cognition	_	
159-17	28631-28632	.	_	

#Text=The ability to maintain behavioural goals in the presence of interference, uncertainty, or bias-broadly the definition of cognitive control-is an integral aspect of feedback learning.
160-1	28633-28636	The	_	
160-2	28637-28644	ability	_	
160-3	28645-28647	to	_	
160-4	28648-28656	maintain	_	
160-5	28657-28668	behavioural	_	
160-6	28669-28674	goals	_	
160-7	28675-28677	in	_	
160-8	28678-28681	the	_	
160-9	28682-28690	presence	_	
160-10	28691-28693	of	_	
160-11	28694-28706	interference	_	
160-12	28706-28707	,	_	
160-13	28708-28719	uncertainty	_	
160-14	28719-28720	,	_	
160-15	28721-28723	or	_	
160-16	28724-28736	bias-broadly	_	
160-17	28737-28740	the	_	
160-18	28741-28751	definition	_	
160-19	28752-28754	of	_	
160-20	28755-28764	cognitive	_	
160-21	28765-28775	control-is	_	
160-22	28776-28778	an	_	
160-23	28779-28787	integral	_	
160-24	28788-28794	aspect	_	
160-25	28795-28797	of	_	
160-26	28798-28806	feedback	_	
160-27	28807-28815	learning	_	
160-28	28815-28816	.	_	

#Text=A breakdown of this system may not only lead to reinforcement learning deficits, but also psychotic symptoms such as delusions as control processes are not adequately exerted in order to update internal models of the environment.
161-1	28817-28818	A	_	
161-2	28819-28828	breakdown	_	
161-3	28829-28831	of	_	
161-4	28832-28836	this	_	
161-5	28837-28843	system	_	
161-6	28844-28847	may	_	
161-7	28848-28851	not	_	
161-8	28852-28856	only	_	
161-9	28857-28861	lead	_	
161-10	28862-28864	to	_	
161-11	28865-28878	reinforcement	_	
161-12	28879-28887	learning	_	
161-13	28888-28896	deficits	_	
161-14	28896-28897	,	_	
161-15	28898-28901	but	_	
161-16	28902-28906	also	_	
161-17	28907-28916	psychotic	_	
161-18	28917-28925	symptoms	_	
161-19	28926-28930	such	_	
161-20	28931-28933	as	_	
161-21	28934-28943	delusions	_	
161-22	28944-28946	as	_	
161-23	28947-28954	control	_	
161-24	28955-28964	processes	_	
161-25	28965-28968	are	_	
161-26	28969-28972	not	_	
161-27	28973-28983	adequately	_	
161-28	28984-28991	exerted	_	
161-29	28992-28994	in	_	
161-30	28995-29000	order	_	
161-31	29001-29003	to	_	
161-32	29004-29010	update	_	
161-33	29011-29019	internal	_	
161-34	29020-29026	models	_	
161-35	29027-29029	of	_	
161-36	29030-29033	the	_	
161-37	29034-29045	environment	_	
161-38	29045-29046	.	_	

#Text=Control-related regions such as prefrontal cortex, which also shows strong functional connectivity with the striatum, may indeed be involved in delusion formation and maintenance.
162-1	29047-29062	Control-related	_	
162-2	29063-29070	regions	_	
162-3	29071-29075	such	_	
162-4	29076-29078	as	_	
162-5	29079-29089	prefrontal	_	
162-6	29090-29096	cortex	_	
162-7	29096-29097	,	_	
162-8	29098-29103	which	_	
162-9	29104-29108	also	_	
162-10	29109-29114	shows	_	
162-11	29115-29121	strong	_	
162-12	29122-29132	functional	_	
162-13	29133-29145	connectivity	_	
162-14	29146-29150	with	_	
162-15	29151-29154	the	_	
162-16	29155-29163	striatum	_	
162-17	29163-29164	,	_	
162-18	29165-29168	may	_	
162-19	29169-29175	indeed	_	
162-20	29176-29178	be	_	
162-21	29179-29187	involved	_	
162-22	29188-29190	in	_	
162-23	29191-29199	delusion	_	
162-24	29200-29209	formation	_	
162-25	29210-29213	and	_	
162-26	29214-29225	maintenance	_	
162-27	29225-29226	.	_	

#Text=Arguably, in the absence of an adequate cognitive control mechanism regulating bias, solely targeting subcortical dopamine with antipsychotics may not suffice to alleviate symptoms.
163-1	29227-29235	Arguably	_	
163-2	29235-29236	,	_	
163-3	29237-29239	in	_	
163-4	29240-29243	the	_	
163-5	29244-29251	absence	_	
163-6	29252-29254	of	_	
163-7	29255-29257	an	_	
163-8	29258-29266	adequate	_	
163-9	29267-29276	cognitive	_	
163-10	29277-29284	control	_	
163-11	29285-29294	mechanism	_	
163-12	29295-29305	regulating	_	
163-13	29306-29310	bias	_	
163-14	29310-29311	,	_	
163-15	29312-29318	solely	_	
163-16	29319-29328	targeting	_	
163-17	29329-29340	subcortical	_	
163-18	29341-29349	dopamine	_	
163-19	29350-29354	with	_	
163-20	29355-29369	antipsychotics	_	
163-21	29370-29373	may	_	
163-22	29374-29377	not	_	
163-23	29378-29385	suffice	_	
163-24	29386-29388	to	_	
163-25	29389-29398	alleviate	_	
163-26	29399-29407	symptoms	_	
163-27	29407-29408	.	_	

#Text=In contrast, NTR patients may have sufficient cognitive control such that alleviating the striatal dysfunction is sufficient to reduce symptoms adequately.
164-1	29409-29411	In	_	
164-2	29412-29420	contrast	_	
164-3	29420-29421	,	_	
164-4	29422-29425	NTR	_	
164-5	29426-29434	patients	_	
164-6	29435-29438	may	_	
164-7	29439-29443	have	_	
164-8	29444-29454	sufficient	_	
164-9	29455-29464	cognitive	_	
164-10	29465-29472	control	_	
164-11	29473-29477	such	_	
164-12	29478-29482	that	_	
164-13	29483-29494	alleviating	_	
164-14	29495-29498	the	_	
164-15	29499-29507	striatal	_	
164-16	29508-29519	dysfunction	_	
164-17	29520-29522	is	_	
164-18	29523-29533	sufficient	_	
164-19	29534-29536	to	_	
164-20	29537-29543	reduce	_	
164-21	29544-29552	symptoms	_	
164-22	29553-29563	adequately	_	
164-23	29563-29564	.	_	

#Text=Our study offers the first task-related neuroimaging evidence for differential caudate function in chronic TRS and NTR patients.
165-1	29565-29568	Our	_	
165-2	29569-29574	study	_	
165-3	29575-29581	offers	_	
165-4	29582-29585	the	_	
165-5	29586-29591	first	_	
165-6	29592-29604	task-related	_	
165-7	29605-29617	neuroimaging	_	
165-8	29618-29626	evidence	_	
165-9	29627-29630	for	_	
165-10	29631-29643	differential	_	
165-11	29644-29651	caudate	_	
165-12	29652-29660	function	_	
165-13	29661-29663	in	_	
165-14	29664-29671	chronic	_	
165-15	29672-29675	TRS	_	
165-16	29676-29679	and	_	
165-17	29680-29683	NTR	_	
165-18	29684-29692	patients	_	
165-19	29692-29693	.	_	

#Text=It has been suggested that metabolic as well as anatomical abnormalities in the basal ganglia including the caudate nucleus are involved in TRS and may also be associated with clozapine response.
166-1	29694-29696	It	_	
166-2	29697-29700	has	_	
166-3	29701-29705	been	_	
166-4	29706-29715	suggested	_	
166-5	29716-29720	that	_	
166-6	29721-29730	metabolic	_	
166-7	29731-29733	as	_	
166-8	29734-29738	well	_	
166-9	29739-29741	as	_	
166-10	29742-29752	anatomical	_	
166-11	29753-29766	abnormalities	_	
166-12	29767-29769	in	_	
166-13	29770-29773	the	_	
166-14	29774-29779	basal	_	
166-15	29780-29787	ganglia	_	
166-16	29788-29797	including	_	
166-17	29798-29801	the	_	
166-18	29802-29809	caudate	_	
166-19	29810-29817	nucleus	_	
166-20	29818-29821	are	_	
166-21	29822-29830	involved	_	
166-22	29831-29833	in	_	
166-23	29834-29837	TRS	_	
166-24	29838-29841	and	_	
166-25	29842-29845	may	_	
166-26	29846-29850	also	_	
166-27	29851-29853	be	_	
166-28	29854-29864	associated	_	
166-29	29865-29869	with	_	
166-30	29870-29879	clozapine	_	
166-31	29880-29888	response	_	
166-32	29888-29889	.	_	

#Text=For example, clozapine responders show hypermetabolism in the thalamus and basal ganglia, which is reduced following successful clozapine treatment.
167-1	29890-29893	For	_	
167-2	29894-29901	example	_	
167-3	29901-29902	,	_	
167-4	29903-29912	clozapine	_	
167-5	29913-29923	responders	_	
167-6	29924-29928	show	_	
167-7	29929-29944	hypermetabolism	_	
167-8	29945-29947	in	_	
167-9	29948-29951	the	_	
167-10	29952-29960	thalamus	_	
167-11	29961-29964	and	_	
167-12	29965-29970	basal	_	
167-13	29971-29978	ganglia	_	
167-14	29978-29979	,	_	
167-15	29980-29985	which	_	
167-16	29986-29988	is	_	
167-17	29989-29996	reduced	_	
167-18	29997-30006	following	_	
167-19	30007-30017	successful	_	
167-20	30018-30027	clozapine	_	
167-21	30028-30037	treatment	_	
167-22	30037-30038	.	_	

#Text=A reduction of metabolism specifically in the caudate after clozapine response was observed more recently and clozapine administration is associated with a reduction of caudate volume.
168-1	30039-30040	A	_	
168-2	30041-30050	reduction	_	
168-3	30051-30053	of	_	
168-4	30054-30064	metabolism	_	
168-5	30065-30077	specifically	_	
168-6	30078-30080	in	_	
168-7	30081-30084	the	_	
168-8	30085-30092	caudate	_	
168-9	30093-30098	after	_	
168-10	30099-30108	clozapine	_	
168-11	30109-30117	response	_	
168-12	30118-30121	was	_	
168-13	30122-30130	observed	_	
168-14	30131-30135	more	_	
168-15	30136-30144	recently	_	
168-16	30145-30148	and	_	
168-17	30149-30158	clozapine	_	
168-18	30159-30173	administration	_	
168-19	30174-30176	is	_	
168-20	30177-30187	associated	_	
168-21	30188-30192	with	_	
168-22	30193-30194	a	_	
168-23	30195-30204	reduction	_	
168-24	30205-30207	of	_	
168-25	30208-30215	caudate	_	
168-26	30216-30222	volume	_	
168-27	30222-30223	.	_	

#Text=Notably, treatment responsive patients were found to have increased dopamine synthesis capacity compared to TRS, a finding which was most strong in the caudate nucleus.
169-1	30224-30231	Notably	_	
169-2	30231-30232	,	_	
169-3	30233-30242	treatment	_	
169-4	30243-30253	responsive	_	
169-5	30254-30262	patients	_	
169-6	30263-30267	were	_	
169-7	30268-30273	found	_	
169-8	30274-30276	to	_	
169-9	30277-30281	have	_	
169-10	30282-30291	increased	_	
169-11	30292-30300	dopamine	_	
169-12	30301-30310	synthesis	_	
169-13	30311-30319	capacity	_	
169-14	30320-30328	compared	_	
169-15	30329-30331	to	_	
169-16	30332-30335	TRS	_	
169-17	30335-30336	,	_	
169-18	30337-30338	a	_	
169-19	30339-30346	finding	_	
169-20	30347-30352	which	_	
169-21	30353-30356	was	_	
169-22	30357-30361	most	_	
169-23	30362-30368	strong	_	
169-24	30369-30371	in	_	
169-25	30372-30375	the	_	
169-26	30376-30383	caudate	_	
169-27	30384-30391	nucleus	_	
169-28	30391-30392	.	_	

#Text=Thus the caudate may constitute an interesting target for further investigation of TRS in studies stratifying patient subgroups by response.
170-1	30393-30397	Thus	_	
170-2	30398-30401	the	_	
170-3	30402-30409	caudate	_	
170-4	30410-30413	may	_	
170-5	30414-30424	constitute	_	
170-6	30425-30427	an	_	
170-7	30428-30439	interesting	_	
170-8	30440-30446	target	_	
170-9	30447-30450	for	_	
170-10	30451-30458	further	_	
170-11	30459-30472	investigation	_	
170-12	30473-30475	of	_	
170-13	30476-30479	TRS	_	
170-14	30480-30482	in	_	
170-15	30483-30490	studies	_	
170-16	30491-30502	stratifying	_	
170-17	30503-30510	patient	_	
170-18	30511-30520	subgroups	_	
170-19	30521-30523	by	_	
170-20	30524-30532	response	_	
170-21	30532-30533	.	_	

#Text=The study has certain limitations common to fMRI studies of a potential selection bias in medicated patients suitable for scanning; however, there are scant studies comparing TRS and NTR patients and withdrawal from medication for the purposes of imaging is not ethical.
171-1	30534-30537	The	_	
171-2	30538-30543	study	_	
171-3	30544-30547	has	_	
171-4	30548-30555	certain	_	
171-5	30556-30567	limitations	_	
171-6	30568-30574	common	_	
171-7	30575-30577	to	_	
171-8	30578-30582	fMRI	_	
171-9	30583-30590	studies	_	
171-10	30591-30593	of	_	
171-11	30594-30595	a	_	
171-12	30596-30605	potential	_	
171-13	30606-30615	selection	_	
171-14	30616-30620	bias	_	
171-15	30621-30623	in	_	
171-16	30624-30633	medicated	_	
171-17	30634-30642	patients	_	
171-18	30643-30651	suitable	_	
171-19	30652-30655	for	_	
171-20	30656-30664	scanning	_	
171-21	30664-30665	;	_	
171-22	30666-30673	however	_	
171-23	30673-30674	,	_	
171-24	30675-30680	there	_	
171-25	30681-30684	are	_	
171-26	30685-30690	scant	_	
171-27	30691-30698	studies	_	
171-28	30699-30708	comparing	_	
171-29	30709-30712	TRS	_	
171-30	30713-30716	and	_	
171-31	30717-30720	NTR	_	
171-32	30721-30729	patients	_	
171-33	30730-30733	and	_	
171-34	30734-30744	withdrawal	_	
171-35	30745-30749	from	_	
171-36	30750-30760	medication	_	
171-37	30761-30764	for	_	
171-38	30765-30768	the	_	
171-39	30769-30777	purposes	_	
171-40	30778-30780	of	_	
171-41	30781-30788	imaging	_	
171-42	30789-30791	is	_	
171-43	30792-30795	not	_	
171-44	30796-30803	ethical	_	
171-45	30803-30804	.	_	

#Text=We did not include patients treated with clozapine in order to maintain the homogeneity of the patient sample and TRS patients fulfilled the standard criteria for treatment resistance-thus avoiding the introduction of sub-groups of patients refractory to clozapine (super-resistant patients).
172-1	30805-30807	We	_	
172-2	30808-30811	did	_	
172-3	30812-30815	not	_	
172-4	30816-30823	include	_	
172-5	30824-30832	patients	_	
172-6	30833-30840	treated	_	
172-7	30841-30845	with	_	
172-8	30846-30855	clozapine	_	
172-9	30856-30858	in	_	
172-10	30859-30864	order	_	
172-11	30865-30867	to	_	
172-12	30868-30876	maintain	_	
172-13	30877-30880	the	_	
172-14	30881-30892	homogeneity	_	
172-15	30893-30895	of	_	
172-16	30896-30899	the	_	
172-17	30900-30907	patient	_	
172-18	30908-30914	sample	_	
172-19	30915-30918	and	_	
172-20	30919-30922	TRS	_	
172-21	30923-30931	patients	_	
172-22	30932-30941	fulfilled	_	
172-23	30942-30945	the	_	
172-24	30946-30954	standard	_	
172-25	30955-30963	criteria	_	
172-26	30964-30967	for	_	
172-27	30968-30977	treatment	_	
172-28	30978-30993	resistance-thus	_	
172-29	30994-31002	avoiding	_	
172-30	31003-31006	the	_	
172-31	31007-31019	introduction	_	
172-32	31020-31022	of	_	
172-33	31023-31033	sub-groups	_	
172-34	31034-31036	of	_	
172-35	31037-31045	patients	_	
172-36	31046-31056	refractory	_	
172-37	31057-31059	to	_	
172-38	31060-31069	clozapine	_	
172-39	31070-31071	(	_	
172-40	31071-31086	super-resistant	_	
172-41	31087-31095	patients	_	
172-42	31095-31096	)	_	
172-43	31096-31097	.	_	

#Text=The differences in striatal RPE activation between groups are apparent at a liberal statistical threshold uncorrected for multiple comparisons; however, the consistent pattern of hypoactivation in NTR patients across the network lends support to this finding as a true positive.
173-1	31098-31101	The	_	
173-2	31102-31113	differences	_	
173-3	31114-31116	in	_	
173-4	31117-31125	striatal	_	
173-5	31126-31129	RPE	_	
173-6	31130-31140	activation	_	
173-7	31141-31148	between	_	
173-8	31149-31155	groups	_	
173-9	31156-31159	are	_	
173-10	31160-31168	apparent	_	
173-11	31169-31171	at	_	
173-12	31172-31173	a	_	
173-13	31174-31181	liberal	_	
173-14	31182-31193	statistical	_	
173-15	31194-31203	threshold	_	
173-16	31204-31215	uncorrected	_	
173-17	31216-31219	for	_	
173-18	31220-31228	multiple	_	
173-19	31229-31240	comparisons	_	
173-20	31240-31241	;	_	
173-21	31242-31249	however	_	
173-22	31249-31250	,	_	
173-23	31251-31254	the	_	
173-24	31255-31265	consistent	_	
173-25	31266-31273	pattern	_	
173-26	31274-31276	of	_	
173-27	31277-31291	hypoactivation	_	
173-28	31292-31294	in	_	
173-29	31295-31298	NTR	_	
173-30	31299-31307	patients	_	
173-31	31308-31314	across	_	
173-32	31315-31318	the	_	
173-33	31319-31326	network	_	
173-34	31327-31332	lends	_	
173-35	31333-31340	support	_	
173-36	31341-31343	to	_	
173-37	31344-31348	this	_	
173-38	31349-31356	finding	_	
173-39	31357-31359	as	_	
173-40	31360-31361	a	_	
173-41	31362-31366	true	_	
173-42	31367-31375	positive	_	
173-43	31375-31376	.	_	

#Text=Subcortical dysfunctions in reward processing in NTR may be particularly hard to detect given that these may be attenuated in chronic patients after antipsychotic medication.
174-1	31377-31388	Subcortical	_	
174-2	31389-31401	dysfunctions	_	
174-3	31402-31404	in	_	
174-4	31405-31411	reward	_	
174-5	31412-31422	processing	_	
174-6	31423-31425	in	_	
174-7	31426-31429	NTR	_	
174-8	31430-31433	may	_	
174-9	31434-31436	be	_	
174-10	31437-31449	particularly	_	
174-11	31450-31454	hard	_	
174-12	31455-31457	to	_	
174-13	31458-31464	detect	_	
174-14	31465-31470	given	_	
174-15	31471-31475	that	_	
174-16	31476-31481	these	_	
174-17	31482-31485	may	_	
174-18	31486-31488	be	_	
174-19	31489-31499	attenuated	_	
174-20	31500-31502	in	_	
174-21	31503-31510	chronic	_	
174-22	31511-31519	patients	_	
174-23	31520-31525	after	_	
174-24	31526-31539	antipsychotic	_	
174-25	31540-31550	medication	_	
174-26	31550-31551	.	_	

#Text=In summary, the data suggest that while the behavioral output during reward learning of patients with treatment resistant and treatment responsive schizophrenia appears to be similar, it is underpinned by different neural systems.
175-1	31552-31554	In	_	
175-2	31555-31562	summary	_	
175-3	31562-31563	,	_	
175-4	31564-31567	the	_	
175-5	31568-31572	data	_	
175-6	31573-31580	suggest	_	
175-7	31581-31585	that	_	
175-8	31586-31591	while	_	
175-9	31592-31595	the	_	
175-10	31596-31606	behavioral	_	
175-11	31607-31613	output	_	
175-12	31614-31620	during	_	
175-13	31621-31627	reward	_	
175-14	31628-31636	learning	_	
175-15	31637-31639	of	_	
175-16	31640-31648	patients	_	
175-17	31649-31653	with	_	
175-18	31654-31663	treatment	_	
175-19	31664-31673	resistant	_	
175-20	31674-31677	and	_	
175-21	31678-31687	treatment	_	
175-22	31688-31698	responsive	_	
175-23	31699-31712	schizophrenia	_	
175-24	31713-31720	appears	_	
175-25	31721-31723	to	_	
175-26	31724-31726	be	_	
175-27	31727-31734	similar	_	
175-28	31734-31735	,	_	
175-29	31736-31738	it	_	
175-30	31739-31741	is	_	
175-31	31742-31753	underpinned	_	
175-32	31754-31756	by	_	
175-33	31757-31766	different	_	
175-34	31767-31773	neural	_	
175-35	31774-31781	systems	_	
175-36	31781-31782	.	_	

#Text=The data support the idea that TRS may represent a different disease from treatment responsive schizophrenia; confirming the evidence from clinical observation that TRS does not fit well into the contemporary dopaminergic dysfunction model of schizophrenia.
176-1	31783-31786	The	_	
176-2	31787-31791	data	_	
176-3	31792-31799	support	_	
176-4	31800-31803	the	_	
176-5	31804-31808	idea	_	
176-6	31809-31813	that	_	
176-7	31814-31817	TRS	_	
176-8	31818-31821	may	_	
176-9	31822-31831	represent	_	
176-10	31832-31833	a	_	
176-11	31834-31843	different	_	
176-12	31844-31851	disease	_	
176-13	31852-31856	from	_	
176-14	31857-31866	treatment	_	
176-15	31867-31877	responsive	_	
176-16	31878-31891	schizophrenia	_	
176-17	31891-31892	;	_	
176-18	31893-31903	confirming	_	
176-19	31904-31907	the	_	
176-20	31908-31916	evidence	_	
176-21	31917-31921	from	_	
176-22	31922-31930	clinical	_	
176-23	31931-31942	observation	_	
176-24	31943-31947	that	_	
176-25	31948-31951	TRS	_	
176-26	31952-31956	does	_	
176-27	31957-31960	not	_	
176-28	31961-31964	fit	_	
176-29	31965-31969	well	_	
176-30	31970-31974	into	_	
176-31	31975-31978	the	_	
176-32	31979-31991	contemporary	_	
176-33	31992-32004	dopaminergic	_	
176-34	32005-32016	dysfunction	_	
176-35	32017-32022	model	_	
176-36	32023-32025	of	_	
176-37	32026-32039	schizophrenia	_	
176-38	32039-32040	.	_	

#Text=Despite extensive research on task-related neural activity in schizophrenia, studies typically do not use key stratifiers to reduce the heterogeneity of the sample and are likely combining neurobiologically distinct subtypes of schizophrenia.
177-1	32041-32048	Despite	_	
177-2	32049-32058	extensive	_	
177-3	32059-32067	research	_	
177-4	32068-32070	on	_	
177-5	32071-32083	task-related	_	
177-6	32084-32090	neural	_	
177-7	32091-32099	activity	_	
177-8	32100-32102	in	_	
177-9	32103-32116	schizophrenia	_	
177-10	32116-32117	,	_	
177-11	32118-32125	studies	_	
177-12	32126-32135	typically	_	
177-13	32136-32138	do	_	
177-14	32139-32142	not	_	
177-15	32143-32146	use	_	
177-16	32147-32150	key	_	
177-17	32151-32162	stratifiers	_	
177-18	32163-32165	to	_	
177-19	32166-32172	reduce	_	
177-20	32173-32176	the	_	
177-21	32177-32190	heterogeneity	_	
177-22	32191-32193	of	_	
177-23	32194-32197	the	_	
177-24	32198-32204	sample	_	
177-25	32205-32208	and	_	
177-26	32209-32212	are	_	
177-27	32213-32219	likely	_	
177-28	32220-32229	combining	_	
177-29	32230-32247	neurobiologically	_	
177-30	32248-32256	distinct	_	
177-31	32257-32265	subtypes	_	
177-32	32266-32268	of	_	
177-33	32269-32282	schizophrenia	_	
177-34	32282-32283	.	_	

#Text=This not only clouds studies of mechanism, but potentially also of treatment trials; missing effects that are specific to one or the other subset of patients.
178-1	32284-32288	This	_	
178-2	32289-32292	not	_	
178-3	32293-32297	only	_	
178-4	32298-32304	clouds	_	
178-5	32305-32312	studies	_	
178-6	32313-32315	of	_	
178-7	32316-32325	mechanism	_	
178-8	32325-32326	,	_	
178-9	32327-32330	but	_	
178-10	32331-32342	potentially	_	
178-11	32343-32347	also	_	
178-12	32348-32350	of	_	
178-13	32351-32360	treatment	_	
178-14	32361-32367	trials	_	
178-15	32367-32368	;	_	
178-16	32369-32376	missing	_	
178-17	32377-32384	effects	_	
178-18	32385-32389	that	_	
178-19	32390-32393	are	_	
178-20	32394-32402	specific	_	
178-21	32403-32405	to	_	
178-22	32406-32409	one	_	
178-23	32410-32412	or	_	
178-24	32413-32416	the	_	
178-25	32417-32422	other	_	
178-26	32423-32429	subset	_	
178-27	32430-32432	of	_	
178-28	32433-32441	patients	_	
178-29	32441-32442	.	_	

#Text=There is an urgent need for stratification of patients by response; both at the chronic stage of the illness and in patients suffering a first episode of psychosis.
179-1	32443-32448	There	_	
179-2	32449-32451	is	_	
179-3	32452-32454	an	_	
179-4	32455-32461	urgent	_	
179-5	32462-32466	need	_	
179-6	32467-32470	for	_	
179-7	32471-32485	stratification	_	
179-8	32486-32488	of	_	
179-9	32489-32497	patients	_	
179-10	32498-32500	by	_	
179-11	32501-32509	response	_	
179-12	32509-32510	;	_	
179-13	32511-32515	both	_	
179-14	32516-32518	at	_	
179-15	32519-32522	the	_	
179-16	32523-32530	chronic	_	
179-17	32531-32536	stage	_	
179-18	32537-32539	of	_	
179-19	32540-32543	the	_	
179-20	32544-32551	illness	_	
179-21	32552-32555	and	_	
179-22	32556-32558	in	_	
179-23	32559-32567	patients	_	
179-24	32568-32577	suffering	_	
179-25	32578-32579	a	_	
179-26	32580-32585	first	_	
179-27	32586-32593	episode	_	
179-28	32594-32596	of	_	
179-29	32597-32606	psychosis	_	
179-30	32606-32607	.	_	

#Text=Indeed recent data following up first episode samples of patients with schizophrenia suggests that over 70% of treatment resistant cases are apparent at onset.
180-1	32608-32614	Indeed	_	
180-2	32615-32621	recent	_	
180-3	32622-32626	data	_	
180-4	32627-32636	following	_	
180-5	32637-32639	up	_	
180-6	32640-32645	first	_	
180-7	32646-32653	episode	_	
180-8	32654-32661	samples	_	
180-9	32662-32664	of	_	
180-10	32665-32673	patients	_	
180-11	32674-32678	with	_	
180-12	32679-32692	schizophrenia	_	
180-13	32693-32701	suggests	_	
180-14	32702-32706	that	_	
180-15	32707-32711	over	_	
180-16	32712-32715	70%	_	
180-17	32716-32718	of	_	
180-18	32719-32728	treatment	_	
180-19	32729-32738	resistant	_	
180-20	32739-32744	cases	_	
180-21	32745-32748	are	_	
180-22	32749-32757	apparent	_	
180-23	32758-32760	at	_	
180-24	32761-32766	onset	_	
180-25	32766-32767	.	_	

#Text=The separation of schizophrenia subgroups will allow the development of clearer hypotheses into the neural mechanisms underlying antipsychotic treatment response and potentially move us closer to being able to use these biomarkers to tailor treatment in a more personalized and effective manner.
181-1	32768-32771	The	_	
181-2	32772-32782	separation	_	
181-3	32783-32785	of	_	
181-4	32786-32799	schizophrenia	_	
181-5	32800-32809	subgroups	_	
181-6	32810-32814	will	_	
181-7	32815-32820	allow	_	
181-8	32821-32824	the	_	
181-9	32825-32836	development	_	
181-10	32837-32839	of	_	
181-11	32840-32847	clearer	_	
181-12	32848-32858	hypotheses	_	
181-13	32859-32863	into	_	
181-14	32864-32867	the	_	
181-15	32868-32874	neural	_	
181-16	32875-32885	mechanisms	_	
181-17	32886-32896	underlying	_	
181-18	32897-32910	antipsychotic	_	
181-19	32911-32920	treatment	_	
181-20	32921-32929	response	_	
181-21	32930-32933	and	_	
181-22	32934-32945	potentially	_	
181-23	32946-32950	move	_	
181-24	32951-32953	us	_	
181-25	32954-32960	closer	_	
181-26	32961-32963	to	_	
181-27	32964-32969	being	_	
181-28	32970-32974	able	_	
181-29	32975-32977	to	_	
181-30	32978-32981	use	_	
181-31	32982-32987	these	_	
181-32	32988-32998	biomarkers	_	
181-33	32999-33001	to	_	
181-34	33002-33008	tailor	_	
181-35	33009-33018	treatment	_	
181-36	33019-33021	in	_	
181-37	33022-33023	a	_	
181-38	33024-33028	more	_	
181-39	33029-33041	personalized	_	
181-40	33042-33045	and	_	
181-41	33046-33055	effective	_	
181-42	33056-33062	manner	_	
181-43	33062-33063	.	_	

#Text=Supplementary Material
#Text=Conflict of interest
#Text=None
#Text=Ethical standards
#Text=The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
182-1	33064-33077	Supplementary	_	
182-2	33078-33086	Material	_	
182-3	33087-33095	Conflict	_	
182-4	33096-33098	of	_	
182-5	33099-33107	interest	_	
182-6	33108-33112	None	_	
182-7	33113-33120	Ethical	_	
182-8	33121-33130	standards	_	
182-9	33131-33134	The	_	
182-10	33135-33142	authors	_	
182-11	33143-33149	assert	_	
182-12	33150-33154	that	_	
182-13	33155-33158	all	_	
182-14	33159-33169	procedures	_	
182-15	33170-33182	contributing	_	
182-16	33183-33185	to	_	
182-17	33186-33190	this	_	
182-18	33191-33195	work	_	
182-19	33196-33202	comply	_	
182-20	33203-33207	with	_	
182-21	33208-33211	the	_	
182-22	33212-33219	ethical	_	
182-23	33220-33229	standards	_	
182-24	33230-33232	of	_	
182-25	33233-33236	the	_	
182-26	33237-33245	relevant	_	
182-27	33246-33254	national	_	
182-28	33255-33258	and	_	
182-29	33259-33272	institutional	_	
182-30	33273-33283	committees	_	
182-31	33284-33286	on	_	
182-32	33287-33292	human	_	
182-33	33293-33308	experimentation	_	
182-34	33309-33312	and	_	
182-35	33313-33317	with	_	
182-36	33318-33321	the	_	
182-37	33322-33330	Helsinki	_	
182-38	33331-33342	Declaration	_	
182-39	33343-33345	of	_	
182-40	33346-33350	1975	_	
182-41	33350-33351	,	_	
182-42	33352-33354	as	_	
182-43	33355-33362	revised	_	
182-44	33363-33365	in	_	
182-45	33366-33370	2008	_	
182-46	33370-33371	.	_	

#Text=The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint first Authors.
183-1	33372-33375	The	_	
183-2	33376-33383	authors	_	
183-3	33384-33388	wish	_	
183-4	33389-33391	it	_	
183-5	33392-33394	to	_	
183-6	33395-33397	be	_	
183-7	33398-33403	known	_	
183-8	33404-33408	that	_	
183-9	33408-33409	,	_	
183-10	33410-33412	in	_	
183-11	33413-33418	their	_	
183-12	33419-33426	opinion	_	
183-13	33426-33427	,	_	
183-14	33428-33431	the	_	
183-15	33432-33437	first	_	
183-16	33438-33441	two	_	
183-17	33442-33449	authors	_	
183-18	33450-33456	should	_	
183-19	33457-33459	be	_	
183-20	33460-33468	regarded	_	
183-21	33469-33471	as	_	
183-22	33472-33477	joint	_	
183-23	33478-33483	first	_	
183-24	33484-33491	Authors	_	
183-25	33491-33492	.	_	

#Text=References
#Text=
#Text=Remission in schizophrenia: proposed criteria and rationale for consensus
#Text=Integration of social and utilitarian factors in decision making
#Text=Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions
#Text=Psychotropic drug directory.
184-1	33493-33503	References	_	
184-2	33505-33514	Remission	_	
184-3	33515-33517	in	_	
184-4	33518-33531	schizophrenia	_	
184-5	33531-33532	:	_	
184-6	33533-33541	proposed	_	
184-7	33542-33550	criteria	_	
184-8	33551-33554	and	_	
184-9	33555-33564	rationale	_	
184-10	33565-33568	for	_	
184-11	33569-33578	consensus	_	
184-12	33579-33590	Integration	_	
184-13	33591-33593	of	_	
184-14	33594-33600	social	_	
184-15	33601-33604	and	_	
184-16	33605-33616	utilitarian	_	
184-17	33617-33624	factors	_	
184-18	33625-33627	in	_	
184-19	33628-33636	decision	_	
184-20	33637-33643	making	_	
184-21	33644-33648	Goal	_	
184-22	33649-33664	representations	_	
184-23	33665-33668	and	_	
184-24	33669-33681	motivational	_	
184-25	33682-33687	drive	_	
184-26	33688-33690	in	_	
184-27	33691-33704	schizophrenia	_	
184-28	33704-33705	:	_	
184-29	33706-33709	the	_	
184-30	33710-33714	role	_	
184-31	33715-33717	of	_	
184-32	33718-33737	prefrontal-striatal	_	
184-33	33738-33750	interactions	_	
184-34	33751-33763	Psychotropic	_	
184-35	33764-33768	drug	_	
184-36	33769-33778	directory	_	
184-37	33778-33779	.	_	

#Text=The professionals’ pocket handbook and aide memoire, Drug treatment options in psychiatric illness
#Text=Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
#Text=Mild Reinforcement Learning Deficits in Patients With First-Episode Psychosis
#Text=Cognitive control over learning: creating, clustering, and generalizing task-set structure
#Text=Management of treatment resistance in schizophrenia
#Text=High central D 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients
#Text=Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions
#Text=Intact ventral striatal prediction error signaling in medicated schizophrenia patients
#Text=Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function
#Text=Dopamine synthesis capacity in patients with treatment-resistant schizophrenia
#Text=Striatal dopamine, reward, and decision making in schizophrenia
#Text=Functional connectivity of human striatum: a resting state FMRI study
#Text=Probabilistic reinforcement learning in patients with schizophrenia: Relationships to anhedonia and avolition
#Text=Effects of emotional preferences on value-based decision-making are mediated by mentalizing and not reward networks
#Text=Patients with schizophrenia show increased aversion to angry faces in an associative learning task
#Text=Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control
#Text=Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal
#Text=Interactions between frontal cortex and basal ganglia in working memory: a computational model
#Text=Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment
#Text=Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review
#Text=Prediction error in reinforcement learning: a meta-analysis of neuroimaging studies
#Text=Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence
#Text=Expected value and prediction error abnormalities in depression and schizophrenia
#Text=Elements of the Intrinsic Organization
#Text=Dopaminergic dysfunction in schizophrenia: salience attribution revisited
#Text=Realising stratified psychiatry using multidimensional signatures and trajectories
#Text=Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
#Text=Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?
185-1	33780-33783	The	_	
185-2	33784-33797	professionals	_	
185-3	33797-33798	’	_	
185-4	33799-33805	pocket	_	
185-5	33806-33814	handbook	_	
185-6	33815-33818	and	_	
185-7	33819-33823	aide	_	
185-8	33824-33831	memoire	_	
185-9	33831-33832	,	_	
185-10	33833-33837	Drug	_	
185-11	33838-33847	treatment	_	
185-12	33848-33855	options	_	
185-13	33856-33858	in	_	
185-14	33859-33870	psychiatric	_	
185-15	33871-33878	illness	_	
185-16	33879-33886	Caudate	_	
185-17	33887-33893	nuclei	_	
185-18	33894-33901	volumes	_	
185-19	33902-33904	in	_	
185-20	33905-33918	schizophrenic	_	
185-21	33919-33927	patients	_	
185-22	33928-33935	treated	_	
185-23	33936-33940	with	_	
185-24	33941-33948	typical	_	
185-25	33949-33963	antipsychotics	_	
185-26	33964-33966	or	_	
185-27	33967-33976	clozapine	_	
185-28	33977-33981	Mild	_	
185-29	33982-33995	Reinforcement	_	
185-30	33996-34004	Learning	_	
185-31	34005-34013	Deficits	_	
185-32	34014-34016	in	_	
185-33	34017-34025	Patients	_	
185-34	34026-34030	With	_	
185-35	34031-34044	First-Episode	_	
185-36	34045-34054	Psychosis	_	
185-37	34055-34064	Cognitive	_	
185-38	34065-34072	control	_	
185-39	34073-34077	over	_	
185-40	34078-34086	learning	_	
185-41	34086-34087	:	_	
185-42	34088-34096	creating	_	
185-43	34096-34097	,	_	
185-44	34098-34108	clustering	_	
185-45	34108-34109	,	_	
185-46	34110-34113	and	_	
185-47	34114-34126	generalizing	_	
185-48	34127-34135	task-set	_	
185-49	34136-34145	structure	_	
185-50	34146-34156	Management	_	
185-51	34157-34159	of	_	
185-52	34160-34169	treatment	_	
185-53	34170-34180	resistance	_	
185-54	34181-34183	in	_	
185-55	34184-34197	schizophrenia	_	
185-56	34198-34202	High	_	
185-57	34203-34210	central	_	
185-58	34211-34212	D	_	
185-59	34213-34214	2	_	
185-60	34214-34215	-	_	
185-61	34215-34223	dopamine	_	
185-62	34224-34232	receptor	_	
185-63	34233-34242	occupancy	_	
185-64	34243-34245	as	_	
185-65	34246-34254	assessed	_	
185-66	34255-34259	with	_	
185-67	34260-34268	positron	_	
185-68	34269-34277	emission	_	
185-69	34278-34288	tomography	_	
185-70	34289-34291	in	_	
185-71	34292-34301	medicated	_	
185-72	34302-34305	but	_	
185-73	34306-34323	therapy-resistant	_	
185-74	34324-34337	schizophrenic	_	
185-75	34338-34346	patients	_	
185-76	34347-34356	Disrupted	_	
185-77	34357-34373	prediction-error	_	
185-78	34374-34380	signal	_	
185-79	34381-34383	in	_	
185-80	34384-34393	psychosis	_	
185-81	34393-34394	:	_	
185-82	34395-34403	evidence	_	
185-83	34404-34407	for	_	
185-84	34408-34410	an	_	
185-85	34411-34422	associative	_	
185-86	34423-34430	account	_	
185-87	34431-34433	of	_	
185-88	34434-34443	delusions	_	
185-89	34444-34450	Intact	_	
185-90	34451-34458	ventral	_	
185-91	34459-34467	striatal	_	
185-92	34468-34478	prediction	_	
185-93	34479-34484	error	_	
185-94	34485-34494	signaling	_	
185-95	34495-34497	in	_	
185-96	34498-34507	medicated	_	
185-97	34508-34521	schizophrenia	_	
185-98	34522-34530	patients	_	
185-99	34531-34544	Antipsychotic	_	
185-100	34545-34554	treatment	_	
185-101	34555-34565	resistance	_	
185-102	34566-34568	in	_	
185-103	34569-34582	schizophrenia	_	
185-104	34583-34593	associated	_	
185-105	34594-34598	with	_	
185-106	34599-34607	elevated	_	
185-107	34608-34617	glutamate	_	
185-108	34618-34624	levels	_	
185-109	34625-34628	but	_	
185-110	34629-34635	normal	_	
185-111	34636-34644	dopamine	_	
185-112	34645-34653	function	_	
185-113	34654-34662	Dopamine	_	
185-114	34663-34672	synthesis	_	
185-115	34673-34681	capacity	_	
185-116	34682-34684	in	_	
185-117	34685-34693	patients	_	
185-118	34694-34698	with	_	
185-119	34699-34718	treatment-resistant	_	
185-120	34719-34732	schizophrenia	_	
185-121	34733-34741	Striatal	_	
185-122	34742-34750	dopamine	_	
185-123	34750-34751	,	_	
185-124	34752-34758	reward	_	
185-125	34758-34759	,	_	
185-126	34760-34763	and	_	
185-127	34764-34772	decision	_	
185-128	34773-34779	making	_	
185-129	34780-34782	in	_	
185-130	34783-34796	schizophrenia	_	
185-131	34797-34807	Functional	_	
185-132	34808-34820	connectivity	_	
185-133	34821-34823	of	_	
185-134	34824-34829	human	_	
185-135	34830-34838	striatum	_	
185-136	34838-34839	:	_	
185-137	34840-34841	a	_	
185-138	34842-34849	resting	_	
185-139	34850-34855	state	_	
185-140	34856-34860	FMRI	_	
185-141	34861-34866	study	_	
185-142	34867-34880	Probabilistic	_	
185-143	34881-34894	reinforcement	_	
185-144	34895-34903	learning	_	
185-145	34904-34906	in	_	
185-146	34907-34915	patients	_	
185-147	34916-34920	with	_	
185-148	34921-34934	schizophrenia	_	
185-149	34934-34935	:	_	
185-150	34936-34949	Relationships	_	
185-151	34950-34952	to	_	
185-152	34953-34962	anhedonia	_	
185-153	34963-34966	and	_	
185-154	34967-34976	avolition	_	
185-155	34977-34984	Effects	_	
185-156	34985-34987	of	_	
185-157	34988-34997	emotional	_	
185-158	34998-35009	preferences	_	
185-159	35010-35012	on	_	
185-160	35013-35024	value-based	_	
185-161	35025-35040	decision-making	_	
185-162	35041-35044	are	_	
185-163	35045-35053	mediated	_	
185-164	35054-35056	by	_	
185-165	35057-35068	mentalizing	_	
185-166	35069-35072	and	_	
185-167	35073-35076	not	_	
185-168	35077-35083	reward	_	
185-169	35084-35092	networks	_	
185-170	35093-35101	Patients	_	
185-171	35102-35106	with	_	
185-172	35107-35120	schizophrenia	_	
185-173	35121-35125	show	_	
185-174	35126-35135	increased	_	
185-175	35136-35144	aversion	_	
185-176	35145-35147	to	_	
185-177	35148-35153	angry	_	
185-178	35154-35159	faces	_	
185-179	35160-35162	in	_	
185-180	35163-35165	an	_	
185-181	35166-35177	associative	_	
185-182	35178-35186	learning	_	
185-183	35187-35191	task	_	
185-184	35192-35205	Resting-state	_	
185-185	35206-35215	glutamate	_	
185-186	35216-35221	level	_	
185-187	35222-35224	in	_	
185-188	35225-35228	the	_	
185-189	35229-35237	anterior	_	
185-190	35238-35247	cingulate	_	
185-191	35248-35256	predicts	_	
185-192	35257-35269	blood-oxygen	_	
185-193	35270-35285	level-dependent	_	
185-194	35286-35294	response	_	
185-195	35295-35297	to	_	
185-196	35298-35307	cognitive	_	
185-197	35308-35315	control	_	
185-198	35316-35323	Anatomy	_	
185-199	35324-35326	of	_	
185-200	35327-35328	a	_	
185-201	35329-35337	decision	_	
185-202	35337-35338	:	_	
185-203	35339-35360	striato-orbitofrontal	_	
185-204	35361-35373	interactions	_	
185-205	35374-35376	in	_	
185-206	35377-35390	reinforcement	_	
185-207	35391-35399	learning	_	
185-208	35399-35400	,	_	
185-209	35401-35409	decision	_	
185-210	35410-35416	making	_	
185-211	35416-35417	,	_	
185-212	35418-35421	and	_	
185-213	35422-35430	reversal	_	
185-214	35431-35443	Interactions	_	
185-215	35444-35451	between	_	
185-216	35452-35459	frontal	_	
185-217	35460-35466	cortex	_	
185-218	35467-35470	and	_	
185-219	35471-35476	basal	_	
185-220	35477-35484	ganglia	_	
185-221	35485-35487	in	_	
185-222	35488-35495	working	_	
185-223	35496-35502	memory	_	
185-224	35502-35503	:	_	
185-225	35504-35505	a	_	
185-226	35506-35519	computational	_	
185-227	35520-35525	model	_	
185-228	35526-35541	Childhood-onset	_	
185-229	35542-35555	schizophrenia	_	
185-230	35555-35556	:	_	
185-231	35557-35562	brain	_	
185-232	35563-35566	MRI	_	
185-233	35567-35573	rescan	_	
185-234	35574-35579	after	_	
185-235	35580-35581	2	_	
185-236	35582-35587	years	_	
185-237	35588-35590	of	_	
185-238	35591-35600	clozapine	_	
185-239	35601-35612	maintenance	_	
185-240	35613-35622	treatment	_	
185-241	35623-35633	Structural	_	
185-242	35634-35637	and	_	
185-243	35638-35648	functional	_	
185-244	35649-35661	neuroimaging	_	
185-245	35662-35670	findings	_	
185-246	35671-35681	associated	_	
185-247	35682-35686	with	_	
185-248	35687-35690	the	_	
185-249	35691-35694	use	_	
185-250	35695-35697	of	_	
185-251	35698-35707	clozapine	_	
185-252	35708-35710	in	_	
185-253	35711-35724	schizophrenia	_	
185-254	35724-35725	:	_	
185-255	35726-35727	a	_	
185-256	35728-35738	systematic	_	
185-257	35739-35745	review	_	
185-258	35746-35756	Prediction	_	
185-259	35757-35762	error	_	
185-260	35763-35765	in	_	
185-261	35766-35779	reinforcement	_	
185-262	35780-35788	learning	_	
185-263	35788-35789	:	_	
185-264	35790-35791	a	_	
185-265	35792-35805	meta-analysis	_	
185-266	35806-35808	of	_	
185-267	35809-35821	neuroimaging	_	
185-268	35822-35829	studies	_	
185-269	35830-35838	Negative	_	
185-270	35839-35847	symptoms	_	
185-271	35848-35851	and	_	
185-272	35852-35855	the	_	
185-273	35856-35863	failure	_	
185-274	35864-35866	to	_	
185-275	35867-35876	represent	_	
185-276	35877-35880	the	_	
185-277	35881-35889	expected	_	
185-278	35890-35896	reward	_	
185-279	35897-35902	value	_	
185-280	35903-35905	of	_	
185-281	35906-35913	actions	_	
185-282	35913-35914	:	_	
185-283	35915-35925	behavioral	_	
185-284	35926-35929	and	_	
185-285	35930-35943	computational	_	
185-286	35944-35952	modeling	_	
185-287	35953-35961	evidence	_	
185-288	35962-35970	Expected	_	
185-289	35971-35976	value	_	
185-290	35977-35980	and	_	
185-291	35981-35991	prediction	_	
185-292	35992-35997	error	_	
185-293	35998-36011	abnormalities	_	
185-294	36012-36014	in	_	
185-295	36015-36025	depression	_	
185-296	36026-36029	and	_	
185-297	36030-36043	schizophrenia	_	
185-298	36044-36052	Elements	_	
185-299	36053-36055	of	_	
185-300	36056-36059	the	_	
185-301	36060-36069	Intrinsic	_	
185-302	36070-36082	Organization	_	
185-303	36083-36095	Dopaminergic	_	
185-304	36096-36107	dysfunction	_	
185-305	36108-36110	in	_	
185-306	36111-36124	schizophrenia	_	
185-307	36124-36125	:	_	
185-308	36126-36134	salience	_	
185-309	36135-36146	attribution	_	
185-310	36147-36156	revisited	_	
185-311	36157-36166	Realising	_	
185-312	36167-36177	stratified	_	
185-313	36178-36188	psychiatry	_	
185-314	36189-36194	using	_	
185-315	36195-36211	multidimensional	_	
185-316	36212-36222	signatures	_	
185-317	36223-36226	and	_	
185-318	36227-36239	trajectories	_	
185-319	36240-36249	Psychosis	_	
185-320	36250-36252	as	_	
185-321	36253-36254	a	_	
185-322	36255-36260	state	_	
185-323	36261-36263	of	_	
185-324	36264-36272	aberrant	_	
185-325	36273-36281	salience	_	
185-326	36281-36282	:	_	
185-327	36283-36284	a	_	
185-328	36285-36294	framework	_	
185-329	36295-36302	linking	_	
185-330	36303-36310	biology	_	
185-331	36310-36311	,	_	
185-332	36312-36325	phenomenology	_	
185-333	36325-36326	,	_	
185-334	36327-36330	and	_	
185-335	36331-36343	pharmacology	_	
185-336	36344-36346	in	_	
185-337	36347-36360	schizophrenia	_	
185-338	36361-36365	Does	_	
185-339	36366-36370	fast	_	
185-340	36371-36383	dissociation	_	
185-341	36384-36388	from	_	
185-342	36389-36392	the	_	
185-343	36393-36401	dopamine	_	
185-344	36402-36404	D2	_	
185-345	36405-36413	receptor	_	
185-346	36414-36421	explain	_	
185-347	36422-36425	the	_	
185-348	36426-36432	action	_	
185-349	36433-36435	of	_	
185-350	36436-36444	atypical	_	
185-351	36445-36459	antipsychotics	_	
185-352	36459-36460	?	_	

#Text=: A new hypothesis
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation
#Text=Altered activation in association with reward-related trial-and-error learning in patients with schizophrenia
#Text=Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
#Text=Treatment refractory schizophrenia
#Text=Marked hypofrontality in clozapine-responsive patients
#Text=Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world
#Text=Substantia nigra/ventral tegmental reward prediction error disruption in psychosis
#Text=Dialogues on prediction errors
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Motivational Context Modulates Prediction Error Response in Schizophrenia
#Text=Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning
#Text=SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine
#Text=Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients.
186-1	36460-36461	:	_	
186-2	36462-36463	A	_	
186-3	36464-36467	new	_	
186-4	36468-36478	hypothesis	_	
186-5	36479-36482	The	_	
186-6	36483-36491	positive	_	
186-7	36492-36495	and	_	
186-8	36496-36504	negative	_	
186-9	36505-36513	syndrome	_	
186-10	36514-36519	scale	_	
186-11	36520-36521	(	_	
186-12	36521-36526	PANSS	_	
186-13	36526-36527	)	_	
186-14	36528-36531	for	_	
186-15	36532-36545	schizophrenia	_	
186-16	36546-36554	Learning	_	
186-17	36555-36558	and	_	
186-18	36559-36568	cognitive	_	
186-19	36569-36580	flexibility	_	
186-20	36580-36581	:	_	
186-21	36582-36596	frontostriatal	_	
186-22	36597-36605	function	_	
186-23	36606-36609	and	_	
186-24	36610-36623	monoaminergic	_	
186-25	36624-36634	modulation	_	
186-26	36635-36642	Altered	_	
186-27	36643-36653	activation	_	
186-28	36654-36656	in	_	
186-29	36657-36668	association	_	
186-30	36669-36673	with	_	
186-31	36674-36688	reward-related	_	
186-32	36689-36704	trial-and-error	_	
186-33	36705-36713	learning	_	
186-34	36714-36716	in	_	
186-35	36717-36725	patients	_	
186-36	36726-36730	with	_	
186-37	36731-36744	schizophrenia	_	
186-38	36745-36748	Two	_	
186-39	36749-36757	distinct	_	
186-40	36758-36766	patterns	_	
186-41	36767-36769	of	_	
186-42	36770-36779	treatment	_	
186-43	36780-36790	resistance	_	
186-44	36790-36791	:	_	
186-45	36792-36800	clinical	_	
186-46	36801-36811	predictors	_	
186-47	36812-36814	of	_	
186-48	36815-36824	treatment	_	
186-49	36825-36835	resistance	_	
186-50	36836-36838	in	_	
186-51	36839-36852	first-episode	_	
186-52	36853-36866	schizophrenia	_	
186-53	36867-36875	spectrum	_	
186-54	36876-36885	psychoses	_	
186-55	36886-36895	Treatment	_	
186-56	36896-36906	refractory	_	
186-57	36907-36920	schizophrenia	_	
186-58	36921-36927	Marked	_	
186-59	36928-36942	hypofrontality	_	
186-60	36943-36945	in	_	
186-61	36946-36966	clozapine-responsive	_	
186-62	36967-36975	patients	_	
186-63	36976-36985	Clozapine	_	
186-64	36986-36989	for	_	
186-65	36990-37009	treatment-resistant	_	
186-66	37010-37023	schizophrenia	_	
186-67	37023-37024	:	_	
186-68	37025-37033	National	_	
186-69	37034-37043	Institute	_	
186-70	37044-37046	of	_	
186-71	37047-37055	Clinical	_	
186-72	37056-37066	Excellence	_	
186-73	37067-37068	(	_	
186-74	37068-37072	NICE	_	
186-75	37072-37073	)	_	
186-76	37074-37082	guidance	_	
186-77	37083-37085	in	_	
186-78	37086-37089	the	_	
186-79	37090-37094	real	_	
186-80	37095-37100	world	_	
186-81	37101-37111	Substantia	_	
186-82	37112-37117	nigra	_	
186-83	37117-37118	/	_	
186-84	37118-37125	ventral	_	
186-85	37126-37135	tegmental	_	
186-86	37136-37142	reward	_	
186-87	37143-37153	prediction	_	
186-88	37154-37159	error	_	
186-89	37160-37170	disruption	_	
186-90	37171-37173	in	_	
186-91	37174-37183	psychosis	_	
186-92	37184-37193	Dialogues	_	
186-93	37194-37196	on	_	
186-94	37197-37207	prediction	_	
186-95	37208-37214	errors	_	
186-96	37215-37223	Spurious	_	
186-97	37224-37227	but	_	
186-98	37228-37238	systematic	_	
186-99	37239-37251	correlations	_	
186-100	37252-37254	in	_	
186-101	37255-37265	functional	_	
186-102	37266-37278	connectivity	_	
186-103	37279-37282	MRI	_	
186-104	37283-37291	networks	_	
186-105	37292-37297	arise	_	
186-106	37298-37302	from	_	
186-107	37303-37310	subject	_	
186-108	37311-37317	motion	_	
186-109	37318-37330	Motivational	_	
186-110	37331-37338	Context	_	
186-111	37339-37348	Modulates	_	
186-112	37349-37359	Prediction	_	
186-113	37360-37365	Error	_	
186-114	37366-37374	Response	_	
186-115	37375-37377	in	_	
186-116	37378-37391	Schizophrenia	_	
186-117	37392-37406	Neurocognitive	_	
186-118	37407-37417	mechanisms	_	
186-119	37418-37420	of	_	
186-120	37421-37430	cognitive	_	
186-121	37431-37438	control	_	
186-122	37438-37439	:	_	
186-123	37440-37443	the	_	
186-124	37444-37448	role	_	
186-125	37449-37451	of	_	
186-126	37452-37462	prefrontal	_	
186-127	37463-37469	cortex	_	
186-128	37470-37472	in	_	
186-129	37473-37479	action	_	
186-130	37480-37489	selection	_	
186-131	37489-37490	,	_	
186-132	37491-37499	response	_	
186-133	37500-37510	inhibition	_	
186-134	37510-37511	,	_	
186-135	37512-37523	performance	_	
186-136	37524-37534	monitoring	_	
186-137	37534-37535	,	_	
186-138	37536-37539	and	_	
186-139	37540-37552	reward-based	_	
186-140	37553-37561	learning	_	
186-141	37562-37567	SPECT	_	
186-142	37568-37573	study	_	
186-143	37574-37576	of	_	
186-144	37577-37585	regional	_	
186-145	37586-37594	cerebral	_	
186-146	37595-37604	perfusion	_	
186-147	37605-37607	in	_	
186-148	37608-37629	neuroleptic-resistant	_	
186-149	37630-37643	schizophrenic	_	
186-150	37644-37652	patients	_	
186-151	37653-37656	who	_	
186-152	37657-37666	responded	_	
186-153	37667-37669	or	_	
186-154	37670-37673	did	_	
186-155	37674-37677	not	_	
186-156	37678-37685	respond	_	
186-157	37686-37688	to	_	
186-158	37689-37698	clozapine	_	
186-159	37699-37722	Fronto-striato-thalamic	_	
186-160	37723-37732	perfusion	_	
186-161	37733-37736	and	_	
186-162	37737-37746	clozapine	_	
186-163	37747-37755	response	_	
186-164	37756-37758	in	_	
186-165	37759-37779	treatment-refractory	_	
186-166	37780-37793	schizophrenic	_	
186-167	37794-37802	patients	_	
186-168	37802-37803	.	_	

#Text=A 99m Tc-HMPAO study
#Text=The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics
#Text=Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia
#Text=Striatal dysfunction during reversal learning in unmedicated schizophrenia patients
#Text=Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions
#Text=Predictive reward signal of dopamine neurons
#Text=Getting formal with dopamine and reward
#Text=Neuronal coding of prediction errors
#Text=Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons
#Text=Antipsychotic drug doses and neuroleptic/dopamine receptors
#Text=Neural correlates of reward processing in schizophrenia—relationship to apathy and depression
#Text=Advances in functional and structural MR image analysis and implementation as FSL
#Text=Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task
#Text=Ubiquity and specificity of reinforcement signals throughout the human brain
#Text=Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction
#Text=Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling
#Text=Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers
#Text=Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia
#Text=
#Text=Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
#Text=Chlorpromazine equivalent doses for the newer atypical antipsychotics
#Text=Dissociable systems for gain-and loss-related value predictions and errors of prediction in the human brain
#Text=Neural response correlating with reward prediction error (RPE) in healthy controls (HC) during wins (A) and losses (B) and well as in treatment resistant schizophrenia (TRS) during wins (C) and losses (D).
187-1	37804-37805	A	_	
187-2	37806-37809	99m	_	
187-3	37810-37818	Tc-HMPAO	_	
187-4	37819-37824	study	_	
187-5	37825-37828	The	_	
187-6	37829-37835	effect	_	
187-7	37836-37838	of	_	
187-8	37839-37848	clozapine	_	
187-9	37849-37851	on	_	
187-10	37852-37859	caudate	_	
187-11	37860-37867	nucleus	_	
187-12	37868-37874	volume	_	
187-13	37875-37877	in	_	
187-14	37878-37891	schizophrenic	_	
187-15	37892-37900	patients	_	
187-16	37901-37911	previously	_	
187-17	37912-37919	treated	_	
187-18	37920-37924	with	_	
187-19	37925-37932	typical	_	
187-20	37933-37947	antipsychotics	_	
187-21	37948-37954	Effect	_	
187-22	37955-37957	of	_	
187-23	37958-37967	clozapine	_	
187-24	37968-37970	on	_	
187-25	37971-37978	caudate	_	
187-26	37979-37986	nucleus	_	
187-27	37987-37993	volume	_	
187-28	37994-37996	in	_	
187-29	37997-38005	relation	_	
187-30	38006-38008	to	_	
187-31	38009-38017	symptoms	_	
187-32	38018-38020	of	_	
187-33	38021-38034	schizophrenia	_	
187-34	38035-38043	Striatal	_	
187-35	38044-38055	dysfunction	_	
187-36	38056-38062	during	_	
187-37	38063-38071	reversal	_	
187-38	38072-38080	learning	_	
187-39	38081-38083	in	_	
187-40	38084-38095	unmedicated	_	
187-41	38096-38109	schizophrenia	_	
187-42	38110-38118	patients	_	
187-43	38119-38125	Reward	_	
187-44	38126-38134	feedback	_	
187-45	38135-38146	alterations	_	
187-46	38147-38149	in	_	
187-47	38150-38161	unmedicated	_	
187-48	38162-38175	schizophrenia	_	
187-49	38176-38184	patients	_	
187-50	38184-38185	:	_	
187-51	38186-38195	relevance	_	
187-52	38196-38199	for	_	
187-53	38200-38209	delusions	_	
187-54	38210-38220	Predictive	_	
187-55	38221-38227	reward	_	
187-56	38228-38234	signal	_	
187-57	38235-38237	of	_	
187-58	38238-38246	dopamine	_	
187-59	38247-38254	neurons	_	
187-60	38255-38262	Getting	_	
187-61	38263-38269	formal	_	
187-62	38270-38274	with	_	
187-63	38275-38283	dopamine	_	
187-64	38284-38287	and	_	
187-65	38288-38294	reward	_	
187-66	38295-38303	Neuronal	_	
187-67	38304-38310	coding	_	
187-68	38311-38313	of	_	
187-69	38314-38324	prediction	_	
187-70	38325-38331	errors	_	
187-71	38332-38345	Antipsychotic	_	
187-72	38346-38351	drugs	_	
187-73	38351-38352	:	_	
187-74	38353-38359	direct	_	
187-75	38360-38371	correlation	_	
187-76	38372-38379	between	_	
187-77	38380-38388	clinical	_	
187-78	38389-38396	potency	_	
187-79	38397-38400	and	_	
187-80	38401-38412	presynaptic	_	
187-81	38413-38419	action	_	
187-82	38420-38422	on	_	
187-83	38423-38431	dopamine	_	
187-84	38432-38439	neurons	_	
187-85	38440-38453	Antipsychotic	_	
187-86	38454-38458	drug	_	
187-87	38459-38464	doses	_	
187-88	38465-38468	and	_	
187-89	38469-38480	neuroleptic	_	
187-90	38480-38481	/	_	
187-91	38481-38489	dopamine	_	
187-92	38490-38499	receptors	_	
187-93	38500-38506	Neural	_	
187-94	38507-38517	correlates	_	
187-95	38518-38520	of	_	
187-96	38521-38527	reward	_	
187-97	38528-38538	processing	_	
187-98	38539-38541	in	_	
187-99	38542-38568	schizophrenia—relationship	_	
187-100	38569-38571	to	_	
187-101	38572-38578	apathy	_	
187-102	38579-38582	and	_	
187-103	38583-38593	depression	_	
187-104	38594-38602	Advances	_	
187-105	38603-38605	in	_	
187-106	38606-38616	functional	_	
187-107	38617-38620	and	_	
187-108	38621-38631	structural	_	
187-109	38632-38634	MR	_	
187-110	38635-38640	image	_	
187-111	38641-38649	analysis	_	
187-112	38650-38653	and	_	
187-113	38654-38668	implementation	_	
187-114	38669-38671	as	_	
187-115	38672-38675	FSL	_	
187-116	38676-38686	Functional	_	
187-117	38687-38695	magnetic	_	
187-118	38696-38705	resonance	_	
187-119	38706-38718	spectroscopy	_	
187-120	38719-38721	of	_	
187-121	38722-38731	glutamate	_	
187-122	38732-38734	in	_	
187-123	38735-38748	schizophrenia	_	
187-124	38749-38752	and	_	
187-125	38753-38758	major	_	
187-126	38759-38769	depressive	_	
187-127	38770-38778	disorder	_	
187-128	38778-38779	:	_	
187-129	38780-38788	anterior	_	
187-130	38789-38798	cingulate	_	
187-131	38799-38807	activity	_	
187-132	38808-38814	during	_	
187-133	38815-38816	a	_	
187-134	38817-38827	color-word	_	
187-135	38828-38834	Stroop	_	
187-136	38835-38839	task	_	
187-137	38840-38848	Ubiquity	_	
187-138	38849-38852	and	_	
187-139	38853-38864	specificity	_	
187-140	38865-38867	of	_	
187-141	38868-38881	reinforcement	_	
187-142	38882-38889	signals	_	
187-143	38890-38900	throughout	_	
187-144	38901-38904	the	_	
187-145	38905-38910	human	_	
187-146	38911-38916	brain	_	
187-147	38917-38926	Selective	_	
187-148	38927-38940	reinforcement	_	
187-149	38941-38949	learning	_	
187-150	38950-38958	deficits	_	
187-151	38959-38961	in	_	
187-152	38962-38975	schizophrenia	_	
187-153	38976-38983	support	_	
187-154	38984-38995	predictions	_	
187-155	38996-39000	from	_	
187-156	39001-39014	computational	_	
187-157	39015-39021	models	_	
187-158	39022-39024	of	_	
187-159	39025-39042	striatal-cortical	_	
187-160	39043-39054	dysfunction	_	
187-161	39055-39062	Altered	_	
187-162	39063-39076	probabilistic	_	
187-163	39077-39085	learning	_	
187-164	39086-39089	and	_	
187-165	39090-39098	response	_	
187-166	39099-39105	biases	_	
187-167	39106-39108	in	_	
187-168	39109-39122	schizophrenia	_	
187-169	39122-39123	:	_	
187-170	39124-39134	behavioral	_	
187-171	39135-39143	evidence	_	
187-172	39144-39147	and	_	
187-173	39148-39166	neurocomputational	_	
187-174	39167-39175	modeling	_	
187-175	39176-39184	Patients	_	
187-176	39185-39189	with	_	
187-177	39190-39203	schizophrenia	_	
187-178	39204-39208	have	_	
187-179	39209-39210	a	_	
187-180	39211-39218	reduced	_	
187-181	39219-39225	neural	_	
187-182	39226-39234	response	_	
187-183	39235-39237	to	_	
187-184	39238-39242	both	_	
187-185	39243-39256	unpredictable	_	
187-186	39257-39260	and	_	
187-187	39261-39272	predictable	_	
187-188	39273-39280	primary	_	
187-189	39281-39292	reinforcers	_	
187-190	39293-39301	Abnormal	_	
187-191	39302-39311	responses	_	
187-192	39312-39314	to	_	
187-193	39315-39323	monetary	_	
187-194	39324-39332	outcomes	_	
187-195	39333-39335	in	_	
187-196	39336-39342	cortex	_	
187-197	39342-39343	,	_	
187-198	39344-39347	but	_	
187-199	39348-39351	not	_	
187-200	39352-39354	in	_	
187-201	39355-39358	the	_	
187-202	39359-39364	basal	_	
187-203	39365-39372	ganglia	_	
187-204	39372-39373	,	_	
187-205	39374-39376	in	_	
187-206	39377-39390	schizophrenia	_	
187-207	39392-39400	Dopamine	_	
187-208	39401-39409	blockade	_	
187-209	39410-39413	and	_	
187-210	39414-39422	clinical	_	
187-211	39423-39431	response	_	
187-212	39431-39432	:	_	
187-213	39433-39441	evidence	_	
187-214	39442-39445	for	_	
187-215	39446-39449	two	_	
187-216	39450-39460	biological	_	
187-217	39461-39470	subgroups	_	
187-218	39471-39473	of	_	
187-219	39474-39487	schizophrenia	_	
187-220	39488-39502	Chlorpromazine	_	
187-221	39503-39513	equivalent	_	
187-222	39514-39519	doses	_	
187-223	39520-39523	for	_	
187-224	39524-39527	the	_	
187-225	39528-39533	newer	_	
187-226	39534-39542	atypical	_	
187-227	39543-39557	antipsychotics	_	
187-228	39558-39569	Dissociable	_	
187-229	39570-39577	systems	_	
187-230	39578-39581	for	_	
187-231	39582-39590	gain-and	_	
187-232	39591-39603	loss-related	_	
187-233	39604-39609	value	_	
187-234	39610-39621	predictions	_	
187-235	39622-39625	and	_	
187-236	39626-39632	errors	_	
187-237	39633-39635	of	_	
187-238	39636-39646	prediction	_	
187-239	39647-39649	in	_	
187-240	39650-39653	the	_	
187-241	39654-39659	human	_	
187-242	39660-39665	brain	_	
187-243	39666-39672	Neural	_	
187-244	39673-39681	response	_	
187-245	39682-39693	correlating	_	
187-246	39694-39698	with	_	
187-247	39699-39705	reward	_	
187-248	39706-39716	prediction	_	
187-249	39717-39722	error	_	
187-250	39723-39724	(	_	
187-251	39724-39727	RPE	_	
187-252	39727-39728	)	_	
187-253	39729-39731	in	_	
187-254	39732-39739	healthy	_	
187-255	39740-39748	controls	_	
187-256	39749-39750	(	_	
187-257	39750-39752	HC	_	
187-258	39752-39753	)	_	
187-259	39754-39760	during	_	
187-260	39761-39765	wins	_	
187-261	39766-39767	(	_	
187-262	39767-39768	A	_	
187-263	39768-39769	)	_	
187-264	39770-39773	and	_	
187-265	39774-39780	losses	_	
187-266	39781-39782	(	_	
187-267	39782-39783	B	_	
187-268	39783-39784	)	_	
187-269	39785-39788	and	_	
187-270	39789-39793	well	_	
187-271	39794-39796	as	_	
187-272	39797-39799	in	_	
187-273	39800-39809	treatment	_	
187-274	39810-39819	resistant	_	
187-275	39820-39833	schizophrenia	_	
187-276	39834-39835	(	_	
187-277	39835-39838	TRS	_	
187-278	39838-39839	)	_	
187-279	39840-39846	during	_	
187-280	39847-39851	wins	_	
187-281	39852-39853	(	_	
187-282	39853-39854	C	_	
187-283	39854-39855	)	_	
187-284	39856-39859	and	_	
187-285	39860-39866	losses	_	
187-286	39867-39868	(	_	
187-287	39868-39869	D	_	
187-288	39869-39870	)	_	
187-289	39870-39871	.	_	

#Text=Group differences in neural reward prediction error related activation during wins.
188-1	39872-39877	Group	_	
188-2	39878-39889	differences	_	
188-3	39890-39892	in	_	
188-4	39893-39899	neural	_	
188-5	39900-39906	reward	_	
188-6	39907-39917	prediction	_	
188-7	39918-39923	error	_	
188-8	39924-39931	related	_	
188-9	39932-39942	activation	_	
188-10	39943-39949	during	_	
188-11	39950-39954	wins	_	
188-12	39954-39955	.	_	

#Text=Subcortical region of interest analysis (p < .05, uncorrected) of group differences in reward prediction error signal during wins (A) and losses (B).
189-1	39956-39967	Subcortical	_	
189-2	39968-39974	region	_	
189-3	39975-39977	of	_	
189-4	39978-39986	interest	_	
189-5	39987-39995	analysis	_	
189-6	39996-39997	(	_	
189-7	39997-39998	p	_	
189-8	39999-40000	<	_	
189-9	40001-40004	.05	_	
189-10	40004-40005	,	_	
189-11	40006-40017	uncorrected	_	
189-12	40017-40018	)	_	
189-13	40019-40021	of	_	
189-14	40022-40027	group	_	
189-15	40028-40039	differences	_	
189-16	40040-40042	in	_	
189-17	40043-40049	reward	_	
189-18	40050-40060	prediction	_	
189-19	40061-40066	error	_	
189-20	40067-40073	signal	_	
189-21	40074-40080	during	_	
189-22	40081-40085	wins	_	
189-23	40086-40087	(	_	
189-24	40087-40088	A	_	
189-25	40088-40089	)	_	
189-26	40090-40093	and	_	
189-27	40094-40100	losses	_	
189-28	40101-40102	(	_	
189-29	40102-40103	B	_	
189-30	40103-40104	)	_	
189-31	40104-40105	.	_	

#Text=Group × emotional bias interaction in prediction error signal during losses.
190-1	40106-40111	Group	_	
190-2	40112-40113	×	_	
190-3	40114-40123	emotional	_	
190-4	40124-40128	bias	_	
190-5	40129-40140	interaction	_	
190-6	40141-40143	in	_	
190-7	40144-40154	prediction	_	
190-8	40155-40160	error	_	
190-9	40161-40167	signal	_	
190-10	40168-40174	during	_	
190-11	40175-40181	losses	_	
190-12	40181-40182	.	_	

#Text=Means (M) and standard deviations (SD) of demographic and clinical variables per group
#Text=\tHC\tNTR\tTRS\t\t\t \t\tM\tSD\tM\tSD\tM\tSD\tGroup statistics\t \t\t \t\t\t\t\t\t\t\tχ2(2)\tP\t \t\t\t \tFemale (%)\t25\t\t14\t\t14\t\t1.18\t.555\t \tSmokers (%)\t17\t\t67\t\t62\t\t14.0\t<.001\t \t\t\t\t\t\t\t\tF(2,63)\tP\t \t\t\t \tAge\t38.4\t10.0\t41.3\t10.4\t41.5\t10.6\t0.67\t.515\t \tWASI\t115.8\t11.7\t91.86\t14.8\t97.1\t16.4\t16.8\t<.001\t \tNS-SEC\t3.13\t1.62\t3.74\t1.88\t3.39\t1.76\t0.65\t.525\t \t\t\t\t\t\t\t\tt(40)\tP\t \t\t\t \tOnset age (years)\t\t\t27.7\t6.2\t26.0\t7.7\t0.80\t.431\t \tIllness duration (years)\t\t\t14.1\t10.1\t15.5\t8.8\t0.46\t.650\t \tCPZ equivalents\t\t\t280.3\t147.1\t383.5\t236.5\t1.67\t.103\t \tPANSS score\t \t   Positive symptoms\t\t\t10.7\t2.1\t20.5\t3.1\t12.10\t<.001\t \t   Negative symptoms\t\t\t13.1\t4.6\t19.5\t4.6\t4.08\t<.001\t \t   General symptoms\t\t\t23.6\t5.1\t34.9\t9.2\t5.91\t<.001\t \t   Total score\t\t\t46.9\t10.3\t76.2\t10.6\t9.14\t<.001\t \t
#Text=Abbreviations: HC, heathy controls; NTR, non-treatment resistant; TRS, treatment resistant schizophrenia; WASI, Wechsler Abbreviated Scale of Intelligence; NS-SEC, National Statistics Socio-economic Classification; CPZ, Chlorpromazine; PANSS, Positive and Negative Symptom Scale.
191-1	40183-40188	Means	_	
191-2	40189-40190	(	_	
191-3	40190-40191	M	_	
191-4	40191-40192	)	_	
191-5	40193-40196	and	_	
191-6	40197-40205	standard	_	
191-7	40206-40216	deviations	_	
191-8	40217-40218	(	_	
191-9	40218-40220	SD	_	
191-10	40220-40221	)	_	
191-11	40222-40224	of	_	
191-12	40225-40236	demographic	_	
191-13	40237-40240	and	_	
191-14	40241-40249	clinical	_	
191-15	40250-40259	variables	_	
191-16	40260-40263	per	_	
191-17	40264-40269	group	_	
191-18	40271-40273	HC	_	
191-19	40274-40277	NTR	_	
191-20	40278-40281	TRS	_	
191-21	40287-40288	M	_	
191-22	40289-40291	SD	_	
191-23	40292-40293	M	_	
191-24	40294-40296	SD	_	
191-25	40297-40298	M	_	
191-26	40299-40301	SD	_	
191-27	40302-40307	Group	_	
191-28	40308-40318	statistics	_	
191-29	40331-40333	χ2	_	
191-30	40333-40334	(	_	
191-31	40334-40335	2	_	
191-32	40335-40336	)	_	
191-33	40337-40338	P	_	
191-34	40345-40351	Female	_	
191-35	40352-40353	(	_	
191-36	40353-40354	%	_	
191-37	40354-40355	)	_	
191-38	40356-40358	25	_	
191-39	40360-40362	14	_	
191-40	40364-40366	14	_	
191-41	40368-40372	1.18	_	
191-42	40373-40377	.555	_	
191-43	40380-40387	Smokers	_	
191-44	40388-40389	(	_	
191-45	40389-40390	%	_	
191-46	40390-40391	)	_	
191-47	40392-40394	17	_	
191-48	40396-40398	67	_	
191-49	40400-40402	62	_	
191-50	40404-40408	14.0	_	
191-51	40409-40410	<	_	
191-52	40410-40414	.001	_	
191-53	40424-40425	F	_	
191-54	40425-40426	(	_	
191-55	40426-40430	2,63	_	
191-56	40430-40431	)	_	
191-57	40432-40433	P	_	
191-58	40440-40443	Age	_	
191-59	40444-40448	38.4	_	
191-60	40449-40453	10.0	_	
191-61	40454-40458	41.3	_	
191-62	40459-40463	10.4	_	
191-63	40464-40468	41.5	_	
191-64	40469-40473	10.6	_	
191-65	40474-40478	0.67	_	
191-66	40479-40483	.515	_	
191-67	40486-40490	WASI	_	
191-68	40491-40496	115.8	_	
191-69	40497-40501	11.7	_	
191-70	40502-40507	91.86	_	
191-71	40508-40512	14.8	_	
191-72	40513-40517	97.1	_	
191-73	40518-40522	16.4	_	
191-74	40523-40527	16.8	_	
191-75	40528-40529	<	_	
191-76	40529-40533	.001	_	
191-77	40536-40542	NS-SEC	_	
191-78	40543-40547	3.13	_	
191-79	40548-40552	1.62	_	
191-80	40553-40557	3.74	_	
191-81	40558-40562	1.88	_	
191-82	40563-40567	3.39	_	
191-83	40568-40572	1.76	_	
191-84	40573-40577	0.65	_	
191-85	40578-40582	.525	_	
191-86	40592-40593	t	_	
191-87	40593-40594	(	_	
191-88	40594-40596	40	_	
191-89	40596-40597	)	_	
191-90	40598-40599	P	_	
191-91	40606-40611	Onset	_	
191-92	40612-40615	age	_	
191-93	40616-40617	(	_	
191-94	40617-40622	years	_	
191-95	40622-40623	)	_	
191-96	40626-40630	27.7	_	
191-97	40631-40634	6.2	_	
191-98	40635-40639	26.0	_	
191-99	40640-40643	7.7	_	
191-100	40644-40648	0.80	_	
191-101	40649-40653	.431	_	
191-102	40656-40663	Illness	_	
191-103	40664-40672	duration	_	
191-104	40673-40674	(	_	
191-105	40674-40679	years	_	
191-106	40679-40680	)	_	
191-107	40683-40687	14.1	_	
191-108	40688-40692	10.1	_	
191-109	40693-40697	15.5	_	
191-110	40698-40701	8.8	_	
191-111	40702-40706	0.46	_	
191-112	40707-40711	.650	_	
191-113	40714-40717	CPZ	_	
191-114	40718-40729	equivalents	_	
191-115	40732-40737	280.3	_	
191-116	40738-40743	147.1	_	
191-117	40744-40749	383.5	_	
191-118	40750-40755	236.5	_	
191-119	40756-40760	1.67	_	
191-120	40761-40765	.103	_	
191-121	40768-40773	PANSS	_	
191-122	40774-40779	score	_	
191-123	40783-40785	  	_	
191-124	40785-40793	Positive	_	
191-125	40794-40802	symptoms	_	
191-126	40805-40809	10.7	_	
191-127	40810-40813	2.1	_	
191-128	40814-40818	20.5	_	
191-129	40819-40822	3.1	_	
191-130	40823-40828	12.10	_	
191-131	40829-40830	<	_	
191-132	40830-40834	.001	_	
191-133	40838-40840	  	_	
191-134	40840-40848	Negative	_	
191-135	40849-40857	symptoms	_	
191-136	40860-40864	13.1	_	
191-137	40865-40868	4.6	_	
191-138	40869-40873	19.5	_	
191-139	40874-40877	4.6	_	
191-140	40878-40882	4.08	_	
191-141	40883-40884	<	_	
191-142	40884-40888	.001	_	
191-143	40892-40894	  	_	
191-144	40894-40901	General	_	
191-145	40902-40910	symptoms	_	
191-146	40913-40917	23.6	_	
191-147	40918-40921	5.1	_	
191-148	40922-40926	34.9	_	
191-149	40927-40930	9.2	_	
191-150	40931-40935	5.91	_	
191-151	40936-40937	<	_	
191-152	40937-40941	.001	_	
191-153	40945-40947	  	_	
191-154	40947-40952	Total	_	
191-155	40953-40958	score	_	
191-156	40961-40965	46.9	_	
191-157	40966-40970	10.3	_	
191-158	40971-40975	76.2	_	
191-159	40976-40980	10.6	_	
191-160	40981-40985	9.14	_	
191-161	40986-40987	<	_	
191-162	40987-40991	.001	_	
191-163	40995-41008	Abbreviations	_	
191-164	41008-41009	:	_	
191-165	41010-41012	HC	_	
191-166	41012-41013	,	_	
191-167	41014-41020	heathy	_	
191-168	41021-41029	controls	_	
191-169	41029-41030	;	_	
191-170	41031-41034	NTR	_	
191-171	41034-41035	,	_	
191-172	41036-41049	non-treatment	_	
191-173	41050-41059	resistant	_	
191-174	41059-41060	;	_	
191-175	41061-41064	TRS	_	
191-176	41064-41065	,	_	
191-177	41066-41075	treatment	_	
191-178	41076-41085	resistant	_	
191-179	41086-41099	schizophrenia	_	
191-180	41099-41100	;	_	
191-181	41101-41105	WASI	_	
191-182	41105-41106	,	_	
191-183	41107-41115	Wechsler	_	
191-184	41116-41127	Abbreviated	_	
191-185	41128-41133	Scale	_	
191-186	41134-41136	of	_	
191-187	41137-41149	Intelligence	_	
191-188	41149-41150	;	_	
191-189	41151-41157	NS-SEC	_	
191-190	41157-41158	,	_	
191-191	41159-41167	National	_	
191-192	41168-41178	Statistics	_	
191-193	41179-41193	Socio-economic	_	
191-194	41194-41208	Classification	_	
191-195	41208-41209	;	_	
191-196	41210-41213	CPZ	_	
191-197	41213-41214	,	_	
191-198	41215-41229	Chlorpromazine	_	
191-199	41229-41230	;	_	
191-200	41231-41236	PANSS	_	
191-201	41236-41237	,	_	
191-202	41238-41246	Positive	_	
191-203	41247-41250	and	_	
191-204	41251-41259	Negative	_	
191-205	41260-41267	Symptom	_	
191-206	41268-41273	Scale	_	
191-207	41273-41274	.	_	
